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ABSTRACT 
It has been reported that HAX1 is a multi-functional protein which protects cells 
from apoptosis, modulates autophagy, regulates membrane protein trafficking and 
promotes cell migration. Many studies have shown it has many different intra-
cellular binding partners (including integrin β6 subunit) and exists in multiple 
cellular locations, including the nucleus, mitochondria and cytoplasm. This 
behaviour seemed unlikely for a single protein. My lab discovered that there are at 
least eight different HAX1 isoforms in humans and this might explain why multiple 
roles and sub-cellular locations are described for HAX1. In this study, I sought not 
only to confirm the role of HAX1 in cell behaviour, but also to examine specifically 
the role of HAX1 isoforms in different biological functions. I screened a panel of 
cancer cell lines for αvβ6-dependent migration, including breast (MCF10.CA1a), 
pancreatic (CFPac1 and Panc04.03), and αvβ1-dependent migration in cervical 
cancer (HeLa); siRNA designed to knockdown all HAX1 isoforms significantly 
decreased cell migration indicating HAX1 is required for cell migration in cells from 
multiple tissues, regulating both αvβ6 and αvβ1-dependent cell migration in various 
cancer types. In order to establish the functions attributable to individual isoforms, I 
re-introduced individual HAX1 isoforms into HAX1-null (siRNA knockdown) cells 
and then studied their subcellular localisation and whether they modulate migration, 
apoptosis and autophagy. The immunofluorescent staining revealed the 
predominantly mitochondrial localisation of HAX1.1, HAX1.4, HAX1.5 whereas 
HAX1.2 showed a very unique pattern of location in the cytoplasm.  Overexpression 
of HAX1.2 decreased cell motility on αv-dependent ligand latency associated 
peptide (LAP) and knockdown of HAX1.2 increased cell migration. Furthermore, 
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HAX1.2 protected cells from cell death induced by various cytotoxic drugs. 
Moreover, HAX1.1, HAX1.2 and HAX1.5 increased autophagy by elevating the 
levels of Beclin-1 and LC3b-II.  
However, it also is clear that much further study is needed to thoroughly understand 
the biology of each isoform. These are the first experimental data that demonstrate 
different HAX1 isoforms have different biological activities in human cancer cells, 
helping to explain the conflicting literature describing HAX1. 
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ELA2: Elastase 2 
EMP: Empty vector 
Eps-15: EGFR-pathway substrate 
ER: Endoplasmic reticulum 
ETO: Etoposide 
FADD: Fas-associated death domain protein  
FAK: Focal adhesion kinase 
FMDV: Foot-and-mouth-disease virus 
G6PC1: Glucose-6-phosphate 
GDP: Guanosine diphosphate 
GFP: Green fluorescent protein 
Grb7: Growth factor receptor bound protein-7  
GST: Glutathione S-transferase 
GTP: Guanosine triphosphate 
HAX1: HS1-associated protein-X 1 
HCV: Hepatitis C Virus 
HGF: Hepatocyte growth factor 
HIV: Human Immunodeficiency Virus  
HRP: Horse-radish peroxidase 
HS1: Haematopoietic cell-specific protein1 
HtrA2: High temperature requirement protein A2, also named as Omi 
IAP: Inhibitor of apoptosis protein 
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IL-1α: Interleukin-1 α 
kDa: KiloDalton 
KSHV: Kaposi‟s sarcoma-associated herpesvirus 
LAP: Latency-associated protein 
LC3: Microtubule-associated protein 1 light chain 3  
LTBP: Latent TGF-β binding protein  
mIgE: Membrane-bound IgE 
Mit: Mitochondria 
MMPs: Matrix metalloproteinases 
MOMP: Mitochondrial membrane membrane permeabilisation 
mTOR : Mammalian target of rapamycin  
MTS: Mitochondria-targeting sequence 
MYPT1: Myosin phosphatase-targeting subunit 1  
n.t.: Nucleotide 
NTC: Non-targeting control vector 
NU: Nuclear 
PAI1: Plasminogen activator inhibitor 1  
PARL: Presenilin-associated, rhomboid-like 
PARP: Poly-ADP-ribose polymerase 
PCR: Polymerase chain reaction  
PE: phosphatidylethanolamine 
PH domain: Pleckstrin homology domain 
PHB2: Prohibitin 2 
PI3K: class III phosphotidylinositol-3-OH kinase  
PKC: Protein kinase C  
PKD2: Polycystic kidney disease 
PLN: Phospholamban 
RA domain: Ras associating domain 
RCC: Renal cell carcinoma 
RGD: Arginine-glycine-aspartic acid 
RhoGEF: Rho guanine-nucleotide exchange factors  
ROCK1: Rho-associated, coiled-coil containing protein kinase 1 
RRE: Rev response element  
RT: Reverse Transcription 
SAGE: Serial analysis of gene expression 
SCC: Squamous cell carcinoma 
SCN: Severe congenital neutropenia  
SERCA2: Sarcoplasmic reticulum Ca
2+ 
ATPase 
SH2: Src homology 2 
SMAC/DIABLO: Second mitochondria-derived activator of caspase  
SR: Sarcoplasmic reticulum 
SRPX: Sushi-repeat containing protein, X-linked 
SV40: Simian virus-40  
TGF-β: Transforming growth factor β 
TNFα: Tumour necrosis factor α  
TRADD: TNFR-1-associated death domain protein  
ULK1: Unc-51-like kinase1 
uPA: Urokinase-type plasminogen activator  
uPAR: Urokinase-type plasminogen activator receptor  
22 
 
VDA2: Voltage-dependent anion channel 2 
VEGA: Vertebrate genome annotation database 
Vpr: Human immunodeficiency virus type 1 viral protein R 
WASP: Wiskott-Aldrich syndrome protein 
WAVE: WASP family Verprolin-homologous protein 
XIAP: X-linked inhibitor of apoptosis protein 
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CHAPTER 1.  INTRODUCTION 
1.1 Haematopoietic cell-specific protein-associated protein 
X-1: HAX1 
1.1.1 Background of the study 
My laboratory is interested in the role of integrins in cancer. This is particularly true 
of the role of integrin αvβ6, since its expression is associated with poor survival in 
many cancers. Attempts to understand the molecular basis of αvβ6-promoted 
invasion identified HAX1 as an intracellular molecule that binds to the β6 
cytoplasmic tail [1]. Further studies showed that HAX1 was required for αvβ6-
dependent carcinoma cell invasion. Moreover, studies from the literature reported 
that HAX1 regulated apoptosis, endocytosis, autophagy and was shown to be 
localised in cytoplasm, ER (endoplasmic reticulum), mitochondria, and nucleus. It 
was considered that so many functions and subcellular localisations were unlikely 
for a single molecule. The beginning of the solution to this confusion was revealed 
when my lab discovered that HAX1 consisted of at least eight alternative spliced 
proteins in humans [2]. Thus we hypothesised that different isoforms could be 
differently located in cells and perform different functions. In this thesis I extend the 
data on the importance of HAX1 in cancer cell migration and investigate the biology 
of individual HAX1 isoforms, concentrating on those isoforms (HAX1.1, HAX1.2, 
HAX1.4 and HAX1.5) that potentially can bind to the β6 cytoplasmic tail. I shall 
now review the discovery and reported biology of HAX1. 
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1.1.2 The discovery and the early studies of HAX1 
HAX1 (haematopoietic cell-specific protein-associated protein X-1) was discovered 
as a binding partner of HS1 (haematopoietic cell-specific protein 1) by Suzuki et al 
in 1997 [3]. HS1 is a 75-kDa molecule expressed mainly in haematopoietic cells [3]. 
HS1 predominantly resides in the cytoplasm and has been shown to translocate to the 
cytoplasmic membrane after it is activated through tyrosine phosphorylation [4,5]. 
HS1 is involved in proliferation and apoptosis downstream of B cell and T cell 
receptor activation [4,6]. Upon the binding to antigen receptor, a number of tyrosine 
kinases become activated and, in turn, phosphorylate cellular proteins including HS1 
[7]. Suzuki and colleagues originally aimed to investigate the mechanism of HS1 in 
the signal transduction of lymphoid cells [3]. Yeast two-hybrid was performed to 
gain more knowledge and as the result HAX1 was identified to interact with the 
amino terminal region of HS1 [3]. Although there was no functional examination in 
this study, this paper revealed that the expression of the HAX1 gene was widely 
distributed among human tissues including heart, brain, placenta, lung, liver, skeletal 
muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, ovary, 
colon and leukocytes [3]. The authors also reported that the protein was localised 
mostly to mitochondria with minor staining on the nuclear envelope and 
endoplasmic reticulum (ER) in human B lymphoma Daudi cells [3]. 
Two years after the first discovery of HAX1, Gallagher et al described the 
interaction of HAX1 with the PKD2 protein (polycystic kidney disease 2), again 
using a yeast two-hybrid screen [8].  The PKD2 protein is located in the ER and it is 
responsible for the second form of autosomal dominant polycystic kidney disease 
25 
 
[9,10]. Co-immunoprecipitation confirmed that exogenous full-length HA-tagged 
human PKD2 and GST–tagged full-length HAX1 interacted [8]. Moreover, by 
transfecting GST/HAX1 fusion protein and a plasmid coding for myc-tagged 
cortactin into COS-1 cells, co-immunoprecipitation and GST pull-down experiments 
with whole-cell lysates indicated that cortactin, also interacts with HAX1 [8]. Further 
double-immunofluorescence studies showed HAX1 and PKD2 co-expression in 
lamellipodia (flat membrane protrusions at the leading edge of migrating cells) in 
COS-1 cells, implying their possible association with cell motility [8]. The idea that 
HAX1 was involved in migration also has been suggested in another study. IL-1α 
(Interleukin-1 α), a cytokine which recently has been indicated to enhance cancer 
cell migration, was found as a binding partner of HAX1, providing further evidence 
for a role of HAX1 in cell migration or adhesion [11]. 
Sharp and colleagues showed HAX1 interacts with the C-terminus of the K15 
protein (a viral protein with unknown function) from Kaposi‟s sarcoma-associated 
herpes virus (KSHV) and also investigated the role of HAX1 in apoptosis [12].  Bax 
(a Bcl-2 family member with a strong pro-apoptotic function) was transfected into 
HeLa cells to induce cell apoptosis. Co-transfection of HAX1 decreased cell death 
induced by Bax, thus protecting the host cell from apoptosis [12]. This paper was the 
first study formally to show a functional link between HAX1 and its ability to 
protect against apoptosis [12]. 
Severe congenital neutropaenia (SCN), or Kostmann‟s disease, was the first inborn 
systemic immune dysfunction disease recognised in 1950 and it is defined by when 
the absolute neutrophil count is less than 1500 cell/ mm
3 
of blood [13,14]. 
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Consequently, patients with SCN are vulnerable to recurrent infections [14]. SCN is 
caused by the maturation-arrest in neutrophil differentiation during 
promyelocyte/myelocyte stages in the bone marrow [15]. SCN is caused by 
mutations in several different genes including ELA2 (elastase 2), AK2 (adenylate 
kinase-2), WASP (Wiskott-Aldrich syndrome protein) and G6PC1 (glucose-6-
phosphate) [16]. Klein and colleagues revealed that HAX1 gene deficiency also 
causes SCN [16]. Sequencing of genomic DNA identified a homozygous single-
nucleotide insertion (position 130-131insA) leading to a premature stop codon 
(W44X) in SCN patients [16]. To directly assess the role of HAX1 in apoptosis, 
neutrophils from affected individuals and healthy donors were purified and analysed 
[16]. The study showed the enhanced neutrophil apoptosis in HAX1-deficient cells 
induced by H2O2, staurosporine and tumour necrosis factor α (TNFα) [16].  
Neutrophils isolated from HAX1-deficient individuals also showed a rapid 
dissipation of mitochondrial inner membrane permeabilisation by staining with JC-1 
(JC-1 is a dye which accumulates in mitochondria and forms J-aggregates emitting 
an orange fluorescence. Upon loss of the mitochondrial membrane potential, the JC-
1 dye accumulates in mitochondria, adopts a monomeric conformation and emits 
green fluorescence) whereas the inner mitochondrial membrane potential in 
neutrophils from healthy individuals was maintained [16]. This study revealed that 
HAX1 deficiency causes SCN and suggested the mechanism involved stabilising the 
mitochondrial membrane potential therefore protecting cells from apoptosis.  
Thus these early studies of HAX1 showed a confusing picture of “the” protein 
HAX1, which was demonstrated to be localised in multiple cellular compartments 
with different binding partners in different cell types. In addition, these studies 
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ascribed multiple biological functions to HAX1. Notwithstanding this lack of clarity, 
these studies have generated much interest in HAX1. In the following sections I will 
review the current knowledge of HAX1 in detail and discuss why it is important to 
understand the roles of individual isoforms of HAX1 in disease, including cancer. 
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1.1.3  Protein domains of HAX1  
HAX1 protein contains several notable domains: an “acid box” of 11 consecutive 
acidic residues (a.a. 30-41, indicated as yellow in Figure 1.1), a putative PEST 
sequence (a.a. 104-147, indicated as red in Figure 1.1), and an αvβ6 binding site (a.a 
271-279, indicated as blue) [2,3] (see Figure 1.1). The acid box is comprised mostly 
of glutamic acid and aspartic acid residues (amino acids 30–41 of HAX1: 
DEDDDEEEEEEG) which was also found in fibroblast growth factor receptor and 
shown to increase retention of this protein at the plasma membrane [2,17]. A PEST 
sequence (proline, glutamic acid, serine, threonine-rich sequence), usually indicates 
a protein with a short half-life [18]. At the C-terminus, a.a. 271-279 were identified 
as the integrin β6 subunit-binding domain which is encoded in the HAX1 isoform 1, 
2, 4 and 5 [1,2]. In the study from Yap and colleagues, overexpression of full-length 
HAX1 (a.a. 1–279) preferentially concentrated in mitochondria in HEK-293 cells; 
upon removal of the first 59 amino acids, the truncated HAX1 (HAX1 a.a. 60-279) 
failed to codistribute with MitoTracker, but instead exhibited a diffuse cytoplasmic 
distribution, indicating the N-terminus of HAX1 (a.a. 1-59) contains residues 
required for entry into mitochondria [19]. The same report also demonstrated a 
region of the C-terminus (a.a. 182-245) as being responsible for ER localisation, 
through the same approach [19] (see Figure 1.1). 
To characterise the HAX1 localisation in cell migration, a study from Cavnar and 
colleagues generated truncation constructs lacking the C-terminal 166 amino acids; 
this truncated HAX1 (1–113–GFP mutant) no longer showed leading edge 
localisation and concentrated in the middle of the cell body of neutrophils [20]. In 
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contrast, even with deletion of the N-terminal 113 a.a., the remaining residues were 
sufficient to localise to the leading edge; thus the C-terminal region (a.a. 113-279) 
contains residues essential for the localisation to the leading edge of the neutrophil 
[20]. Apart from the subcellular localisation studies, there also are several studies 
that showed specific HAX1 sequences linked to particular biological functions. A 
study from Han et al showed full length HAX1 protects myocytes from cell death 
induced by caspase-9 overexpression [21].  Mutants lacking amino acids from 1 to 
261 of HAX1 lost anti-apoptotic activity in response to caspase-9 overexpression, 
indicating the a.a 1-261 of HAX1 are required for full anti-apoptotic effects [21]. 
Another study showed that the full-length HAX1 and N-terminal 113 amino acids of 
HAX1, rescued neutrophil adhesion and motility and uropod retraction in PLB-985 
cells, indicating this N-terminal region ( a.a. 1-113) is responsible for these functions 
in neutrophils [20]. In Figure 1.1, I have also noted two major functions that often 
were ascribed to HAX1: anti-apoptosis and regulation of cell migration and the 
binding partners associated with these activities. Figure 1.1 shows C-terminal 
sequence of HAX1 contributes to the interaction with other molecules.  
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Figure 1.1 HAX1 protein domains.  
The full length of human HAX1 contains 279 a.a.  An acid box, from a.a. 30-41, is 
indicated as yellow colour and a putative PEST sequence, which is from a.a. 104 to 
147, is shown in red. Integrin β6 binding site exists in the C-terminal end from 271-
279 a.a., indicated as blue. The N-terminal of HAX1 (a.a. 1-59) is required for 
mitochondrial (Mit) localisation [22] whereas C-terminal (a.a 182-243) is required 
for endoplasmic reticulum (ER) localisation [22]. This figure shows some of the 
HAX1-binding proteins discovered to date and the regions of HAX1 they were 
reported to bind to, illustrates that the C-terminal of HAX1 seems to be responsible 
for most protein interaction identified to date. Proteins are classified into two major 
groups according to their cellular functions: anti-apoptosis and cell migration. 
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1.1.3.1 HAX1 distribution in human tissues 
HAX1 expression in human tissues has been analysed in several different studies. In 
general, it is expressed ubiquitously in human tissues with the highest expression 
levels found in metabolically active tissues [3,23,24]. Suzuki et al were the first to 
report the differentially regulated expression of HAX1 mRNA in multiple tissues 
from humans [3]. In that study, HAX1 expression was assessed by Northern Blot and 
data showed the highest levels of HAX1 expression in the heart and colon, followed 
by slightly lower levels in the skeletal muscle, lung, liver, and pancreas [3]. On the 
other hand, the brain, placenta, kidney, spleen, thymus, intestine, prostate, ovary, and 
testes exhibited lower levels of expression [3]. Highest expression level of HAX1 
mRNA was also found in skeletal and heart muscles by Mirmohammadsadegh et al 
who also reported lower levels in kidney, liver, lung; the placenta contained the least 
amounts of HAX1 [23]. Carlsson et al used quantitative RT-PCR analysis to 
examine the mRNA expression patterns of different HAX1 isoforms in 20 different 
human tissues and showed both HAX1.1 and HAX1.4 (discussed later in section 
1.1.5) were detected in all tissues analysed [24]. Interestingly, the authors found that 
the amounts of isoform 1 mRNA were about 20-fold higher than isoform 4 in all 
tissues analysed [24]. Collectively, the studies suggested HAX1 is expressed 
ubiquitously throughout human tissues but with the highest expression in human 
cardiac and skeletal muscles (Table 1.1). 
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Tissue  Relative expression  
Suzuki et al, 1997 
Northern Blot/Total HAX1 mRNA 
 
  Heart 
  Colon 
  Skeletal muscle 
  Lung 
  Liver 
  Pancreases 
  Brain 
  Thymus 
  Spleen 
  Intestine 
  Testis 
  Prostate 
  Ovary 
  Placenta 
++++ 
++++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
Mirmohammadsadegh et al, 2003 
Northern Blot  
 
  Skeletal muscle 
  Heart 
  Liver 
  Pancreases 
  Brain 
  Kidney 
  Lung 
  Placenta  
++++ 
+++ 
++ 
++ 
+ 
+ 
+/- 
+/- 
Carlsson et al, 2008 
RT-PCR  
 
Cumulative levels of HAX1.1 and HAX1.4 
  Testis 
  Skeletal muscle 
  Heart 
  Brain 
  Liver 
Relative expression of HAX1.1 
  Skeletal muscle 
  Testis 
  Heart 
  Brain 
  Liver 
Relative expression of HAX1.4 
  Testis 
  Skeletal muscle 
  Heart 
  Brain 
  Liver  
 
++++ 
+++ 
++ 
+ 
+ 
 
++++ 
+++ 
++ 
+ 
+ 
 
++++ 
++ 
++ 
+ 
+ 
Table 1.1 HAX1 mRNA expression in human tissues.  
Table shows the tissue expression pattern of HAX1 by three different studies. It 
shows that HAX1 is ubiquitously expressed in human tissues. Data adapted from 
[25]. 
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1.1.3.2 Subcellular localisation of HAX1  
Since the very first paper to describe HAX1, many studies have attempted to 
investigate the subcellular distribution of HAX1 for the better understanding of its 
cellular functions. Exogenous HAX1 expressed from transfected plasmids have 
largely been employed to observe HAX1 for its localisation; the data from different 
studies showed HAX1 exists in different subcellular compartments including, 
predominantly in the cell mitochondria (in HeLa, COS-7, HEK293, DG75, B 
lymphoma and striated muscle cells [3,12,19,26,27]), in the nucleus (COS-7 and 
DG75 [3,27]), in the ER (in COS-7, HeLa, HEK293 cells [3,12,28]) and in the 
cytoplasm (COS-7 and HEK293 cells [21,29]). HAX1 was also shown to be 
expressed in the plasma membrane and the lamellipodia in COS-7 cells [8]. Cell 
fractionation studies also revealed the mitochondrial residence of endogeneous 
HAX1 in HEK cells [30]. Table 1.2 shows the subcellular localisation of HAX1 
described from different studies. 
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Cell type  Subcellular localisation Co-
transfection 
Reference 
 MT ER NU Others  
Exogenous HAX1     
COS-7 
B-lymphoma 
COS-7 
HeLa 
HeLa 
COS-7 
HeLa 
MDCK-II 
HeLa 
HeLa 
Cardiocytes 
HEK293 
HEK293 
HEK293 
 v 
v 
- 
- 
- 
- 
v 
- 
v 
- 
v 
v 
v 
v 
v 
- 
- 
v 
- 
- 
v 
- 
- 
- 
- 
- 
v 
- 
v 
- 
- 
- 
- 
- 
- 
- 
- 
v 
- 
- 
- 
- 
 
 
cytoplasmic 
 
lamellipodia 
lamellipodia 
 
apical cell 
membrane 
 
 
cytoplasmic 
- 
- 
EBNA-LP 
- 
PKD2 
Cortactin 
- 
BSEP 
- 
Vpr 
- 
- 
PLN 
SERCA 
 
[3] 
[3] 
[29] 
[8] 
[8] 
[8] 
[12] 
[31] 
[26] 
[26] 
[21] 
[28] 
[28] 
[28] 
Endogenous HAX1 
  
    
DG75  
HEK293 
Testis 
Striated muscles 
v 
v 
v 
v 
- 
- 
- 
- 
 v 
- 
v 
- 
 
 
 
sarcoplasmic 
reticulum 
- 
- 
- 
- 
[27] 
[30] 
[32] 
[19] 
Table 1.2 Summary of studies on the subcellular distribution of HAX1.  
Table shows the reported subcellular localisation of HAX1 from different studies; 
the table is modified from [25]. MT, mitochondria; ER, endoplasmic reticulum; NU, 
nuclear. The tick “V” indicates positive and “-“ indicates negative 
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1.1.4 HAX1 functions 
1.1.4.1 HAX1 regulates trafficking of membrane proteins 
Endocytosis of adhesion molecules from the cell membrane and exocytosis to the 
leading edge of migrating cells are crucial steps for cell migration [33] (see section 
1.2.3.3). The first study to reveal HAX1 regulates membrane molecule trafficking 
showed that HAX1 promoted BSEP (bile salt export protein) endocytosis in a 
clathrin-dependent pathway [31]. In this study, HAX1 was found as a binding 
partner for BESP; depletion of HAX1 by siRNA in  Madin-Darby canine kidney 
(MDCK) cells suppressed internalisation of BSEP and resulted in a 70% increased 
surface expression, while BSEP translation, post-translational modification, delivery 
to the plasma membrane, or half-life were not affected [31]. Oberndorfer et al 
demonstrated the direct interaction of murine HAX1 with the cytoplasmic tail of 
mIgE (membrane-bound IgE) and this modulated mIgE-mediated antigen 
internalisation to BCR (B cell receptor) [34]. In order to test for the ability to 
internalise BCR after BCR stimulation with anti-IgE antibody, the authors used a 
siRNA to knockdown murine HAX1 expression [34]. The data showed HAX1 
depletion reduced the BCR internalisation efficiency after stimulation with anti-IgE 
Ab in murine B cells [34]. No further biological functions were provided but the 
existence of an interaction of these two molecules leads to the suggestion that this 
interaction is important for the efficient antigen-internalisation in mIgE(+) B cells 
which is crucial for its antigen presentation to T cells during B cell proliferation [34]. 
In a previous study from my lab, Ramsay et al showed HAX1 bound to the integrin 
6 subunit and this promoted oral squamous carcinoma cell migration by regulating 
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αvβ6 endocytosis [1]. Using capture-ELISA assays, oral squamous carcinoma cells 
transfected with HAX1 siRNA decreased the internalisation rate of integrin v6 
(while no effect was apparent on β1 and αvβ5) but had no effect on the recycling rate 
[1]. This study was the first to reveal that HAX1 may play an important role in 
cancer progression via regulating integrin endocytosis and cancer cell migration and 
invasion (further details see 1.1.4.3) [1].   
1.1.4.2 HAX1 and mRNA regulation 
HAX1 has been reported to have a mRNA transcript binding property that interacts 
with mRNAs encoding for vimentin and rat DNA polymerase β [32,35]. There are 
common features of these two transcripts for HAX1 to bind to: both interact with 
HAX1 via their 3‟ untranslated region (UTR) and both are characterised as having 
hairpin structures [32,35].  
The hairpin structure is reported to stabilise mRNA transcripts by binding to factors 
that protect them from nuclease cleavage, and it also regulates mRNA transport [32]. 
HAX1 was shown to associate with the 3‟UTR hairpin region of vimentin mRNA in 
HeLa cells and the authors suggested this interaction facilitated the proper 
localisation of the transcript to the perinuclear cytoplasm [35]. Perinuclear 
localisation of certain transcripts, and their subsequent translation at this site, could 
facilitate efficient nuclear import of newly synthesised proteins [36]. By transporting 
mRNA transcripts to certain subcellular localisations, there could be benefit from 
this mechanism [36]. Vimentin is a cytoskeletal protein involved in cell migration of 
mesenchymal type cells and the vimentin transcript localisation alters cell 
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morphology and motility [37]. Thus HAX1 was suggested to regulate vimentin 
mRNA transport/ stability and therefore modulate cell motility [35].  
HAX1 was also reported to bind to the hairpin structure of the 3‟UTR of rat DNA 
polymerase β mRNA [32]. The disruption of this hairpin structure generated by site-
directed mutagenesis impaired the interaction with HAX1, implying the hairpin 
structure is important for this RNA-protein binding [32]. The study suggested that 
the hairpin structure is associated with (i) mRNA degradation, (ii) enhanced mRNA 
transport and/or enhanced translation [32].  Therefore the role of HAX1 binding to 
DNA polymerase β is proposed to stabilise its mRNA and/or regulate post-
transcriptional expression [32].  Interestingly, vimentin and DNA polymerase β are 
not functionally related to each other and also not involved in the same pathway. The 
U-rich single-stranded regions (vimentin: AGUUUU in the terminal loop, DNA 
polymerase β: AGUUAU in the internal loop) represents the only similarity between 
the two structures [32]. The lack of similarities has suggested that the HAX1-binding 
mechanism might be different for these two structures [32]. 
Apart from directly interacting with hairpin structures of mRNAs from mammalian 
cells, HAX1 is also reported to mediate viral RNA transcription via binding to the 
viral protein Rev [38]. The HIV-1 Rev protein facilitates the nuclear export of viral 
mRNAs containing the Rev response element (RRE) [39]. A study demonstrated that 
HAX1 mediates the RRE regulation by interacting with Rev [38]. By using 
immunofluorescence studies, co-transfection of HAX1 and Rev revealed that full-
length HAX1 altered the original localisation of Rev from the nucleus to the 
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cytoplasm in COS-1 cells [38]. By changing the localisation of Rev, it was suggested 
that HAX1 could therefore interfere with the stability/export of RRE-containing 
mRNAs and thus inhibit RRE-mediated gene expression [38]. The authors implied 
that by generating small molecules that mimic HAX1, to specifically interfere with 
the viral protein pathway, such an approach could become useful in the treatment of 
HIV-1-infected AIDS (acquired immunodeficiency syndrome) patients [38]. 
1.1.4.3 HAX1 regulates cell migration 
1.1.4.3.1 Cytoskeleton dynamics in cell migration 
Cell migration is mediated by coordinated actions between the cytoskeleton and 
integrin-mediated adhesion. The integrin–mediated migration is discussed in section 
1.2.3.2. In this section I will review the cell migration regulated by other cytoskeletal 
molecules as this will set the scene for other HAX1 binding partners. 
During cell movement, cells rearrange the cytoskeleton to form actin stress fibres 
that attach to ECM (extracellular matrix) surface at the front, followed by retraction 
and destabilisation of adhesions at the rear of the cell [40]. Stress fibres are actin 
filaments that are organised into thick bundles which are essential for cell motility 
[40]. The actin cytoskeleton is critical for the process of cell migration, including 
polarisation, leading edge protrusion and contraction [40]. The first step for the cell 
movement is polarisation and extending the protrusions which are driven by the 
polymerisation of actin filaments [41]. The protrusion structures, including 
lamellipodia and filopodia, are modulated by signalling pathways stimulating actin 
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cytoskeleton arrangement [42]. Within these two structures, actin filaments exhibit 
specific patterns of assembly-disassembly and translocation dynamics that are 
directed by the actin regulatory proteins [42]. The actin filaments‟ protrusion 
formation is mediated by actin-related protein 2/3 (Arp 2/3) complex that is 
regulated by the small GTPases RhoA, Rac and Cdc42 [42]. Rac and Cdc42 are 
activated at the leading edge whereas RhoA is more prominently activated at the cell 
rear [43]. Rac and Cdc42 induce protrusions by activating the WASP (Wiskott–
Aldrich syndrome protein) homologue domain containing proteins, neural-WASP 
(NWASP) and WAVE (WASP family Verprolin-homologous protein), which in turn 
induce actin polymerisation by activating the Arp2/3 complex [41]. Arp 2/3 complex 
initiates the actin branches and nucleates new actin filament branches in the sides of 
pre-existing filaments which drives lamellipodia protrusion [44]. In the rear of the 
cell, RhoA activates ROCK1 (Rho-associated, coiled-coil containing protein kinase 
1) and ROCK2, which act as inhibitors of myosin phosphatases (myosin 
phosphatase-targeting subunit 1 [MYPT1]), and thus sustain myosin II 
phosphorylation and therefore promotes cell contraction [43]. Myosin II mediates the 
contraction of actin stress fibres and moves antiparallel actin filaments past each 
other providing the force to rearrange the actin cytoskeleton [45]. RhoA also 
activates the formin mDia1 to promote actin polymerisation [40]. These pathways 
contribute to actin polymerisation, bundling and adhesion formation [45]. 
1.1.4.3.2 HAX1 regulates cell migration via cytoskeleton-associated proteins 
Cortactin is a cytoskeletal protein which promotes actin assembly and is also 
associated with tumour invasiveness and metastasis [46]. Cortactin interacts with the 
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Arp2/3 complex, promoting actin polymerisation during actin network 
reconstruction in motile cells [46]. Guanine nucleotide-binding proteins (G proteins) 
are signalling transduction molecules that bind to the intracellular side of membrane 
bound G protein coupled receptors and regulate cell migration [47]. G proteins are 
unified by a common activation mechanism involving exchange of bound GDP 
(Guanosine diphosphate; inactive form) with GTP (Guanosine triphosphate: active 
form), resulting in a conformational change in the protein [48]. Gα13, a subfamily of 
G proteins, interacts with Rho guanine-nucleotide exchange factors (RhoGEF) and 
thus activates RhoA facilitating changes in the actin cytoskeleton, and promoting cell 
adhesion [48]. In the study from Radhika et al, HAX1 was identified as the binding 
partner of Gα13 from human HeLa cell cDNA library and the interaction was 
confirmed by co-immunoprecipitation and confocal imaging studies [49]. Decrease 
of stress fibre formation and increase in actin-rich structures at the leading edges is a 
characteristic feature of cell migration [49]. Transfection of full-length HAX1 
caused a reduction of Gα13-induced stress fibre formation and less cell spreading as 
well as increased cell migration in NIH3T3 cells [49,50]. In reverse, HAX1 silencing 
reduced cell migration [49]. These data indicated HAX1 is an important regulator for 
Gα13-mediated cell migration [49]. According to the immunoprecipitation studies 
and the observations that Gα13 stimulates the activation of Rac, which is potentiated 
by HAX1, the authors suggested a model whereby HAX1 forms a complex with 
Gα13, cortactin and Rac, therefore bringing these molecules closer to Gα13 which 
allows cortactin to be stimulated by G13-activated Rac1, resulting in actin 
polymerisation and cell migration [49]. This was the first report to reveal the pro-
motility function of HAX1 (Figure 1.2).  
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Figure 1.2 Model for how HAX1 promotes cell migration and adhesion by 
forming a complex with Gα13, cortactin and Rac.  
The interaction of HAX1 and Gα13 negatively regulates the Gα13-mediated 
activation of Rho while it increases Gα13-mediated activation of Rac. By forming a 
complex with Gα13, cortactin and Rac, HAX1 brings Gα13 closer to cortactin 
which, in turn, can be stimulated by Gα13-activated Rac, to initiate actin 
polymerisation, cell protrusion, and subsequent cell movement. It is likely that the 
group of Gα13, Rac, HAX1, and cortactin stimulates cell migration by countering 
Gα13- Rho-mediated cell adhesion [49].  
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Growth factor receptor bound protein-7 (Grb7) was identified originally as an SH2 
(Src homology 2) domain-containing adaptor protein bound to the activated EGF 
(epidermal growth factor) receptor and also has been reported to regulate cancer cell 
migration [51,52]. Grb7 mediates cell migration through an interaction with focal 
adhesion kinase (FAK) via the Grb7-SH2 domain [52]. By yeast two-hybrid 
analysis, HAX1 was demonstrated to interact with the RA (Ras associating) and PH 
(Pleckstrin homology) domains of Grb7. This HAX1-Grb7 association was 
confirmed by co-transfecting full-length HAX1 and full-length Grb7 in HeLa cells 
followed by co-immunoprecipitation [53]. Although there were no further 
experiments to determine the biological impact of this interaction, it was proposed 
that HAX1 may participate in Grb7 mediated cell migration signalling [53]. 
PELO is a cytoplasmic protein which is important for germline stem cell self-
renewal by repressing the Bam-independent differentiation pathway and it was 
recently found to be responsible for degrading aberrant mRNAs [54,55]. A recent 
study showed the interaction between PELO,  HAX1 , eukaryotic initiation factor  
EIF3G (eukaryotic translation initiation factor 3, subunit G) and apoptosis-inducing 
tumour suppressor SRPX (sushi-repeat containing protein, X-linked) [56]. EIF3G 
represents a subunit of the eukaryotic translation initiation factor 3 (eIF3) [56] and it 
has been reported to associate with AIF (apoptosis-inducing factor) that induces 
apoptosis through inhibition of protein synthesis [57]. SRPX, was originally isolated 
as a suppressor of v-src transformation [58]. Subsequent reports found that SRPX 
induced apoptosis through an ER-dependent pathway and suggested that this 
pathway might contribute to the suppression of tumour formation [59]. The 
interaction of HAX1 and PELO was then confirmed by GST-pull down and co-
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immunoprecipitation studies [56]. This study also employed bimolecular 
fluorescence complementation assays (BiFC assay) to show the interactions between 
PELO and HAX1, EIF3G or SRPX and these were mainly localised to cytoskeletal 
filaments in HeLa cells [56]. This approach is based on the complementation 
between two non-fluorescent fragments of EGFP, which are brought together by 
interaction of two proteins fused to each EGFP fragment, resulting in visualisation of 
the restored fluorescence in living cells [60]. Cells transfected with either both empty 
vector or with either PELO-GFPC (full length PELO cDNA in-frame to the C-
terminal half of EGFP) or HAX1-GFPN (N-terminal half of EGFP fused with 178-
279 a.a of HAX1) alone did not show any fluorescence [56]. In contrast, cells co-
transfected with PELO-GFPC and HAX1-GFPN displayed fluorescence, which was 
accumulated mainly at the cytoskeletal filaments [56]. Moreover, overexpression of 
PELO showed disassembly of actin stress fibres and reduction in cell spreading 
(measurement of spreading velocity was done according to the distinct differences in 
surface area and morphology of adherent cells) in Hep2G cells, reminiscent of the 
Gα13 study described above (a phenomenon caused by HAX1 overexpression) 
[49,56].  
In a separate study, HAX1 (and another 11 molecules) was identified as a binding 
partner for supervillin [61]. Supervillin is a cytoskeletal protein that regulates cell 
motility and the authors showed transfection of a.a. 144–279 of HAX1 (supervillin-
binding sequence of HAX1) decreased HeLa cell spreading on fibronectin [61]. 
Interestingly, supervillin also physically associated with one of the binding partners 
of HAX1: cortactin [62]. The interaction of these molecules may play a role in cell 
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motility regulation and further investigation is needed to develop a detailed 
mechanism.  
The urokinase-type plasminogen activator receptor (uPAR) is an important regulator 
of ECM proteolysis [63]. The interaction with its ligand, the serine protease 
urokinase-type plasminogen activator (uPA; also known as urokinase), regulates the 
cleavage of plasminogen and this leads to ECM degradation and facilitates cell 
penetration of tissue boundaries [63] (see1.2.3.2). HAX1 has been identified as a 
binding partner for uPAR by yeast two-hybrid screening of a breast cancer cDNA 
library and this was confirmed by GST-pull down, co-immunoprecipitation assays 
and confocal microscopy [64]. Additional studies from the same lab showed that the 
endogenous HAX1 is localised in the cytoplasm (however the possibility for HAX1 
to be localised in mitochondria or ER was not demonstrated) in human embryonic 
kidney, HEK293, cells and human breast cancer, MDA-MB-231 cells, [65].  Upon 
the stimulation to activate uPAR with EGF (epidermal growth factor), uPA, or uPA-
ATF (amino-terminal fragment of uPA), HAX1 redistributed and colocalised with 
uPAR in the cell membrane, suggesting a physiological role for HAX1 in the 
regulation of uPAR signal transduction [65]. Overexpression of HAX1 in HEK293 
and MDA-MB-231 cells increased the cell migration upon uPA and EGF stimulation 
[65]. 
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1.1.4.3.3 HAX1 regulates cell migration by mediating endocytosis of integrin 
αvβ6  
The integrin αvβ6 expression is low or absent on resting epithelial cells and the 
enhanced expression of this integrin is linked to various cancers and also indicates 
more aggressive invasive carcinoma cell behaviour and poorer clinical prognosis 
[66-70]. By using the yeast two-hybrid assay, HAX1 (a.a 270-279, the sequence in 
the C-terminal end which is encoded in the HAX1 isoform 1, 2, 4 and 5) was 
identified as a binding partner for the β6 cytoplasmic tail  (a.a 731-758, which 
incorporates the juxtamembrane region and cytodomain 1) from a human 
keratinocyte cDNA library [1]. This binding was confirmed by co-
immunoprecipitation [1]. By using a siRNA targeting to HAX1 in oral squamous 
carcinoma cell lines, VB6 and H400, migration on the v6-specific ligand latency 
associated peptide (LAP) was significantly decreased whereas migration toward 
laminin, type 1 collagen, and vitronectin, mediated by non-v6  integrins was 
unaffected by HAX1 depletion [1]. During cell migration, integrins internalise 
continually from the plasma membrane into endosomal compartments, and recycle 
back to the cell surface [33]. To investigate the mechanism of HAX1 in v6 
regulation, the membrane permeant peptide Tat (from HIV-1) was synthesised as a 
conjugate with the β6-binding site of HAX1 (HAX1 peptide) [1]. This HAX1 
peptide was shown to disrupt completely the intracellular interaction of HAX1 and 
β6 by co-immunoprecipitation [1]. With the HAX1 peptide treatment, Clathrin-
dependent internalisation of v6 was significantly decreased, and there was 
decreased cell migration and invasion [1]. These data imply that the interaction of 
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HAX1 and v6 is crucial for cancer cell migration and invasion; this study was the 
first to reveal that HAX1 possibly plays an important role in cancer progression [1]. 
 
Figure 1.3 Schematic model of how HAX1 regulates integrin v6-mediated 
cell migration and invasion.   
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1.1.4.3.4 HAX1 regulates cell migration via RhoA 
Severe congenital neutropaenia (SCN or Kostmann‟s disease) is an inherited disorder 
due to nonsense HAX1 mutations and premature stop codons [16,71]. The SCN 
patients are vulnerable to recurrent infections caused by lack of mature neutrophils in 
peripheral blood (absolute neutrophil count is less than 1500 cell/ mm
3
) [71]. A 
recent study showed HAX1 regulates motility of neutrophils by modulating the 
localised polarity of F-actin dynamics [20]. HAX1-deficient neutrophils revealed 
less F-actin at the uropod compared with the control cells, implying that HAX1 
regulates the polarity of F-actin dynamics and rear detachment [20]. The same study 
also observed these HAX1-deficient cells displayed impaired motility and an 
elongated uropod during chemotaxis on fibrinogen [20]. The abnormal uropod 
morphology and detachment phenotype are similar to that which has been reported 
previously with Rho inhibition [72], suggesting that HAX1 may modulate rear 
retraction by regulating Rho GTPase signalling. Pull-down assays demonstrated that 
RhoA activation was significantly decreased in HAX1-deficient neutrophils 
stimulated with N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP, a strong 
chemoattractant for neutrophils) [20]. In contrast, Rac activation was increased in 
HAX1 knockdown cells [20]. Moreover, depletion of RhoA increased neutrophil 
adhesion and impaired migration, and constitutively active RhoA rescued adhesion 
and partially rescued motility of HAX1-deficient neutrophils suggesting that HAX1 
regulates neutrophil adhesion and chemotaxis through RhoA [20]. 
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1.1.4.3.5 HAX1 regulates cell migration via CXCR4 
HAX1 was recently shown to regulate the expression of CXCR4, a chemokine 
receptor tightly linked to lymphocyte homeostasis and cancer [73]. CXCR4-
expressing cells migrate towards its receptor CXCL12, which is expressed by bone 
marrow stromal cells and this is crucial for B cell maturation [73]. In a study 
investigating lymphocyte development, HAX1-knockdown B cells from HAX1-
deficient mice showed a significantly reduced expression of CXCR4 [73]. This 
decreased expression of CXCR4 has been suggested to cause the impaired migratory 
behaviour of B-cell precursors resulting in a failure to be retained in the bone 
marrow [73]. It will be interesting to further investigate the relationship of HAX1 
and CXCR4 in a cancer environment. 
In summary, HAX1 is reported to mediate cell migration by binding to multiple 
cytoskeleton associated molecules, including Gα13, Cortactin, PKD2, PELO, which 
contribute to actin dynamics. HAX1 also mediates endocytosis for the integrin αvβ6 
and this process is crucial for cell migration. Table 1.3 shows a brief review of how 
HAX1 regulates cell migration by different pathways. 
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Pathway Cell lines Mechanism 
uPAR HEK, 
MDA-231  
Endogenous HAX1 is showed to localise with uPAR 
upon stimulation, and the exogenous HAX1 is shown 
to increase cell migration in scratch wound healing 
assays [65]. 
Grb-7 HeLa  It is proposed that HAX1 regulates migration via 
interaction with protein Grb-7 [53]. 
Supervillin HeLa,  
COS7-2  
Supervillin and its interaction partners coordinate 
actin and microtubule motors and therefore facilitate 
cell movement [61]. 
PELO HeLa Interactions between PELO and HAX1 are mainly 
localised to cytoskeletal filaments [56] 
RhoA PLB-985 HAX1 knockdown in neutrophils showed decreased 
RhoA-GTP level and this is associated with changes 
in neutrophil uropod detachment and directed 
migration. Constitutively active RhoA rescues 
adhesion and partially rescues motility of HAX1-
deficient neutrophils suggesting that HAX1 regulates 
neutrophil adhesion and chemotaxis through RhoA 
[20]. 
Gα13 COS-7,  
NIH3T3  
HAX1 binds to Gα13 and exogenous HAX1 
overexpression showed reduction of the formation of 
actin stress fibres and focal adhesion complexes and 
increased cell migration in Gα13-expressing cells 
[49].  
CXCR4 mouse splenic 
B lymphocytes 
Real-time PCR showed a reduced CXCR4 
expression of HAX1-deficient B cells. The authors 
suggested this caused the observation of defects in 
B-cell development owing to the failure of B cell 
migration [73]. 
αvβ6 VB6 and H400 HAX1 regulates oral cancer cell migration via 
clathrin-mediated integrin αvβ6 endocytosis [1]. 
Table 1.3 HAX1 regulates cell migration via different pathways. 
50 
 
1.1.4.4 HAX1 and autophagy 
1.1.4.4.1 Autophagy 
Autophagy is a cellular mechanism that has been described as a “self-eating” process 
[74]. In normal cellular homeostasis, autophagy is a cellular function that contributes 
to the removal of damaged organelles and misfolded proteins by directing them to 
lysosomal degradation [75]. In stress situations, autophagy also is activated to 
degrade intracellular materials to provide a source of energy, thereby enabling cells 
to survive during harsh conditions, such as nutrient deprivation or the treatment to 
induce inhibition of mammalian target of rapamycin (mTOR) [75]. Autophagic flux 
is a term which refers to the complete process of autophagy which begins with the 
formation of the phagophore and ends with end stage autophagosomes [76-78]. The 
general process of autophagy involves sequestration of cytosol contents into a 
double-membrane vesicle, termed the autophagosome, which will then fuse with 
lysosomes to become an autolysosome where the cargo is degraded by acidic 
lysosomal enzyme [79]. The kinase mTOR is a critical regulator of autophagy 
induction, with activated mTOR (via Akt and MAPK signalling) suppressing 
autophagy, and negative regulation of mTOR (via AMPK and p53 signalling) 
promoting it [80]. Once mTOR kinase is inhibited, the Unc-51-like kinase1 (ULK1) 
is activated and forms a large complex with the autophagy-related gene13 (Atg13) 
and the scaffold protein FIP200 [80].  This complex leads to the recruitment of the 
downstream mammalian homologue of yeast Atg6 (Beclin-1) complex which 
includes class III phosphatidylinositol-3-OH kinase (PI3K), Atg14 and the 
mammalian homologue of yeast Vps15 (P150) [75,81]. The Beclin-1 complex then 
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induces the sequestration process which requires a group of Atg proteins for the 
formation of the autophagosome [82]. The initial sequestering compartment is called 
the phagophore and it is controlled by two conjugation systems: Atg12 system and 
the microtubule-associated protein 1 light chain 3 (LC3b or Atg8) system [82]. 
Atg12-conjugation is essential for the formation of the phagophore whereas LC3-
modification is essential for the formation of autophagosomes [83]. Atg12 is 
activated by Atg7 and Atg10 and then conjugates to Atg5 and subsequently interacts 
with Atg16 to form a large complex to initiate the early stage of the phagophore [82]. 
After translation, LC3/Atg8 is cleaved at its C terminus by Atg4 protease to generate 
the cytosolic LC3-I [80]. LC3-I is activated by Atg7, transferred to Atg3, and 
conjugated to phosphatidylethanolamine (PE) as the lapidated form LC3-II [84]. 
LC3-II is then attached to the autophagosome membrane and often is used as an 
autophagosomal marker [85]. Sequestosome-1 (p62), a ubiquitin-binding protein, 
binds LC3 and ubiquitylated proteins and might contribute as a cargo receptor for 
autophagic degradation, so that the autophagosome contains only its cargo and 
excludes other cytosolic components [84]. 
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Figure 1.4 A schematic model illustrating the autophagy pathway.  
Picture adapted from [86]. 
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1.1.4.4.2 The role of HAX1 in autophagy 
A recent study reported the direct linkage of HAX1 to autophagy. Li et al aimed to 
understand the role of Omi/HtrA2 in neuron degenerative disease [87]. Omi/HtrA2 is 
an homotrimeric serine protease that localises to the mitochondria and promotes 
apoptosis by both caspase-dependent and caspase-independent pathways [88,89]. 
The involvement in autophagic-mediated cell death pathway was therefore 
investigated. As HAX1 was previously reported as a specific substrate of Omi, the 
role of HAX1 was also investigated in this study [30]. Overexpression of Omi/HtrA2 
decreased the level of endogenous HAX1 in HeLa cells, therefore these authors 
investigated whether HAX1 regulates autophagy through interaction/regulation of 
Beclin-1 which is similar to other Bcl-2 family proteins [87]. Overexpression of 
HAX1 attenuated Omi/HtrA2-induced autophagy and also decreased LC3b-II level, 
and this inhibition is rescued by overexpression of Beclin-1 [87]. By 
immunoprecipitation and GST pull-down, HAX1 has been found to bind to Beclin-1 
and to repress autophagy [87]. Moreover, a HAX1 mutant that was designed to 
delete the Omi/HtrA2 binding sequence, demonstrated the enhanced inhibition of 
Omi/HtrA2-induced autophagy, suggesting Omi/HtrA2 activates autophagy by 
binding and cleaving HAX1, therefore abolishing its ability to inhibit Beclin-1 [87]. 
The authors suggested further that HAX1 can be digested by Omi/HtrA2 to elicit 
autophagy in response to autophagic stimuli or to stimulate apoptosis when cells 
ultimately are sentenced to die [87] (Figure 1.5).  
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Figure 1.5 A schematic model illustrating the role of Omi and HAX1 in the 
regulation of autophagy through the Beclin-1 pathway.  
Picture modified and adapted from [87]. 
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1.1.4.5 HAX1 and apoptosis 
In the original study from Suzuki et al, it was suggested that HAX1 contained 
sequences homologous to the anti-apoptotic protein Bcl-2 and therefore a 
proapoptotic function was proposed for HAX1 [3]. Although a later study showed, 
by sequence analysis and secondary structure prediction, that HAX1 is extremely 
unlikely to be a Bcl-2-family-related protein because it lacks Bcl-2 homology 
modules [90], after more than a decade since the discovery of HAX1 its anti-
apoptosis function has become the most well-established biological role assigned to 
HAX1. Many studies have discovered various different anti-apoptotic mechanisms 
of HAX1 to protect cells from cell death, these include inhibiting caspases; 
maintaining mitochondria membrane integrity and modulating calcium homeostasis 
in the sarcoplasmic reticulum. It is also reported that many viral proteins interact 
with HAX1 to hijack the anti-apoptosis function in order to replicate in the surviving 
host cells. In the following sections I will discuss the molecular mechanisms of 
apoptosis and then review the antiapoptosis functions ascribed to HAX1. 
1.1.4.5.1 Cell apoptosis 
Cell apoptosis is a type of programmed cell death that plays a fundamental role in 
development and tissue homeostasis (such as in development, wound healing and 
intestinal cell turnover) by eliminating excess cells [91,92]. Apoptosis typically is 
induced via two pathways: the intrinsic and the extrinsic pathways. Both 
mechanisms result in similar morphological changes, including cell rounding, 
pseudopod retraction, reduction of cellular volume, chromatin condensation, nuclear 
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fragmentation (karyorrhexis), plasma membrane blebbing, but little or no 
ultrastructural modifications of the cytoplasmic organelles [93,94]. The apoptosis 
process is executed by a cascade of caspase (cysteinyl, aspartate-specific proteases) 
family members which cleave and activate their own substrates at short tetrapeptide 
recognition motifs terminating in an aspartate residue (X-X-X-Asp) [95]. The 
caspases are divided into two groups: initiators (caspase-2, 8, 9) and effectors 
(caspase-3, 6, 7) and they are synthesised as inactive zymogens containing several 
domains: an N-terminal prodomain (for initiator caspases), a large subunit (p20) and 
a small subunit (p10) (Figure 1.6) [95,96]. The prodomains of initiator caspases 
contain further distinct motifs: the death effector domain (DED) and the caspase 
recruitment domain (CARD) (Figure 1.6) [97]. These domains interact between 
procaspases and their adapters and consequently lead to caspase activation [97]. The 
large and small subunits are then cleaved and this induces proximity of two caspase 
monomers which promote and lead to the formation of an active caspase tetramer 
that contains two small and two large subunits [95,98]. Initiator caspase activation 
induces the activation of the downstream executioner caspases which can cleave 
various death substrates to induce apoptosis [97]. 
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Figure 1.6 Schematic of the structure of caspases.  
Caspases contain three main domains: a prodomain and large (p20) and small (p10) 
catalytic subunits. The large domain contains the active site Cys residue. Activation 
of caspases involves the proteolytic cleavage of zymogens, the removal of the 
prodomain and separation of the p20 and p10 subunits, or allosteric conformational 
changes. The prodomains of activator and inflammatory caspases contain protein–
protein-interaction domains (such as the caspase-recruitment domain (CARD) and 
the death-effector domain (DED) that link them to apoptosis signalling molecules 
[96]. 
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Apoptosis can be induced by various factors and, as mentioned, this is divided into 
two major pathways: intrinsic and extrinsic [99]. The intrinsic pathways, also known 
as the mitochondrial pathway or stress pathway, are activated by a range of stress 
stimuli including DNA damage, cytoskeletal damage, endoplasmic reticulum stress, 
growth-factor deprivation and oncogenic factors [100]. These intrinsic activations 
trigger translocation of proapoptotic Bcl-2 family members (e.g. Bid or Bax) to the 
mitochondrial cytosol. In particular, Bid is cleaved by caspases or other proapoptotic 
proteases to form truncated Bid (tBid), which then localises to the mitochondria 
[101]. Here, tBid interacts with other proapoptotic Bcl-2 member proteins such as 
Bax and/or Bak, resulting in pore formation and permeabilisation of the outer 
mitochondrial membrane permeabilisation (MOMP) [100,101]. MOMP is the „point 
of no return‟ during apoptosis as it results in the release proapoptotic molecules into 
the cytosol from the mitochondria intermembrane space including cytochrome c, a 
second mitochondria-derived activator of caspase (SMAC; also known as DIABLO), 
and HtrA2/Omi [94,100]. After release from mitochondria, cytochrome c binds to 
the apoptotic protease activating factor 1 (APAF1) forming a structure termed the 
apoptosome [102]. The apoptosome recruits, and activates, the initiator caspase-9, 
which then cleaves and activates its effector caspases-3 and -7 [94]. Moreover, along 
with other molecules released from mitochondria, cytochrome c, DIABLO and 
HtrA2/Omi also can bind directly to X-linked inhibitor of apoptosis protein (XIAP) 
which antagonises its ability to inhibit caspases [88,103,104] (Figure 1.7). 
The extrinsic pathway involves the stimulation of various cell-surface 
transmembrane death receptors such as Fas (CD95), tumour necrosis factor-α (TNF-
α) or the granzyme/perforin system [105-107]. Death receptor stimulation results in 
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the formation of death-inducing signalling complex (DISC) by the adaptor proteins 
Fas-associated death domain protein (FADD) and TNFR-1-associated death domain 
protein (TRADD) and these act as platforms for the activation of pro caspase-8 
[108]. This further activates the downstream caspase-3 and caspase-7 and also 
activates intrinsic signalling through the cleavage of Bid (Figure 1.7). 
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Figure 1.7 The caspase cascade in cell apoptosis.  
Both the intrinsic and extrinsic pathways use related principles in sensing an 
apoptotic signal and executing apoptosis. In the intrinsic pathway, an apoptotic 
stimulus in the cell leads to the assembly of the apoptosome, which activates 
caspase-9. An extrinsic apoptotic signal, by contrast, is mediated by binding of an 
extracellular ligand to a transmembrane receptor, leading to the formation of the 
death-inducing signalling complex (DISC), which is capable of activating the 
initiator caspase-8. Once activated, either caspase-9 or caspase-8 cleaves executioner 
caspase-3 and caspase-7 and leads to apoptosis. Picture adapted from [101]. 
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1.1.4.5.2 HAX1 and associated viral proteins in apoptosis 
HAX1 has been reported to interact with a number of viral proteins including: 
Epstein-Barr virus nuclear antigen 5 (EBNA5, also designated as Epstein-Barr virus 
Nuclear Antigen leader protein, EBNA-LP) from Epstein-Barr virus (EBV) [27,29], 
K15 from Kaposi‟s sarcoma-associated herpes virus (KSHV) [12], Vpr and Rev 
protein from Human Immunodeficiency Virus (HIV) [38] [26], HCV core protein 
from Hepatitis C Virus (HCV) [109] and N
pro
 from classical swine fever virus 
(CSFV)[110]. Viruses have developed multiple strategies to regulate host cell 
apoptosis for their own benefit. Many viral proteins are capable of binding to 
apoptosis-associated molecules in order to suppress apoptosis in infected cells. For 
example, the Epstein–Barr nuclear antigens (EBNA) 3A and 3C (EBNA3A and 
EBNA3C) protected Burkitt's lymphoma cells from various cytotoxic drugs by 
downregulating the proapoptotic Bcl-2-family member Bcl-2-interacting mediator of 
cell death (Bim), and hence reduce the propensity of host cells to undergo apoptosis 
[111,112]. Potentially, HAX1 binds and destabilises viral proteins by altering their 
distribution and therefore affect cell apoptosis. In this section, I will overview the 
current understanding of, and the impact of, the interaction between HAX1 and 
different viral proteins. 
It has been demonstrated that EBNA5 physically associates with HAX1 in the 
cytoplasm in COS-7 cells and predominantly in mitochondria in the DG75 Burkitt‟s 
lymphoma cell line [27,29]. EBNA5 is one of the proteins produced in EBV-infected 
cells and it is responsible for the immortalisation of those infected cells [112]. 
Although there was no further information on the interaction, it was suggested that 
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the possible role of HAX1 was in preventing cell death of EBV-infected cells 
[27,29]. 
In contrast to these findings, another study showed that the role of HAX1-viral 
protein interaction was to destabilise the viral RNA. HAX1 interacts with two HIV 
(Human Immunodeficiency Virus) proteins: Rev and Vpr [26,38]. Rev protein 
recognises and exports viral RNA which carries the RRE (Rev-response element) 
sequence, shuttling between the nucleus and the cytoplasm in a complex with RRE-
containing RNA [38]; this is crucial for the expression of unspliced, or singly 
spliced, viral mRNA that encodes the structural (Gag, Pol, and Env) and accessory 
(Vif, Vpr, Vpu) proteins [113]. HAX1 binds to and inhibits Rev from binding to its 
target RRE RNA, consequently causing destabilisation and degradation of viral RNA 
in the host cell nucleus; thus suggesting that HAX1 provides protection against 
virally infected cells [38]. Another study showed HAX1 interacts with Vpr (Human 
immunodeficiency virus type 1 viral protein R) and caused a protein redistribution 
[26]. Vpr is required for viral pathogenesis and has been implicated in T-cell 
apoptosis through its destabilisation of mitochondrial membrane potential and 
subsequently activation of caspase-3 and caspase-9 [26]. Overexpression of Vpr 
causes the egress of HAX1 from the mitochondria into the cytoplasm and this 
resulted in mitochondrial instability and cell death [26]. Conversely, overexpression 
of HAX1 suppressed the pro-apoptotic activity of Vpr [26].  Together, these studies 
support the notion that Rev and Vpr share some common steps that interface with the 
nuclear import/export pathways modulated by HAX1. Furthermore small peptides 
that mimic HAX1, and specifically interfere with the pathway(s) shared by Rev and 
Vpr, could provide a valuable therapeutic approach against AIDS [26]. 
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Although the majority of studies demonstrated the anti-apoptosis function of HAX1, 
there is a study which has reported a converse function of this molecule. Banerjee et 
al reported that decreased HAX1 levels promoted cell apoptosis in the presence of 
HCV (Hepatitis C Virus) core protein after treatment with 5-fluorouracil (5-FU) 
[109]. 5-FU is a drug which is known to modulate p53 and is used widely for cancer 
treatment, such as against gastrointestinal, pancreatic, breast, bladder and prostatic 
cancers [114]. 5-FU belongs to the antimetabolite class of chemotherapy agents and 
interrupts the cell cycle by interfering with DNA synthesis through the inhibition of 
the enzyme thymidylate synthase in cancer cells, ultimately causing cell death [114]. 
Previous studies have shown that 5-FU treatment results in activation of p53 [115]. 
HCV core protein is a viral protein that enhances HCV infected cells to become 
immortalised, resulting in chronic infection and hepatocellular carcinoma [109]. In 
this study, the authors reported that HepG2 cells expressing HCV-core protein were 
more susceptible to 5-FU-induced growth inhibition than control cells, whereas cell 
survival was enhanced after suppression of HAX1 by small interfering RNA [109]. 
Depletion of HAX1 by siRNA did not significantly alter the status of p53 after 5-FU 
treatment in HepG2 cells [109]. Interestingly, the reduction of HAX1 in core-
expressing cells by siRNA prior to 5-FU treatment led to the loss of p53 
enhancement in response to treatment, indicating that HAX1 itself cannot potentiate 
the accumulation of p53 [109]. The same study also showed suppression of HAX1 
by siRNA did not significantly increase procaspase-9 cleavage in core-expressing 
hepatocytes after 5-FU treatment compared to cells treated with unrelated siRNA as 
a negative control [109]. Thus the HCV core protein can potentiate the activity of 5-
FU through the induction of p53, and subsequent cell death, via a mechanism that 
relies upon the expression of HAX1 [109]. 
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1.1.4.5.3 HAX1 regulates apoptosis by regulating caspase activity 
Apoptosis requires the activity of a group of cysteine-dependent proteinases known 
as caspases. Apoptosis, or programmed cell death, results in the permeabilisation of 
mitochondria and release of the apoptotic-activating protein cytochrome c into the 
cytosol, which then results in activation of caspase-9 and caspase-3 that drives 
apoptosis [116] (see section 1.1.4.5.1 ). 
A study from Li and colleagues, using flow cytometry, showed that HAX1 siRNA 
treatment increased the sub-G1 fractions (often apoptotic cells) in melanoma cells 
and this observed cell death was blocked by a broad-spectrum caspase inhibitor, Z-
VAD-fmk, indicating that HAX1 protects cells from apoptosis by inhibiting caspases 
[117]. Although there were no further experiments from this study, to investigate 
which specific caspase was involved in those cells, the data indicated caspase-
dependent apoptosis is induced by the absence of HAX1 [117].  
In other studies, HAX1 has been found to interact with caspase-3 and caspase-9 and 
subsequently blocks their activation, and thus, the cell apoptosis pathway, protecting 
cells from programmed cell death [21,28,118,119]. In cardiac research, HAX1 is a 
survival factor for cardiac cells exposed to hypoxia and protects cells from apoptosis 
by inhibiting activated caspase-3 and  -9 [28]. In the first study that reported the 
physical interaction between HAX1 and a caspase, Han et al found caspase-9 was 
expressed to a significantly higher level in normal adult cardiac tissue (specifically 
cardiac myocytes) compared with other tissues (brain, liver, kidney, lung, skeletal 
muscles, spleen), but these cells were, strangely, resistant to caspase-induced cell 
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apoptosis [21]. In order to investigate this, wild type procaspase-9 was used as bait 
in a yeast-two-hybrid study and HAX1 was identified as a binding partner of this 
molecule [21]. Full length HAX1 also was pulled-down with caspase-9-GST [21]. In 
addition, a co-immunoprecipitation assay, using human anti-caspase-9 and anti-
HAX1 antibodies, further confirmed the interaction of caspase-9 and HAX1 [21]. To 
define the effect of the interaction, HAX1 function was examined in a cell-free 
caspase activation system [21]. In this system, the addition of in vitro translated 
caspase to a mixture of cytochrome c/dATP and S100 fraction results in caspase 
processing [21,120,121]. The result showed HAX1 not only inhibited the activation 
of caspase-9 but also caspase-3 and the overexpression of HAX1 revealed its 
protection of cardiac myocytes from H2O2-induced apoptosis through blocking 
caspase-9 activation [21]. This was the first paper describing HAX1 protection of 
cell death by directly interacting with and inhibiting caspases-9 and -3 [21]. Thus 
HAX1 negatively regulates caspase family members and thereby exerts an anti-
apoptosis effect in cardiac myocytes (Figure 1.8) [21].  
X-linked inhibitor of apoptosis protein (XIAP) is a member of the IAP (inhibitor of 
apoptosis protein) family and it is known to prevent apoptosis by inhibiting caspase-
3, -7 and -9 [122]. XIAP interacts with caspase-9 in the cytosol by binding to the 
active caspase-9-Apaf-1 holoenzyme complex through the amino terminus of the 
linker peptide on the small subunit of caspase-9, exposed after proteolytic processing 
at Asp315 [122]. During apoptosis, the protein level of XIAP is regulated by 
ubiquitination [123]. To investigate whether HAX1 may affect the ubiquitination of 
XIAP, Kang et al performed in vitro ubiquitination assays [123]. GST-XIAP was 
expressed in HEK 293T cells with or without FLAG-HAX1 and HA-ubiquitin, and 
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GST-XIAP was then isolated by incubation with glutathione agarose beads [123]. In 
the absence of FLAG-HAX1, polyubiquitinated XIAP was identified as a ladder of 
protein bands [123]. In contrast, the addition of FLAG-HAX1 significantly 
suppressed the level of ubiquitinated XIAP, indicating that the interaction between 
HAX1 and XIAP blocked the polyubiquitination of XIAP [123]. The cell viability 
was also measured by CCK-8 assay and the data showed that HAX1-XIAP 
interaction inhibited cell death triggered by Etoposide in HEK293 cells (data did not 
show HAX1 alone) [123]. Taken together, it was suggested that the association of 
HAX1 and XIAP provided protection to XIAP from degradation via poly-
ubiquitination, thereby inhibiting cell apoptosis [123]. 
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Figure 1.8 Apoptosis pathways in cardiac myocytes.   
Death signal (stress-inducing stimuli) activate apoptosis by depolarising 
mitochondria and opening permeability transition pores. Pro-apoptotic factors, such 
as cytochrome c, Smac (second mitochondrial activator of caspases), AIF (apoptosis-
inducing factor), Omi/HtrA2, are then released into the cytoplasm. Cytochrome c 
and pro-caspase-9 from the apoptosome trigger the activation of downstream 
caspase-3, -6, -7 to execute cell apoptosis. In the presence of HAX1, caspase-9 is 
blocked thereby blocking downstream death factors. Figure adapted from [119].  
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1.1.4.5.4 HAX1 modulates calcium homeostasis in the sarcoplasmic reticulum 
(SR) 
Cardiac function is tightly controlled by calcium regulation. When the demand 
arises, the heart can respond to the stress and increase blood flow to peripheral 
tissues immediately [124].  Adrenaline is the hormone that, when released into blood 
by demand, initiates an important signal-transduction pathway in the heart by 
binding to β-adrenergic receptors in the cardiac myocyte cell membrane [124]. The 
activated adrenaline receptor can phosphorylate the downstream molecules and 
subsequently increases cell contraction by elevating the cytosolic calcium 
concentration [125]. The sarcoplasmic reticulum (SR) is the calcium storage site in 
cardiac cells, and the Ca
2+
 can be transported to the cytoplasm by phospholamban 
(PLN) and its substrate, also a Ca
2+
 pump, SR calcium ATPase (SERCA) [126]. PLN 
is a small integral membrane protein (52 residues) localised in the SR membrane, 
and it mediates downstream signals for the adrenaline-signalling pathway upon 
stimulation [125]. PLN can be reversibly phosphorylated and its phoshorylation 
status regulates the calcium flow [127]. Unphosphorylated PLN binds to and inhibits 
SERCA, the enzyme which is a calcium pump, that is responsible for calcium re-
uptake into the SR lumen from the cytosol, by reducing its affinity for calcium [126]. 
The inhibition of SERCA results in an elevated cytosolic Ca
2+
 level and initiation of 
the heart muscle contraction [126]. To allow muscle relaxation between the heart 
muscle contractions, cytosolic Ca
2+
 needs to be decreased rapidly. Upon adrenergic 
stimulation, protein kinase A phosphorylates PLN and this releases the inhibition to 
SERCA and therefore restores SERCA activity, as a result cytosolic Ca
2+
 is 
decreased as Ca
2+
 is transported back to the SR, and causes muscle relaxation [125].  
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These events are responsible for normal heart functioning and if disrupted may lead 
to heart failure [128]. 
In order to investigate further the mechanism of the regulation of PLN/SERCA, 
Vafiadaki et al used the yeast two-hybrid approach to identify additional proteins 
that may interact with PLN [28]. In this study, HAX1 was identified to interact with 
PLN from an adult human cardiac cDNA library and this was confirmed by GST-
pull down in human and mouse cardiac cells [28]. The binding region of HAX1 for 
PLN was in the C-terminal fragment (a.a. 203–245), whereas the PLN binding 
region contained residues 16–22, a region that includes both the Ser16 and Thr17 
phosphorylation sites [28]. It has been shown that PLN can be phosphorylated at 
three distinct sites: Ser16 by cAMP and cGMP dependent protein kinases (PKA and 
PKG, respectively), Thr17 by Ca
2+–calmodulin-dependent protein kinase II 
(CaMKII), and Ser10 by protein kinase C (PKC) [127,129]. These data imply HAX1 
may play an important role in regulating the activation of PLN. The study also 
showed phosphorylation of PLN, or elevation of the concentration of Ca
2+
,
 
led to 
dissociation of exogenous HAX1 from PLN [28]. Phosphorylation of PLN by cAMP 
dependent protein kinase reduced binding to HAX1, while increasing concentrations 
of Ca
2+
 diminished the PLN/HAX1 interaction in a dose dependent manner , and this 
is similar to the findings on the PLN/SERCA2a interaction, implicating the 
physiological/pathophysiological significance of PLN/HAX1 association in cardiac 
muscle [28]. The same study also showed the presence of PLN enhanced the HAX1 
protective effects from hypoxia/reoxygenation induced HEK293 cell death measured 
by the MTT assay [28]. These findings imply a possible link between the Ca
2+
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handling by the sarcoplasmic reticulum and cell survival mediated by the 
PLN/HAX1 interaction [28]. 
Interestingly, HAX1 is in fact a binding partner for both PLN and its substrate 
SERCA2 with almost an identical binding domain (a.a. 203-225 for PLN, and aa. 
203-245 for both PLN and SERCA2) reported by the same group in a subsequent 
study [28,130]. PLN can exist as an oligomer, in which form it is unable to bind to 
SERCA2 [130]. The study showed that HAX1 overexpression enhanced formation 
of PLN monomers which are active for binding with SERCA2, and promoted the 
inhibition to SERCA2 [130]. The authors also showed that both elevated calcium 
level and phosphorylated PLN can reduce the PLN/SERCA2 and PLN/HAX1 
interaction [28,130]. PLN also played a role of modulating HAX1 expression as 
decreased HAX1 mRNA and protein were found in PLN knockdown cells whereas 
PLN was not affected by HAX1 levels, indicating the PLN may be an upstream 
regulator of HAX1 [28]. The HAX1 expressing cells exhibited increased viability 
and cotransfection with PLN resulted in a further increase in cellular survival in the 
treatments of H2O2 and thapsigargin, a selective inhibitor of SERCA2, that induces 
apoptosis through ER stress after perturbation of Ca
2+
 levels [130]. On the contrary, 
co-transfection with SERCA2 caused a reduction in cell viability in HAX1 or in 
PLN/ HAX1 co-transfected HEK293 cells [130]. All together, these findings suggest 
that PLN enhances the protective role of HAX1 against cell death, but SERCA2 
promotes the opposite phenomenon, suppressing the antiapoptotic capacity of HAX1 
[28,130]. 
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Interestingly, studies showed other antiapoptotic proteins such as Bcl-2, BAX and 
BAK influence cell survival through regulation of ER Ca
2+ 
homeostasis by 
decreasing ER and mitochondrial Ca
2+
 levels [131-133]. These molecules also 
prevent sustained Ca
2+ 
increase in the cytoplasm and mitochondria that would trigger 
activation of cell death signalling cascades [131,132]. HAX1 presents a similar anti-
apoptotic role through the same pathway as these apoptotic proteins. Overall, the 
evidence indicates that HAX1 regulates SR/ER Ca
2+ 
homeostasis and this represents 
a critical determinant of cellular sensitivity to apoptotic stimuli in cardiac muscle 
[28,130].  
1.1.4.5.5 HAX1 regulates mitochondrial permeability by binding to 
Omi/HtrA2 and PARL  
High temperature requirement protein A ( HtrA2 also named as Omi) is a 
mitochondrial serine protease that belongs to the HtrA family of proteases [89]. The 
mammalian HtrA2 protease, Omi, is much better known than other HtrA family 
members for its proapoptotic activity [134]. Omi/HTRA2 resides in the 
mitochondrial intermembrane space and translocates to the cytoplasm where it binds 
to, and cleaves, its downstream substrates, inhibitor of apoptosis proteins (IAPs) and 
therefore facilitates caspase-dependent and caspase-independent apoptosis 
[88,89,134].  
To investigate the mechanism of Omi-induced apoptosis, Cilenti et al set out to 
isolate novel substrates that are cleaved by this protease and HAX1 was found to be 
a substrate of Omi/HtrA2 [30]. By overexpression of HtrA2/Omi, it was 
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demonstrated that HtrA2/Omi-mediated degradation of endogenous HAX1 
correlated with extensive cell death  induced by Etoposide, cisplatin and H2O2 in HK-
2 cells [30].  In contrast to Omi /HtrA2, endogenous HAX1 protein levels were 
significantly reduced but remained associated with mitochondria of cisplatin- and 
H2O2-treated HEK293 cells [30] Overexpression of HAX1 significantly increased 
resistance to cisplatin-induced apoptosis compared with cells transfected with the 
empty vector [30].  
In a separate study, a different role for HAX1 and Omi/Htra2 was suggested. Chao et 
al reported that HAX1 is a mediator which presents inactive Omi/HtrA2 to another 
mitochondrial protease PARL (presenilin-associated, rhomboid-like) [135]. 
Omi/HtrA2 contains a MTS (mitochondria-targeting sequence) which is cleaved in 
the active form [136]. Omi/HtrA2 binds to HAX1/PARL complex in the 
mitochondrial inner membrane and this interaction allows PARL to cleave the MTS 
(mitochondrial-targeting sequence) of Omi/HtrA2 and turns it into the processed 
form [135]. The cleaved Omi/HtrA2 is subsequently released to the mitochondrial 
inter-membrane space and removes pro-apoptosis proteins, such as active Bax, 
therefore promoting cell survival [135]. 
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1.1.4.5.6 HAX1 modulates cell apoptosis by interaction with a mitochondrial 
protein, PHB2 (Prohibitin 2) 
Prohibitin (PHB) comprises two subunits, PHB1 and PHB2,  and they are ubiquitous 
proteins that are mainly localised in mitochondria [137]. These two proteins 
assemble into a ring-like macromolecular structure at the inner mitochondrial 
membrane and protrude into the intermembrane space [138]. The first mammalian 
prohibitin (PHB1) was identified as a potential tumour suppressor with anti-
proliferative activity and hence was named prohibitin [139]. PHB2 was identified to 
repress nuclear estrogen receptor activity by interacting with and inhibiting the 
transcriptional activity of  the estrogen receptor [140]. To study the regulatory 
mechanism of PHB2 in mammalian cells, Kasashima et al identified HAX1,  ANT2 
(adenine nucleotide translocator 2) and VDAC2 (voltage-dependent anion channel 2) 
as binding partners for PHB2 using mass spectrometric analysis [141]. In PHB2 
knockdown HeLa cells, the endogenous HAX1 was down-regulated with associated 
cell apoptosis increased (by measuring cell count and staining with rhodamine123, 
which indicates decrease of mitochondrial membrane potential, and also cytochrome 
c); this evoked cell death was suppressed by caspase inhibitor Z-VAD-FMK, 
indicating apoptosis was caused by a caspase-dependent pathway [141]. In contrast, 
PHB2 protein levels were unchanged after HAX1 knockdown, suggesting PHB2 
might be an upstream regulator of HAX1 and thus PHB2 may prevent cell apoptosis 
through maintaining HAX1 levels [140]. 
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Figure 1.9 HAX1 forms a complex with PHB2 in mitochondria.  
HAX1, ANT2 (adenine nucleotide translocator 2), VDA2 (voltage-dependent anion 
channel 2), and PHB2 comprise a mitochondrial complex in the intermembrane 
space. PHB2 protects cell from apoptosis by interacting with HAX1 and maintains 
the mitochondrial morphology via OPA1 (optic atrophy 1). Figure adapted from 
[140]. 
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In conflict with these reports, a study from Jeyaraju and colleagues pointed out that 
HAX1 does not possess a C-terminal α-helix by sequence analysis, which is required 
for the transmembrane domain that anchors in mitochondrial membrane [90]. Also, 
HAX1 does not contain cysteine residues required for mitochondrial intermembrane 
space protein import through the MIA (mitochondrial intermembrane space 
assembly) pathway or any predictable mitochondrial import peptide [90,142]. The 
cell fractionation data showed that heavy membranes contain HAX1, but that the 
protein is absent in highly purified, intact mouse liver mitochondria preparations 
[90]. Thus the activity of HAX1 cannot be mechanistically coupled to PARL 
because the two proteins are confined in distinct cellular compartments in vivo, 
suggesting their interaction in vitro is an artefact [90]. The authors concluded that 
HAX1 is not imported inside the mitochondria, although it might be peripherally 
associated with the organelle [90]. 
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1.1.4.5.7 HAX1 regulates cell apoptosis in neutrophils 
In a recent paper demonstrating that HAX1 regulates neutrophil functions, it was 
shown that, a mild increase in the H2O2 induced apoptosis of HAX1-deficient cells 
compared with control cells by annexin V staining, suggesting that HAX1 modulates 
the sensitivity of  pro-apoptotic stimuli in the neutrophil-like PLB-985 cells [20]. 
1.1.4.6 Summary of HAX1 functions 
Thus the HAX1 protein has been implicated in various cellular functions with 
different binding partners: these functions include mediating endocytosis of 
membrane protein; promoting cell migration and invasion; possibly having a role in 
stabilising mRNA; autophagy regulation and anti-apoptosis. The HAX1 binding 
proteins and functions are summarised in Table 1.4 
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Proteins  Interaction in HAX1 
(isoform 1) 
Cell line studied  Functions  
Membrane proteins 
mIgE 50-279 J558L myeloma cells HAX1 protein levels influence Ag-internalisation 
efficiency [34] 
αvβ6  271-279 VB6 and H400 oral cancer cell 
lines  
The interaction promotes β6 internalisation and is 
required for cancer cell invasion [1] 
BSEP  - HEK293, MDCK, liver cells HAX1 and cortactin promote BSEP internalisation 
[31] 
Cytoplasmic proteins 
HS1  114-279  COS-7 cells Suggestion of regulating B cell signalling [3] 
PKD2  179-279  HeLa cells HAX1 links PKD2 to cell-matrix contacts [8] 
Gα13  176-247  COS-7, NIH3T3 cells  HAX1 promotes Gα13-mediated cell migration [49] 
IL-1  187-279  Skin fibroblast,HEK293 cells  The link between IL-1α and HAX1 suggest effects on 
cell motility/adhesion [11] 
PELO  176-279  HeLa cells  Suggestion of mediating cell migration or degradation 
of No-Go mRNAs [50] 
Supervillin  144-279  HeLa, COS7-2 cells Promotion of cell motility [61] 
XIAP 128-279 HEK293 cells Stabilises XIAP which inhibits apoptosis [143] 
PrP 38-129 293T Protect cells to resist the challenge of H2O2 
Grb7 - HeLa cells Possible  role in cell migration [53] 
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Mitochondrial proteins  
PHB2  - HeLa cells Stabilises mitochondrial morphology, anti-apoptosis 
[140] 
Caspase-9  175-206  Adult rat cardiomyocytes  Inhibits caspape-mediated apoptosis [21,119]  
Caspase-3 - HeLa cells Caspase-3 cleaves HAX1 at the Asp
127
, 
overexpression of HAX1 protects cell from apoptosis 
[118] 
Omi/HtrA2  187-235  HEK293, HK-2 cells  Omi/HtrA2 cleaves and degrades HAX1, activating 
apoptosis [30] 
PARL  79-100,187-235  COS-7 cells Processes Omi/HtrA2 and protects cell from cell 
death [135] 
 
ER protein  
PLN  203-225  Cardiac muscle, HEK293 cells Regulate ER/SR Ca2+ homeostasis and promote cell 
survival [28] 
SERCA2 203-245 HEK239 cells HAX1 promotes cell survival by binding and 
inhibiting SERCA2 [130] 
Nuclear proteins 
DNA polymerase 
β mRNA  
129-279 Rat hepatoma FTO-2B cells Post-translational regulation (stabilises) mRNA[32] 
Vimentin  - HeLa cells Suggestion of  helping mRNA translocation [35] 
Viral proteins  
EBNA-LP  - COS-7  cells Suggestion of the anti-apoptosis function in EBV-
infected cells [27,29] 
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Table 1.4 HAX1-interacting proteins.   
This table illustrates the HAX1 binding proteins described to date and catalogues them according to their subcellular localisations.  The HAX1 
binding regions for each are shown as the amino acid residue numbers (a.a.). The biological functions of the interactions between HAX1 and 
each protein are briefly explained in the Table.  
K15  109-279 HeLa cells Suggestion of viral-associates anti-apoptosis and 
invasion [12] 
Vpr  117-143  HeLa cells HAX1 inhibits apoptosis by suppressing Vpr [26] 
Rev  176-261  HEK293, COS-1 cells  HAX1 binds to Rev and inhibits its function to 
transport viral RRE-containing mRNA [38] 
HCV core protein - HepG2, Huh7, Hep3B cells Promote the growth inhibition in 5-FU-mediated 
apoptosis [109] 
N
pro
 - Max cells Regulate subcellular localisation N
pro 
[110]
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1.1.5 HAX1: a family of splice variants 
The human HAX1 gene is located on chromosome 1 (location 1q21.3, GenBank 
gene ID10456) and it has a processed pseudogene located on chromosome X (Xq28) 
[2]. To date, there are at least eight HAX1 variants identified in human tissue, which 
are generated by alternative splicing, encoding separate isoforms ranging in size 
from 15kDa to 32 kDa [2] (Figure 1.10 and Figure 1.11). Sequence comparison of 
the GenBank and VEGA (Vertebrate Genome Annotation Database) HAX1 entries 
revealed that the GenBank variant 1 is identical with VEGA HAX1-001 and that the 
GenBank variant 2 corresponds to the full-length version of VEGA HAX1-004. In 
my study, I follow the HAX1-001-to-HAX1-008 VEGA annotation referring to the 
isoforms as HAX1.1 to HAX1.8 (Figure 1.10). 
From previous work in my lab, the specific primers for HAX1 isoforms1-8 were 
designed based on the sequences published in GenBank and Ensembl and were used 
to screen a panel of 19 human cell lines as well as primary fibroblasts, primary oral 
keratinocytes and peripheral blood mononuclear cells [2]. All the cells expressed the 
HAX1 isoforms 1, 3, 5, 6, and 8 whereas the isoforms 2, 4 and 7 were absent in 
some of the cells [2]. All cells tested expressed six to eight HAX1 isoforms [2]. 
As shown in Figure 1.10 and Figure 1.11, the full length HAX1 isoform 1 (HAX1.1) 
contains seven exons and encodes a 279 a.a. protein (molecular mass = 31.62 kDa) 
[2]. HAX1.2 lacks the first exon, and uses an alternative start codon 27 bases inside 
exon 2 (of HAX1.1) and it is in-frame with the original stop codon, producing a 
protein that lacks the first 26 a.a., starting just 3 a.a. before the acid box  (molecular 
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mass = 28.64 kDa) [2]. HAX1.3 has intron retention between exon 2-3 and ends 11 
nucleotides before the original end of exon 3, resulting in a putative protein that is 
identical with isoform 1 for the first 105 a.a. and is followed by an unique and 
truncated C-terminus ending at a stop codon 56 nucleotides into intron 3 (molecular 
mass = 14.23 kDa) [2]. Isoform 4 uses an internal splicing site in exon 2, skipping 
the first 144 nucleotides of this exon [2]. This results in an internal deletion of 48 a.a. 
and produces a protein that lacks the acid box but retains an identical 3‟ end to 
HAX1.1 (molecular mass = 26.09 kDa) [2]. HAX1.5 contains an internal splice site 
at the end of intron 2 which introduces 24 nucleotides in-frame, resulting in an 8 a.a. 
insertion into the PEST sequence (positions 106–113) (molecular mass = 32.41 kDa) 
[2]. HAX1.6 uses an alternative splice site in exon 2, creating a 64 nucleotide 
deletion in the end of exon 2 and this introduces a frameshift with a unique C-
terminal end  from a.a. 84 in the isoform (molecular mass = 21.80 kDa) [2]. HAX1.7 
and HAX1.8 both start in exon 3; HAX1.7 has a retention in intron 4-5, and intron 5-
6 retained in isoform 8 [2].  This encodes a putative  HAX1.7 protein of 90 aa with 
the first 38 aa identical with HAX1.6 (a.a. 127–164) and a new C-terminal sequence 
for HAX1.7 (molecular mass = 10.02 kDa) [2]. The putative protein of HAX1.8 is 
65 aa long (molecular mass = 7.48 kDa) and is 100% identical with the last 65 a.a. of 
HAX1.6 [2]. Even the intron 5–6 is retained at the mRNA level in HAX1.8, this has 
no impact on the protein produced as it terminates 26 bases before this intron 
sequence [2]. The predicted protein sequences encoded by the mRNA and protein 
are depicted in Figure 1.10 and Figure 1.11. 
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Figure 1.10 Genomic structures of human HAX1 gene and mRNA splice 
variants.  
HAX1 genomic organisation: exons are shown in blue, introns are shown in gray and 
the alternatively spliced sequences are in red. The arrows indicate the positions of 
the specific primers used for RT-PCR. Splice variants depicted here are named 
according to VEGA with the GenBank nomenclature in brackets. Figure adapted 
from [2].   
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Figure 1.11 HAX1 protein isoforms translated from the eight variants: 
Different domains are indicated in different colours. An acid box exists in isoform 1, 
2, 3, 5, 6 (yellow) and a β6-interacting domain is possessed by isoforms 1,2,4,5. The 
HAX1 isoforms depicted here are named according to VEGA with the GenBank 
nomenclature in brackets. Figure adapted from [2]. 
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1.1.6 Association of HAX1 with disease 
1.1.6.1 HAX1 deficiency in severe congenital neutropaenia (SCN; 
Kostmann’s disease) 
HAX1 deficiency in mice was described in the study from Chao et al [59]. The 
heterozygous HAX1 deleted mice were found to be viable and fertile whereas 
homozygous-null mice died within 14 weeks due to loss of motor coordination and 
activity resulting in a failure to eat [135]. Histological analysis of these null animals 
identified that there was an extensive apoptosis of neurons in the striatum and the 
cerebellum [135]. Deletion of HAX1 also resulted in the loss of lymphocytes, with 
age, in the spleen, bone marrow and thymus and this was associated with increased 
cell apoptosis [135]. Nevertheless, in bone marrow there was a preferential loss of 
progenitor-B cell and  pre-B cell populations and an associated increase in apoptotic 
cells [135]. 
In humans, loss of HAX1, due to nonsense mutations and premature stop codons, has 
been linked to severe congenital neutropaenia (SCN) or Kostmann‟s disease. This 
was the first inborn systemic immune dysfunction disease recognised in 1950 [13].  
Patients have severe neutropaenia which is defined as the absolute neutrophil count 
is less than 1500 cell/ mm
3 
blood
 
[14]. Consequently, patients with SCN are 
vulnerable to recurrent infections [14]. SCN is caused by the maturation-arrest in 
neutrophil differentiation during promyelocyte/myelocyte stages in the bone marrow 
due to the mutations in several different genes including ELA2 (elastase 2), AK2 
(adenylate kinase-2),  WASP (Wiskott-Aldrich syndrome protein), G6PC1 (glucose-
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6-phosphate); HAX1 deficiency is found in approximately one third of SCN patients  
[13]. 
In general, two human splice variants were reported and changes in these developed 
different phenotypes of SCN: loss of isoform 1 and the additional loss of isoform 4 
[24,144]. Isoform 4 is characterised by a splice event removing part of exon 2 and is 
preferentially expressed in neuronal cells (see 1.1.5) [2,144]. Mutations affecting 
only isoform 1 (mutations in 3‟ terminal of exon 2) gave rise to a phenotype 
restricted to congenital neutropenia, while mutations affecting both isoform 1 and 
isoform 4 were associated with a phenotype of congenital neutropenia plus variable 
degrees of neurological impairment [24,144]. 
Many HAX1 mutations have now been discovered, most of which are located in 
exon 2 and 3  and these translational frame-shift mutations result in premature stop 
codons and missense mutations, resulting in loss of the functional full-length protein 
[16,24,144] (Figure 1.12). Klein and colleagues were the first to report HAX1 is 
associated with Kostmann‟s disease and sequencing data revealed all affected 
patients had a premature stop codon (Trp44X) in exon 2, which was induced by 
homozygous single nucleotide insertion (a.a. 130-131), affecting only isoform 1 but 
not isoform 4, showing the neutropenia phenotype without neurological impairment 
[16]. Later studies confirmed the striking correlation between the genotype and 
phenotype: mutations affecting only isoform 1 were associated with neutropenia 
(Ala25Val, Glu31LysfsX54, Ser43LeufsX11, Trp44X, Glu59X, Glu60Asp), whereas 
mutations affecting both transcript variants 1 and 4 caused neutropenia and 
neurologic symptoms, including epilepsy and neurodevelopmental delay 
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(Leu130Arg, Arg86X in exon 2; Gln123LeufsX4, Arg126fsX128, Gln137X, 
Val144GlyfsX5, Gln155ProfsX14 in exon 3; Val172Ile in exon 4 and Gln190X in 
exon 5) (Figure 1.12)  [16,24,144-148]. It was suggested that different mutations 
could have different impacts on the expression of the HAX1 variants in different 
tissues, regardless of the specific HAX1 mutations, all SCN patients display a HAX1 
isoform 1 deficiency in the bone marrow, whereas SCN patients harbouring the 
mutation affecting isoform 4 may also be deficient for HAX1 protein expression in 
the brain/neurons [24]. This speculation was confirmed by PCR which showed the 
tissue expression pattern of isoform 1 and 4 [24]. The overall pattern of expression 
was similar for both transcripts; isoform 4 was less abundant in the bone marrow, 
whilst clearly detectable in the brain [24]. So, in theory, when the mutations are only 
affecting isoform 1 (e.g. Trp44X), isoform 4 could still be expressed normally in the 
brain of SCN patients, whilst isoform 1 should not be expressed in the bone marrow 
of the same individuals with the Trp44X mutation [24]. Thus two different types of 
HAX1 mutations, the first affecting both splice variants 1 and 4, and second 
affecting splice variant 1 only could result in divergent outcomes in terms of protein 
expression, and explain the resulting differences in clinical manifestations. The 
known HAX1 mutations and their locations are shown in Figure 1.12. 
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Figure 1.12 HAX1 human mutations and their locations.  
A number of HAX1 mutations have been reported. The mutations in the blue box 
affect both HAX1.1 and HAX1.4 whereas mutations in the green box only affect 
isoform 1. The amino acid residue number for each mutation is indicated as well as 
the replaced amino acid. Introns are shown in light gray, exons are shown in dark 
gray and the alternatively spliced sequences are in red. 
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1.1.6.2 HAX1 overexpression in psoriasis 
Overexpression of HAX1 is reported both in psoriasis and in many types of 
malignancy [1,23,65,117,149]. Interestingly, both cancer and psoriatic cells share the 
common feature of diminished susceptibility to apoptosis. Since HAX1 is implicated 
strongly as an anti-apoptosis protein, and it is shown that the association of 
abnormally high levels of HAX1 in cancer and psoriasis, this finding perhaps is not 
inexplicable. 
Overexpression of HAX1 has been observed in lesional psoriasis, a chronic  
inflammatory disease characterised by increased proliferation and diminished 
apoptosis [23]. By using mRNA differential display to search for disease-associated 
genes, Mirmohammadsadegh et al demonstrated the overexpression of HAX1 in 
lesional psoriatic skin by Northern Blot, Western blot, in situ hybridisation and 
immunohistochemistry. [23]. This confirmed the relatively weaker HAX1 expression 
in healthy and non-lesional skin compared with hyperproliferative psoriatic lesions 
[23]. In the same study, the authors also showed caspase-3 activity was increased 
after HAX1 depletion by HAX1 siRNA after UVB treatment of the HaCat 
karatinocyte cell line, suggesting an antiapoptotic role for HAX1 [23]. Thus it was 
suggested that, in psoriasis, the epidermal differentiation could be disturbed due to 
the increased expression of HAX1 and hence there was a prolonged resistance to 
terminal differentiation [23].  
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1.1.6.3 HAX1 overexpression in cancer 
There are many functions attributable to HAX1 that could lead it to contribute to 
promoting the progress of cancer: thus the ability of HAX1 to inhibit members of the 
caspase family [21,117,118]; maintaining mitochondrial membrane integrity and 
regulating calcium homeostasis which are crucial for cell survival 
[28,30,130,135,140]; promoting cell migration by regulating cell cytoskeleton 
arrangement and modulating activity of signalling molecules (Gα protein and RhoA) 
that regulate motility [20,49]. Collectively, the involvement of HAX1 in inhibition of 
cell apoptosis and promotion of cell migration suggest HAX1 could be associated 
with carcinogenesis. Indeed, several studies have linked HAX1 to malignancy. The 
previous work from my group, by Ramsay et al reported that up-regulated HAX1 
expression is observed in oral cancer tissues by immunostaining [1]. Expression of 
HAX1 occasionally occurred at a low level in normal epithelial tissue, but it was up-
regulated in SCC (squamous cell carcinoma), with moderate to strong expression in 
90% of tumours [1]. HAX1 was also demonstrated to be expressed in melanoma 
cells and it was associated with cancer cell survival [117]. According to Oncomine, a 
cancer  microarray  database,  HAX1  is  overexpressed  in  hepatoma,  lung  cancer,  
lymphoma,  melanoma,  leukaemia  and  myeloma [150]. In a gene expression 
profiling study utilising serial analysis of gene expression (SAGE), HAX1 
overexpression was demonstrated to  be induced specifically by hypoxia in renal cell 
carcinoma (RCC) cells [151]. A recent study also reported HAX1 overexpression in 
breast cancer and lung cancer and melanoma by using a cDNA array panel [149]. 
Further RT-PCR analysis from the same study showed HAX1.2 was detected in 
breast cancer cases (8 out of 15 cases) but not in the matching normal tissues [149]. 
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This suggests that upregulation of isoform 2 may be related to breast cancer 
development and also suggests there may be different regulation for different HAX1 
isoforms and that this may associate with the various stages/types of cancers. The 
fact that different HAX1 isoforms associate with various functions also gave us the 
confidence to hypothesise that different isoforms may well perform different 
functions and that this might be related to specific subcellular localisation. Thus, 
elucidating the particular roles of each isoform may provide novel therapeutic 
opportunities for targeting diseases associated with HAX1. More evidence is needed 
to explain the contributions of each isoform, and this is the goal of my study. In the 
next section I will introduce the connection of HAX1 and integrins focusing 
specifically on integrin αvβ6 since my lab already has shown it interacts with HAX1. 
1.2 Integrins  
1.2.1 Integrin Structure and Function 
Integrins are a group of cell-surface adhesion molecules which mediate extracellular 
binding to extracellular matrix (ECM) glycoproteins and, in some cases, proteins 
expressed on other cells (e.g. 2 integrins binding immunoglobulin superfamily 
proteins such as ICAM1) [152-154]. Thus integrins act as a bridge between cells and 
the ECM across which information can pass in both directions [152]. They are 
transmembrane αβheterodimers, comprising 24 distinct integrins in humans 
constituted by 18 α-subunits and 8 β-subunits (Figure 1.13) [153]. Integrins have an 
extracellular domain which is exposed on the cell surface and interacts with its 
ligands; a transmembrame domain anchored in the cell membrane and a relatively 
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shorter cytoplasmic domain [155]. Physically they appear (at electron microscopy 
levels) as a globular (ligand-binding) head on two thin stalks that traverse the 
membrane [156]. Not all cells express all integrins as some integrins are tissue-
specific (e.g. αIIbβ3 on platelets and α6β4 on epithelial cells) whereas some are 
more widely expressed (e.g. 5β1 is on many epithelial and mesenchymal derived 
cells) [152,157].  
The ECM is a glycoprotein scaffold to support tissues and organs and it is produced 
jointly by epithelial, endothelial, and stromal cells [158]. It is composed of a mixture 
of different molecules including structural proteins, such as fibronectin, collagens, 
laminins, proteoglycans, in which are embedded growth factors [159]. Some ECM 
proteins are recognised by many different integrins. For example, laminins are 
recognised by α1β1, α2β1, α3β1, α6β1, α6β4, α7β1 whereas collagen is recognised 
by α1β1, α2β1, α10β1, α11β1, αvβ3 [153]. The reasons why there are so many 
different integrins for some ligands are not always clear but may relate to the 
different intracellular signals generated by the different integrins [158] 
Integrins bind to discrete amino-acid motifs in their ligands and individual integrins 
are specific for particular proteins.  The most common motif recognised by integrins 
is RGD (arginine-glycine-aspartic acid) which occurs in many ECM proteins (such 
as fibronectin, vitronectin and TGFβ latency-associated peptide [LAP]) 
[153,160,161]. There are eight integrins that bind to RGD as part of their recognition 
site (αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, αIIbβ3, α8β1 and α5β1) [162]. In my thesis, I 
shall concentrate on the expression and regulation of one integrin, αvβ6, and its 
cytoplasmic binding partner HAX1. 
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Figure 1.13 The integrin family.  
Integrins are heterodimeric transmembrane receptors comprising alpha and beta 
subunits. 18α and 8β subunits form 24 distinct human integrin heterodimers [152]. 
These constitute several subfamilies based on evolutionary relationships (colouring 
of α subunits), ligand specificity and, in the case of β2 and β7 integrins, restricted 
expression on white blood cells. α subunits with gray stippling recognise collagen. 
Such α subunits are restricted to chordates, as are α4 and α9 (green) and subunits β2-
β8. Purple indicates the α subunits with specificity for laminins whereas blue is for 
RGD. Asterisks denote alternatively spliced cytoplasmic domains. Each of the 24 
integrins shown appears to have a specific, nonredundant function. Figure adapted 
from [152]. 
 93 
 
1.2.2 Regulation of integrin activation and signalling 
Integrins act not only as anchors of cells to ECM by linking them to the actin 
cytoskeleton, but also mediate a great variety of cellular functions via their 
cytoplasmic tails [152]. Binding to their ligands transmits signals bi-directionally 
and regulates a vast number of downstream cellular functions such as adhesion, 
survival, cell proliferation and cell motility [152,153,163] (Figure 1.14). Integrins 
can exist in different states of activation and this regulation controls the ability of 
integrins to bind to their ligands; the regulation of the switch for on and off is critical 
for pathological consequences. Many integrins are not constitutively active, as they 
can be expressed in an inactive state which cannot bind to ligands and, therefore, 
cannot signal [152]. The activation of integrin is associated with a major 
conformational change of the heterodimers by the disruption of the non-covalent 
binding [152]. Electron microscopy studies show that in inactive integrins the 
globular head is bent toward the cell membrane whereas in activated integrins the 
integrin „flicks‟ up extending the binding region from the cell membrane [156]. In 
the inactive state, the α-subunit and β cytoplasmic tails interact with each other 
through a membrane-proximal salt bridge, and this interaction keeps the integrin in 
the inactive state [163].  
Regulation of integrin activation from within cells is referred to as “inside-out” 
signalling and this regulates integrin affinity for their extracelluar ligands  [152]. 
Essentially inside-out signalling regulates the dissociation of the intracellular salt-
bridge and, as consequence, the integrin becomes activated by exposing the ligand-
binding site in the extracellular region [158,163]. This dissociation of heterodimer is 
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caused by the binding to the cytoplasmic tail of cellular adaptor proteins such as 
talin, filamin or tensin [155,163,164] and this separation transforms the integrin to a 
high-affinity ligand binding state [165]. In addition to conformational changes, 
inside-out signals also control integrin clustering and accumulation at specific 
regions of the plasma membrane [166]. In leukocytes, these activating signals can be 
transduced by chemokine and other cell membrane receptors (inflammatory 
receptors, adhesion molecule receptors) [166]. For example, IIb3 is presented on 
the circulating platelets as inactive integrin and this inactive status is necessary for 
preventing the inadvertent occurrence of platelet aggregation [167]. Upon 
stimulation, triggered by G-protein coupled receptors, by the von Willebrand factor 
receptor or by collagen-binding integrin receptors, the activated IIb3 binds to 
fibrinogen and thereby generates a fibrin-platelet clot promoting fibrin deposition; 
however, since platelet activation is induced by factors released (e.g. thrombin) or 
exposed (e.g. collagen) at sites of damage, inappropriate fibrin clots that could be 
lethal are avoided [167]. 
Apart from “inside-out” signalling, integrins also mediate “outside-in” signalling 
regulation [152]. Upon ligand binding to the extracellular domain, the integrins 
activate downstream intracellular signalling [33]. When ligands such as fibronectin, 
collagen, vitronectin bind to integrins, the integrins cluster leading to the formation 
of a macro-molecular complexes of integrins with their cytoplasmic tail associated 
molecules [163]. Although integrins lack intrinsic kinase activity, they are able to 
transduce signals by recruiting kinases at these macromolecular complexes which 
become activated when they come into juxtaposition with activators in the complex; 
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this may be through dimersation (e.g. FAK [focal adhesion kinase]) or via activity of 
other molecules in the complex (e.g. src, phosphorylates multiple sites on FAK) 
[168]. A common structure seen when cells adhere to rigid planar surfaces, the focal 
adhesion, actually is just such a macromolecular complex [159]. Through focal 
adhesions, integrins can regulate signalling functions as well as interacting with 
cytoskeleton and therefore mediate a vast number of cellular functions (Figure 1.14) 
[161]. Through focal adhesions, integrin tails bind and activate intracellular kinases 
such as FAK, Serine/threonine kinases, lipid kinases (eg PI 3-kinase), 
phosphorylases (e.g. RPTPα), and these enzymes modulate cellular proteins post-
transcriptionally [169]. Also, integrins regulate cell motility by interacting with the 
actin cytoskeleton directly or indirectly [168]. Many different molecules are 
recruited to the focal adhesion complex and these regulate different cell signals in 
response to the various integrin-ECM binding events (Figure 1.14) [159].  
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Figure 1.14 Integrins clustered at a focal adhesion.  
Integrins bind to ECM proteins and cluster together which recruits structural and 
signalling molecules. Clustering of integrin receptors, or particularly integrin  
cytoplasmic domains, activates non-receptor tyrosine kinases such as focal adhesion 
kinase (FAK) leading to localised increases in the levels of tyrosine-phosphorylated 
proteins. Serine/threonine kinases including members of the protein kinase C family, 
and lipid kinases such as PI3-kinase are also regulated by integrin engagement and 
clustering. These kinase and phosphatase signalling pathways induce post-
translational modifications regulating the protein interactions and/or enzymatic 
activity of the substrates. They specify protein recruitment to adhesion complexes 
and thereby selectively link matrix adhesions to various downstream signalling 
cascades that control cytoskeletal organisation, gene regulation, and diverse cellular 
processes and functions. Figure adapted from [159]. 
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Thus, integrins transmit signals bi-directionally: inside-out signalling is the 
separation of integrin subunit cytoplasmic tails by the action of the intracellular 
molecules and this activates the extracellular domains for ligand binding; outside-in 
signalling, the binding to the extracellular ligands, may result in clusters of integrin 
and therefore contribute to intracellular signal transduction by allowing interaction of 
cytoskeletal proteins and signal transduction molecules. The bi-directional signalling 
is required for integrins to mediate or promote many cellular behaviours including 
adhesion, migration, invasion, differentiation, survival and gene expression 
[152,163,165]. In the following section I will give examples of data describing many 
of these processes, mostly using the integrin v6 as an example. 
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1.2.3  Integrin functions 
1.2.3.1 Integrins and cell survival 
Cell growth and differentiation requires interaction of cells with ECM through 
integrins, and loss of matrix attachment can lead to anoikis [170]. Anoikis is a term 
to describe a phenomenon of programmed cell death due to lack of appropriate 
anchorage to ECM or neighbouring cells [171]. Integrins interact with their ligands 
in ECM and this relays survival signals whereas unbound integrins can promote cell 
apoptosis; such adhesions to the ECM are crucial to determine whether the cell is in 
a correct location within tissues [172]. For example, unoccupied αvβ3 integrins 
activate apoptosis in cells by recruiting caspase-8 [173]. α6β4 binding to laminin-5 
protects breast cancer cells from several death signals (activated by treatment with 
TNF-α, Fas or Etoposide) [174]. Also, successful keratinocyte growth in three-
dimentional methylcellulose requires the interaction between α5β1 and its ligand, 
fibronectin [175]. Moreover, melanoma cells required interaction of the integrin 
αvβ3 to sustain viability and growth in three-dimensional collagen [176]. However, 
many cancer cells develop mechanisms to resist anoikis and grow in an anchorage-
independent way in order to survive beyond the basement membrane [172,177]. 
FAK is a nonreceptor tyrosine kinase predominantly localised in focal adhesions of 
adherent cells [168,178]. FAK activation and phosphorylation by integrin-mediated 
cell adhesion provided anchorage-independent growth of cancer cells by signalling 
through phosphatidylinositol 3-kinase (PI3K) to the Akt/protein kinase B (PKB) 
[179]. Janes and Watt (2004) found that up-regulation of αvβ6 protects squamous 
carcinoma cells from anoikis by activating Akt survival signals, a downstream target 
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of FAK and PI3K signalling [68]. They also reported that this involved a switch 
from αvβ5 to αvβ6 integrin expression, to the advantage of the αvβ6-expressing cells 
enabling them to grow in an anchorage independent fashion [68]. This anchorage-
independent growth is proposed to allow the invasive tumour cells to survive beyond 
the confines of the basement membrane [172]. 
1.2.3.2 Integrins and cell migration and invasion 
The cytoskeleton, the intracellular scaffolding of each individual cell, provides the 
strength of cell structure. The cytoskeletal network integrates with various 
intracellular signalling molecules and organelles, generating coordinated force for 
cells to change their shape during cell migration [180]. The main elements of 
cytoskeleton include actin filaments, microtubules, and intermediate filaments, and 
their polymerisation and depolymerisation controls cell structure as well as motility 
[41]. In the leading edge of migrating cells, integrin-ligand interaction triggers actin 
filament assembly into stress fibres which generate protrusion at the front, whereas 
actin-myosin filaments produce contraction at the rear [155]. Also, as a result of 
focal adhesion induced by integrins, the cytoplasmic tails of integrins bind directly to 
cytoskeleton and signalling molecules such as α-actinin, FAK and vinculin, or 
through indirect binding to adaptor proteins, such as talin, filamin, and tensin, and 
these associations promote cell movement [155,164]. 
Integrin αvβ6 is expressed only by epithelial cells and then usually only when cells 
are undergoing tissue-remodelling, including development, wound healing, chronic 
inflammation and cancers [69]. Thomas et al showed that αvβ6 on normal and 
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transformed keratinocytes promoted adhesion to, and migration toward, fibronectin 
and latency-associated peptide (LAP), the pro-peptide of TGF-β [181]. Adhesion to 
fibronectin of transformed keratinocytes was also mediated by 51 but only v6 
mediated the migration on this ligand  [182]. Overexpression of v6, by retroviral 
vector delivery of 6 cDNA, increased migration on fibronectin and also enhanced 
cell invasion in 3D environments [70]. 
1.2.3.2.1 Integrins and MMP family 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that 
degrade a range of ECM components such as collagens, laminins, vitronectin, and 
fibronectin [183,184]. MMPs are produced as inactive enzymes (zymogens) which 
need proteolytic cleavage to be activated, subsequently resulting in ECM 
degradation which is crucial for cancer cell migration and invasion. The activation of 
MMPs is activated by proteolytic removal of an autoinhibitory N-terminal domain 
by different molecules including integrins [158]. Integrins regulate MMPs via 
different mechanisms, including recruiting the proteases to the cell surface and also 
regulating matrix degradation [158]. There are 25 MMPs which have been identified 
and most of them exist as secreted forms, except six membrane-anchored (MT) 
MMPs (MT1-MMP to MT6-MMP, also named as MMP-14, MMP-15, MMP-16, 
MMP-17, MMP-24 and MMP-25) [185].  A vast number of studies have shown 
MMPs (MT1-MMP, and MMP-1, -2, -3, -7, -9, and -13) are upregulated in cancers 
and associate with tumour metastasis [184-186].  
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For example, direct binding of MMP2 to αvβ3 is required for presenting activated 
matrix MMP2 on the cell surface of invasive cells [187,188]. αvβ3 recruits pro-
MMP2 to the cell surface where the pro-MMP2 is cleaved and activated, and 
subsequently can degrade basement membrane [187]. This study demonstrated that 
the presence of activated MMP2 correlated with expression of αvβ3 in human 
melanoma cells both in vitro and in vivo, and the expression of both factors was 
required for melanoma cell invasion and metastasis formation [187]. Binding of oral 
SCC (squamous carcinoma cells) to fibronectin or LAP resulted in an increased 
secretion of pro-MMP2 and pro-MMP9 which promoted invasion through Matrigel 
[189]. Ramos et al also reported that αvβ6 promoted oral SCC invasion by 
increasing pro-MMP3 secretion [189]. Agrez et al showed that the C-terminal 11 
amino-acid of the β6 subunit is required for promoting proliferation of colon cancer 
cells [190] whereas Morgan et al showed these same 11 a.a. sequence were required 
for v6-dependent invasion and also were sufficient to transfer a pro-invasive 
ability to αvβ3 when expressed de novo in epithelial cells; this increased invasive 
ability correlated with an increase in release of pro-MMP2 [191]. 
1.2.3.2.2 Integrins and the uPAR activation system 
Urokinase-type plasminogen activator receptor (uPAR) is an important regulator of 
ECM proteolysis. uPAR binds to the serine protease urokinase-type plasminogen 
activator (uPA; also known as urokinase) and its zymogen form, pro-uPA and 
regulates the activity of the plasminogen activation system [63]. uPA is one of the 
plasminogen activators that converts the extracellular plasminogen into plasmin and 
this, in turn, promotes an extracellular proteolytic cascade which degrades ECM 
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components including fibrinogen, fibronectin and vitronectin but also activates 
MMPs [63,192]. The plasmin also cleaves and activates pro-uPA as a positive 
feedback loop [63]. The plasminogen activation system is negatively regulated by 
plasminogen activator inhibitor 1 (PAI1; also known as SERPINE1) and PAI2 (also 
known as SERPINB2) [193] (Figure 1.15). “Cleaved” PAI-1 is unable to interact 
with its target plasminogen activators uPA and tissue-type PA (tPA) to inhibit 
plasmin-based proteolysis but retains its ability to bind the low-density lipoprotein 
receptor-related protein- 1 (LRP1) and this enhances cell migration, through a 
uPA/tPA complex-independent interaction [194] (Figure 1.15). 
Several integrins are associated with uPA which provides an additional proteolysis 
function and enhances cancer cell migration and invasion [195]. αvβ3 is a marker of 
progression in malignant melanoma, and it was reported that αvβ3 expression is 
correlated with uPA [196]. αvβ6 is also correlated with expression levels of uPA and 
its receptor uPAR [66]. Another example, in oral keratinocytes, has indicated αvβ6 
plays an important role in modulating cell-surface uPA proteolytic activity by 
decreasing uPAR expression through the β6 cytoplasmic domain [197]. In contrast, 
PAI-1 can inhibit integrin binding to the extracellular ligands and therefore alter the 
cell functions.  For example, PAI-1 inhibits cell migration by inhibiting integrins‟ 
binding to their ligands. Vitronectin promotes cell migration via RGD-dependent 
interactions with integrins αvβ3 and also by binding with uPAR [198,199]. PAI-1 
competes with uPAR for the binding to vitronectin (to the same domain) and as a 
result alters the ability of these receptors to engage vitronectin [198,199]. The uPAR 
activation system is illustrated in Figure 1.15. 
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Figure 1.15 Function and regulation of uPAR in the plasminogen activation 
system.  
Urokinase-type plasminogen activator receptor (uPAR) binds the protease urokinase-
type plasminogen activator (uPA) in its active and zymogen (pro-uPA) forms. uPA 
cleaves plasminogen, generating the active protease plasmin. Plasmin activates pro-
uPA as positive feedback. Increased cell surface concentration of uPA or pro-uPA 
(by binding to uPAR) and plasmin or plasminogen (via multiple receptors) 
accelerates their mutual activation. Plasmin cleaves and activates matrix 
metalloproteases (MMPs). Both plasmin and MMPs degrade many ECM 
components and activate growth factors or liberate them from ECM sequestration. 
The proteolytic activities of uPA and plasmin are antagonised by the serine protease 
inhibitors (serpins) plasminogen activator inhibitor 1 (PAI-1; also known as 
SERPINE1) and PAI-2 (also known as SERPINB2) and α2-antiplasmin. uPA–uPAR 
binding promotes clustering of uPAR in the plasma membrane, and increases its 
ability to bind the ECM protein vitronectin. uPA also cleaves uPAR in the linker 
between its first and second domains (D1 and D2), generating a soluble D1 fragment 
and a membrane-associated D2–D3 fragment. uPAR cleavage abrogates uPA 
binding, thereby inactivating the function of uPAR in proteolysis, and also 
inactivates or modifies the signalling functions of uPAR. Picture adapted from [63] 
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1.2.3.2.3 Integrins and oncogenes 
It also has been reported that integrins can cooperate with oncogenes to promote 
cancer cell invasion. For example, integrin α6β4 is vital for tumour formation in 
breast cancer as it cooperates with EGFR, the receptor for epidermal growth factor 
(EGF), with ERBB2, and with c-Met and this promotes spontaneous mammary 
tumour formation and tumour cell invasion [200].  Also, Trusolino et al reported that 
complex formation between c-MET and integrin α6β4 enhances hepatocyte growth 
factor (HGF)-induced signals, including tumour cell invasion [201]. This effect may 
be due to the potentiation of HGF-induced Ras and PI3K signalling by α6β4-
mediated recruitment of proteins such as Shc1 and PI3K [201].  
1.2.3.3 Integrins and endocytosis 
Endocytosis of integrins influences their biological functions (such as cell migration) 
by recycling the adhesion molecules to the front where cells need the adhesion 
molecules to interact with ligands in ECM [202]. There is more than one endocytosis 
pathway involved in integrin trafficking. In general, they are divided into two main 
groups:  clathrin-dependent and clathrin-independent pathways [33]. In the clathrin-
dependent pathway, clathrin assembles into a lattice-like structure around the 
vesicles forming a clathrin coat [203]. The clathrin coat needs certain intracellular 
molecules, called adaptor proteins, to bind to specific cargoes [203]. Common 
adaptor proteins include AP-2 (adaptor protein-2), Numb, Eps-15 (EGFR-pathway 
substrate) and cortactin [204]. Once the clathrin-coated vesicle forms, this integrin-
packaged vesicle travels to early endosomes and then to sorting-endosomes where 
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the fate of the cargo is determined, recycling back to the cell surface or sent to late 
endosomes and lysosomes for degradation; in both routes different members of the 
Rab GTPase family are required [33].  In addition to the classical clathrin-dependent 
mechanism of endocytosis, several pathways do not use a clathrin coat. These other 
vesicular uptake processes (clathrin-independent pathways) can be associated with, 
for instance, RhoA, Rac, Cdc42, Arf6, caveolae and macropinocytosis [205]. It is 
reported that some integrins use both ways for endocytosis (e.g. α5β1, αvβ3 and 
α2β1) [43]. The integrin vβ6 was shown to be endocytosed by the clathrin-
mediated mechanism but non-clathrin pathways were not investigated [1]. In the 
previous work from my lab, HAX1 was investigated as an adaptor protein for this 
integrin [1]. HAX1 binds directly to the β6 cytoplasmic tail of integrin αvβ6 [1]. The 
internalisation rate of αvβ6 was reduced to similar levels by either siRNA to HAX1 
or clathrin, suggesting both were part of the same endocytotic pathway [1]. Also, the 
endocytosis of αvβ6 was reduced significantly by treating cells with a membrane-
permeant peptide corresponding to the β6 binding site of HAX1 [1]. This peptide 
inhibited the direct interaction between HAX1 and β6, reducing endocytosis of αvβ6 
but also blocking the migration and invasion ability of oral squamous carcinoma 
cells [1]. These data suggests the internalisation of integrin αvβ6 is crucial for 
biological functions such as migration and invasion, and that HAX1 plays the role of 
an adaptor protein to regulate this process [1].  
1.2.3.4  αvβ6 and cancer 
αvβ6 is an epithelial-specific integrin and its expression is limited to development 
[206], wound healing [69], chronic inflammation [67] and cancer [1,69,189,207-
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209], all processes that involve tissue remodelling; in contrast, it is absent/low in 
healthy adult tissue [210,211]. Expression of αvβ6 is linked to poor survival in 
certain cancers. Yang et al have shown  patients who were αvβ6-positive had higher 
liver metastasis rates [212]. In colon cancer, high αvβ6 expression was associated 
with a reduction in median survival time from 16 to 5 years compared with v6-
negative or v6-low cancers [207]. In line with this observation, another study 
showed that gastric carcinoma patients who were v6 negative had much longer 
survival times than those who were v6 positive and its value as a prognostic 
marker is significant for early stage tumours [213]. This integrin also has been 
reported in ovarian cancer, where the expression of αvβ6 is much more significant in 
Grade III tumours than low Grade tumours [66]. In cervical squamous cell 
carcinoma, strong expression of αvβ6 in tumour cells correlated with different 
clinical-pathological parameters and with worse overall and disease-free survival 
[214]. Furthermore, αvβ6 expression correlated positively with TGF-β1 mRNA 
expression as well as with fibronectin expression in cervical cancer, suggesting αvβ6 
is a prognostic factor for decreased survival for cervical squamous cell carcinoma 
[214]. In a separate report, the expression of αvβ6 was detected by tissue microarray 
in early-stage, non-small cell lung carcinoma (NSCLC) [215]. Log-rank test and Cox 
regression analyses showed that expression of this integrin was significantly 
associated with poor patient outcome, indicating that αvβ6 is a prognostic biomarker 
for NSCLC and may serve as a receptor for targeted therapies [215]. Since in vitro 
and in vivo data show αvβ6 promotes a variety of processes that appear to promote 
cancer, including migration, invasion, MMP secretion and survival (discussed 
above), these clinical observations are possibly explained by these biological 
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activities of αvβ6. Thus, since αvβ6 is implicated strongly in carcinogenesis, the 
molecular mechanisms that regulate this molecule and how this integrin promotes 
cancer progression are questions which need to be answered. The mechanism by 
which αvβ6 promotes cancer is not completely known but is likely to be a 
combination of its direct functions including promoting secretion of MMPs, 
invasion, survival and its direct functions via the activation of  TGF-β.  
Aa mentioned, a major function of αvβ6, which is very likely to contribute to its role 
in cancer progression, is the ability to activate transforming growth factor β (TGF-β). 
TGF-β is a cytokine family (TGF-β1, TGF-β2 and TGF-β3) which modulates 
multiple cellular functions such as cell proliferation, inflammation, matrix synthesis, 
and angiogenesis [69,216]. TGF-β is secreted as a biologically inactive (latent) 
protein complex consisting of the TGF-β homodimer (25 kDa) bound to the latency 
associated protein (LAP) (75 kDa). LAP is further associated with latent TGF-β 
binding protein (LTBP) (190 kDa) glycoprotein via a disulphide bond (Figure 1.16) 
[216,217]. In most conditions, active TGF-β is generated by dissociation from a 
large latent protein complex (LLC) that sequesters latent TGF-β in the extracellular 
matrix (ECM) (Figure 1.16) [217]. When αvβ6 binds to the RGD sequence in LAP 
(from TGF-β1 or TGF-β3; TGF-β2 LAP does not have an RGD motif), the 
activation of TGF-β1 is triggered by an αvβ6-dependent physical force, requiring an 
intact cytoskeleton, that results in a conformational change of the complex [216]. 
This then exposes active TGF-β1 and allows it bind to its receptor, probably on 
adjacent cells, thus initiating downstream pathways [181]. Thus the TGF-β-αvβ6 
interaction is important for cancer progression, not only for the independent activity 
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of the TGF-1 but also as it has been shown to promote cell migration and MMP-9 
expression in carcinoma [69,181].  
 
Figure 1.16 Schematic of the structure of TGF-β1.  
TGF-β is secreted as a biologically inactive complex as the large latent complex 
(LLC) consists of TGF-β1, LAP and the fibrillin-superfamily member LTBP-1. 
Together, TGF-β1 and LAP form the small latent complex (SLC) which is 
intracellularly formed as a homodimer linked by disulphide bonds. TGF-β1 contains 
four mannose-6-phosphate moieties that are required to associate with LAP. LAP-β1 
and LAP-β3 contain the amino acid sequence motif RGD serving as recognition site 
for various integrins. LTBP-1 contains three cysteine-rich domains, and the second 
cysteine-rich domain binds the SLC via disulphide bonds whereas the third cysteine-
rich domain at the N-terminus of LTBP-1 links the protein complex to the ECM via 
transglutamination. The flexible hinge region, separating the central hybrid domain 
and the third cysteine-rich domain, is sensitive to proteolytic digestion (arrowhead). 
Another protease-sensitive site is present close to the C-terminus of LTBP-1 
(arrowhead). Picture adapted from [217]. 
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1.3 Summary of HAX1 biology to date and the goals of this 
study 
The previous section has discussed multiple functions implicating HAX1 in many 
different biological processes. Most of these studies did not consider that HAX1 was 
a family of proteins and therefore which isoforms were principally responsible for 
the observed results was not addressed. Only in a few genetic studies ([147,148]) 
were researchers able to point out the differences of the isoforms and only recently 
are studies ([19,149]) attempting to characterise which isoforms are critical. In this 
study, I have attempted to address this problem by combining genetic and 
immunological methods. Thus the hypothesis is:  
The multiple functions and subcellular localisation attributed to HAX1 are due to 
the presence of multiple isoforms whose individual functions and subcellular 
localisation may differ from each other. 
In our lab, we want to investigate the role of individual isoforms of HAX1 in cancer, 
in particular, their variations in subcellular localisation, proliferation, migration, 
apoptosis and autophagy. Since my lab has an interest in the integrin αvβ6, I have 
chosen to focus on HAX1.1, HAX1.2, HAX1.4 and HAX1.5 as these isoforms 
possess the β6 binding site. Specifically, the main aims of my PhD are: 
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1) To investigate the role of HAX1 in cell migration in a range of cancer cell 
lines from different tissues, and establish the role of individual isoforms in 
migration.  
2) To generate oral carcinoma cell lines that stably have HAX1 knocked down. 
These lines will be analysed at the protein and RNA level for expression of 
HAX1 isoforms and also the protein level of v6.  
3) To characterise the cellular functions of these cells in terms of growth, 
migration, and susceptibility to apoptosis and autophagy. 
4) To re-introduce singly the various HAX1 isoforms into HAX1-null cells and 
study the subcellular localisation and biological functions dependent upon 
this re-introduction. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell lines and tissue culture 
2.1.1 Cell lines, media and cell maintenance 
VB6 and H400 are human oral squamous cell carcinoma lines. H400 expresses 
integrin αvβ6 endogenously [1] whereas VB6 was engineered, by retroviral vector 
transduction, to express high αvβ6 levels [70]. Both cell lines are cultured in KGM 
(keratinocyte growth medium: α-MEM supplemented with 0.18mM adenine (Sigma-
Aldrich), 0.4µg/ml hydrocortisone (Sigma-Aldrich), 10ng/ml EGF (Sigma-Aldrich), 
5µg/ml insulin (Sigma), 220mM glutamine (PAA Labs), 0.1x10
-7
mM cholera toxin 
and 10% foetal bovine serum (FBS; PAA Labs). 1.25 µg/ml of puromycin (Sigma-
Aldrich, #p9620) was employed to select pGIPZ lentivirus-infected VB6 and H400 
cell lines. HEK 293T cells are human embryonic kidney cells, used for lentivirus 
packaging. The culture media used for HEK239 cells is DMEM (Dulbecco‟s 
modification of Eagle‟s medium) supplemented with 10% FBS. CFPAC1 and 
Pac04.03 are pancreatic adenocacinoma cell lines and grow in RPMI media (Sigma-
Aldrich), supplemented with 10% FBS. MCF10CA1a is a breast malignant epithelial 
cell line and is cultured in DMEM/F-12 (1:1) medium (Sigma-Aldrich) 
supplemented with 5% horse serum. HaCat is an immortalised normal human 
keratinocyte line and the culture medium consists of 10% FBS in DMEM (Sigma-
Aldrich). HeLa cell is a malignant cervical epithelial cell line and growth occurs in 
DMEM (Sigma-Aldrich) with 10% FBS. All the cell lines were cultured as adherent 
 112 
 
monolayer in sterile tissue culture flasks in an humidified atmosphere at 37°C, 8% 
CO2.   
2.1.2 Trypsin detachment of cells 
Cells were detached from plastic using a solution of trypsin/EDTA 
(0.5%(w/v)/5mM) (PAA Laboratories, #L11-003). Trypsin cleaves peptide bonds at 
lysine and arginine residues and hydrolyses intracellular junctions whereas EDTA 
binds to divalent cations, such as calcium and magnesium, which are essential for 
functioning of integrins and E-cadherin adhesion molecules. Briefly, old media was 
removed and sufficient trypsin/EDTA added to cover the cells (eg 1.5ml/75cm
2
 
flask) for 5 minutes incubation at 37°C to detach the cells from the surface. The cells 
were resuspended with suitable growth media (with serum) to inactive trypsin and 
passaged into new flasks. 
2.1.3 Freezing and thawing cells 
Log-phase growing cells were trypsinised, as described in the above section, and 
were collected by centrifugation at 250 x g, 3 minutes. The supernatant was aspirated 
off and cells were resuspended with 1ml freezing fluid (70% DMEM, 20% FCS, 10% 
DMSO). Cells were then frozen overnight at -1°C per minute to -80°C, and then 
transferred to liquid nitrogen. In the thawing procedure, cells were recovered to 37°C 
as quickly as possible to prevent ice crystal formation and induced cell death. The 
Cryovials were placed into a waterbath and the cells allowed to thaw out. The cell 
suspensions were then transferred to a tube containing 10ml pre-warmed media. The 
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DMSO was removed by centrifugation at 250 x g for 3 minutes and resuspending the 
cell pellets with growth media. 
2.2 Small interfering RNA (siRNA) oligos 
siRNA oligos were used to transiently knockdown endogenous HAX1 expression. 
Si192 targets to 3‟UTR of HAX1 recognising isoforms1-9. Si1-6 targets to exon2 
and knocksdown isoforms 1-6. Si86 targets to the beginning of exon3, recognising 
isoforms1-6. The sequences of siRNA are shown in Table 2.1 
 
Table 2.1 Sequences of siRNA oligos.  
This table shows the siRNA and their sequences, the targeted HAX1 isoforms are 
indicated as “V”. 
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2.3 Lentiviral vectors 
Lentiviral vectors were used for stable HAX1-knockdowns. Four pGIPZ plasmids 
(p86, p87, p89, p90) were obtained from Open Biosytems, each encoding a different 
short-hairpin RNA (shRNA) to HAX1. The sequences of the hairpins of shRNAs are 
comprised of a 19nt loop and 22nt of dsRNA. Table 2.2 shows the sequences and 
also the isoforms targeted. The detailed information on the vectors is discussed in the 
Results section. 
 
Table 2.2 pGIPZ vectors and targeted HAX1 isoforms. 
This table shows four different shRNAs to HAX1 and their sequences, the targeted 
HAX1 isoforms are indicated as “V”. 
 115 
 
2.4 Mutant HAX1 isoforms 
Mutated HAX1 isoforms were generated to resist siRNA degradation (by Dr. 
Delphine Lees). Mutants were created by site-directed mutagenesis: C249T, A252G, 
A255G, T390C, G393A, T396C. These mutated bases are designed to protect from a 
specific siRNA (si86) which targets to exon 3 of HAX1. Mutated isoforms 1,2,4,5 
were generated with a pFLAG-CMV2 vector (Sigma) with a FLAG-tag inserted on 
the N-terminal of the isoform sequences. The mutations and the sizes of each mutant 
isoform are shown in the Table 2.3. The detailed vector map is shown in Appendix 
II. 
Vectors  Insert size (bp)  Mutated Sequence  
HAX1.1  840   
 
 C249T_A252G_A255G  
 T390C_G393A_T396C  
HAX1.2  762  
HAX1. 4 696  
HAX1.5 864  
Table 2.3 Mutated sequence of HAX1 isoforms.  
HAX1 isoforms with sequence mutated: C249T, A252G, A255G, T390C, G393A, 
T396C were created by site-directed mutagenesis and inserted into pFLAG-CMV2 
vector. 
2.5 Antibodies 
Table 2.4 shows the antibodies used for this study.  
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Table 2.4 Summary of antibodies used in this study. 
WB, Western blotting; IF, immunofluorescent staining 
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2.6 Plasmid amplification and purification 
shRNA plasmids were supplied as bacterial stabs. The bacteria were streaked on to 
agar plates with appropriate antibiotics (100µg/ml of ampicillin; Sigma-Aldrich) and 
incubated at 37 °C overnight. Single colonies were picked and used to incubate a 
starter culture of 5 ml LB (Luria Broth; Sigma-Aldrich) medium containing 
100µg/ml of ampicillin at 37°C for 8 hours with vigorous shaking (300 rpm). The 
starter culture was then diluted 1/500 in 250ml of the selective LB medium, and 
incubated at 37°C overnight with vigorous shaking (300 rpm). Bacterial cells were 
harvested by centrifugation at 6000xg for 15 minutes at 4°C. Maxiprep kits (Qiagen, 
#12163) were used to purify plasmid DNA according to the manufacturer‟s protocol. 
The procedure is based on the alkaline lysis of bacterial cells followed by adsorption 
of DNA onto the Maxiprep membrane in high-salt buffer and its elution in low-salt 
buffer. 
2.7 Agarose gel electrophoresis 
Vectors were analysed by agarose gel electrophoresis to examine the purity. 1% 
agarose gels were prepared by dissolving agarose in TBE buffer (Fisher Bioreagents, 
#BP2430-20) by boiling in a microwave oven with regular stirring. Once cooled, 
0.5ug/ml ethidium bromide (Invitrogen; #15585-011) was added to the gel to 
facilitate visualisation of DNA fragments under UV light. The warm solution was 
poured into a gel cassette containing combs to form wells. 5 µl of each sample was 
loaded in to the wells alongside Hyper Ladder I DNA ladder (Bioline, #BIO-30025), 
and the gel was run for 40 minutes at 100V to separate the DNA fragments. Samples 
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were visualised on a UV transilluminator (UVP Products), and digital images 
captured on Labworks software. 
2.8 Transfections 
2.8.1 Oligofectamine transfection-for siRNA 
Oligofectamine Transfection Reagent (Invitogen, #12252-011) forms stable 
complexes with oligomers, permitting efficient transfection into eukaryotic cells. 
Cells were grown in a well of a 6-well plate to about 50% confluency at the time of 
transfection. The transfection mixture was generated by mixing siRNA dilution (2µl 
of 100nM siRNA with 348 µl Opti-MEM [Invitrogen]) and Oligofectamine dilution 
(10 µl of oligofectamine with 40 µl Opti-MEM). The trasfection mixture was then 
incubated for 10 minutes at room temperature. Cells were rinsed with Opti-MEM, 
fed with 800 µl Opti-MEM before adding the transfection mixture. 
2.8.2 pGIPZ-lentiviral transfection for stable knockdown 
To generate lentiviruses required a triple transfection of three plasmids into HEK 
293T cells; the 3 plasmids were the shRNA encoding pGIPZ, p8.91vector (encoding 
gag and pol) and the pMDG.2 vector (encoding VSV-G) which contain viral 
structural and envelope encoding genes, respectively. The plasmids were obtained 
from Open Biosytems and an illustration of the process is demonstrated in Figure 
2.1. 
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Figure 2.1 Lentiviral vectors for shRNA expression.  
In the RNA interference processes after lentiviral infection of the target cell, shRNA 
is produced by the sequence that became integrated into the host genome. The pre-
miRNA, which is a long primary double-stand RNA, is produced in the nucleus, and 
then cleaved by the endoribonuclease, Drosha, into shorter pre-miRNA with 
approximately 70 nucleotides. These are exported out into the cytoplasm by 
Exportin-5 and then cut by the enzyme Dicer into functional miRNA of about 22 
nucleotides. Subsequently, the anti-sense strand of the miRNA will be introduced 
into the RNA-induced silencing complex (RISC) and the RISC functions to 
recognise its mRNA target for gene silencing. Figure adapted from [218]. 
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2.8.2.1 Lentivirus packaging 
The packaging cell line, HEK293T cells, was seeded in 75cm
2
 flasks to achieve sub-
confluence (approximately 70%) the next day. Plasmid transfection was performed 
using Fugene 6 method (Roche, # 11815091001) with 1 µg of packaging plasmids 
(pMDG and p8.91) and 1.5 µg of pGIPZ vectors (15 µl total volume). The plasmid 
mixture was added to the Fugene 6 mixture (10 µl Fugene reagent with 200µl Opti-
Mem), and incubated for 15 minutes at room temperature. The culture media was 
replaced with 8 ml fresh growth media before the plasmid mixtures were added to 
the cells and then incubated at 37 °C overnight. The next day, media was then 
replaced with 8ml of fresh media and the cells were placed back at 37°C. 24 hours 
later, the media containing virus particles was collected and filtered through a 
0.45µm filter, and the samples stored at -80°C until used. Media (8 ml) was similarly 
collected for each of the next two days. Six days after transfection, HEK293T cells 
were trypsinised and analysed for GFP expression to determine transfection 
efficiency by flow cytometry.  
2.8.2.2 Lentiviral Infection 
Target cells were seeded in 25cm
2
 flasks to reach sub-confluence and the media was 
replaced with 2 ml of virus-containing media described in the previous section and 
supplemented with polybrene (1:2000, Millipore, #TR-1003-G). Polybrene is a 
polycation which is a positively charged molecule that is able to help negatively 
charged proteins to bind to negatively charged cell membranes, thus promoting 
transfection. Cells were incubated at 37°C for four hours and then 2 ml of growth 
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media was added to the cells which were incubated at 37°C overnight. 24 hours after 
viral infection, puromycin selection was performed by replacing fresh media 
containing 1.25µg/ml puromycin to the cells. Flow cytometry was used to observe 
the efficiency of infection (by detecting turbo-GFP). 
2.8.3 Fugene6 transfection- for isoform plasmid restoration 
Fugene 6 transfection reagent (Roche, # 11815091001) utilises cationic polymers for 
transduction of DNA. The negatively charged DNA binds to the polycation (eg. 
lipid) present in the reagent, and the complex is taken into cells via endocytosis. The 
optimal ratio of transfection complex is 1 µg plasmid: 6 µl Fugene Reagent in 100 µl 
Opti-MEM according to the manufacturer‟s instructions. Thus 6µl Fugene 6 
Transfection Reagent was added to 100 µl of Opti-MEM and incubated for 5 minutes 
at room temperature. 1µg of plasmid DNA was added to the mixture and incubated 
for 15 minutes at room temperature. The DNA mixture was added to the cells in 12 
well-plates. Cells were harvested and the protein lysates were examined by Western 
blotting 48 hours after transfection. 
2.9 Western blotting 
2.9.1 Cell lysate preparation 
Confluent cells were washed with cold PBS and lysed with NP40 lysis buffer 
(50mM Tris [pH 7.4], 250mM NaCl, 5mM EDTA, 50mM NaF, 1mM Na3VO4, 1% 
Nonidet p40 [NP40], 0.02% NaN3) supplemented with 1mM dithiothreitol (DTT; 
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Invitrogen, #D-1532) and protease inhibitor cocktail (Calbiochem, #539134).The 
lysates were collected using cell scrapers and sonicated at 4 °C to form homogenous 
cell lysates. Protein concentrations were quantified with the DC Protein assay kit 
(Bio-Rad Laboratories) according to manufacturer‟s instructions using a bovine 
serum albumin (BSA) standard curve. Samples containing equal amounts of protein 
were added to 2x loading buffer (Fermentas) and heated for 10 minutes at 70°C. 
2.9.2 Western blot analysis 
Samples were loaded onto SDS-PAGE pre-cast gels (12% acrylamide; Invitrogen 
system). 10ul of Prestained protein ladder (Fermentas, #SM0671) was loaded in one 
well of each gel to confirm molecular weights. Gels were electrophoresed for 100 
minutes at 125 volts or until the dye front had reached the bottom of the gel. 
Separated proteins were electro-transferred to a nitrocellulose membrane (GE 
Healthcare Life Sciences) for 1 hour at 30V (Invitrogen system). The membrane was 
then stained with Ponceau Red solution (Fluka Chemicals, #09276-6X1EA-F) to 
visualise the quality of the protein transfer. The Blot was incubated for 30 minutes at 
room temperature with blocking buffer (TBS with 0.1% Tween 20 and 5% (w/v) 
non-fat milk protein [Marvel]) which was used to reduce non-specific protein 
binding. The Blots were placed in 50ml centrifuge tubes and indicated primary 
antibodies (see section 2.5 ) diluted in 4 ml blocking buffer added overnight at 4°C 
under continuous rotation (Jencons-PLC, UK) . The membrane was washed with 
wash buffer (TBS/ 0.1% Tween 20) four times for 20 minutes. Appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody (see section 2.5) was 
incubated with the membrane in blocking buffer for 30 minutes at room 
 123 
 
temperatures. After washing, bound antibodies were detected with enhanced 
chemiluminescence (ECL) reagents (GE Amersham).  
2.9.3 Densitometry analysis 
Digital images of autoradiographs were collected and densitometric analysis of 
specific bands was done using Image J software. Detection of endogenous HSC70 
was used as a loading control. For the autophagy experiments, LC3b-II was 
normalised with LC3b-I. 
2.10 RNA analysis 
2.10.1 RNA extraction 
RNA extraction was performed with Absolutely RNA Miniprep Kit from Stratagene 
(#400800). Following the manufacturer‟s protocol, cells were placed in a 6-well 
plate till confluent and were lysed with lysis buffer (2.5 µl β-Mercaptoethanol with 
350 µl lysis buffer [Absolutely RNA Miniprep Kit, Stratagene] per well). Cell 
lysates were mixed by pipetting and transferred to a microcentrifuge tube. Cell 
lysates were then vortexed to homogeneity. The manufacturer‟s instructions were 
followed and total RNA was eluted from the RNA binding tube with Elution Buffer 
provided. 
All samples were quality assessed by agarose gel electrophoresis (Bio-Rad system) 
and quantified by measuring the optical density (OD) at 260 nm with Nanodrop 
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Spectrophotometry (Thermo) (as nucleic acids absorb ultraviolet light at 260nm). 
RNA samples were stored at -80 °C. 
2.10.2 Reverse Transcription (RT) 
Reverse transcription (RT) was performed using Reverse Transcription Kit from 
Promega (#A3500). 1µg total RNA was used to generate cDNA. The reactions were 
prepared on ice as follows (1mM dNTP [deoxynucleoside triphosphates] mix, 5µM 
MgCl2,  1x Transcription Buffer, 0.5 µg Random primers/ oligo dT primers, 1u/ µl 
Recombinant Ribonuclease Inhibitor, 15u/ µg AMV [Avian Myeloblastosis Virus] 
and Reverse transcriptase and Nuclease–free water to a final 20 µl total reaction 
volume).  The reaction programme for random primer RT was: 22°C/ 10 min, 
48°C/30 min, 95°C/ 5 min, 4°C. For oligo dT primer RT, the programme was: 48°C/ 
30 mins, 95°C/ 5 min, 4°C. After the RT reaction, 1µg of total RNA generated a 
corresponding 1µg of cDNA. 
 
 125 
 
 
Figure 2.2 Alternative types of PCR primer.  
Random primers start reverse transcription at multiple points along the transcripts, 
normally useful for long mRNA. Oligo dT primers are comprised of oligomers of dT 
sequence, which can recognise and bind to the poly A tail of mRNA, and an adaptor 
sequence at the 5‟ end; it is generally used for amplification if the target sequence is 
adjacent to the poly adenylation region. Figure adapted from Promega. 
2.10.3 Polymerase chain reaction (PCR) 
All PCR products (25 µl) were loaded in to a well in 1% agarose gel, alongside the 
DNA ladder IV (Bioline, #BIO-33029). Image J software was used to quantify PCR 
products by densitometry and all the data were generated relative to GAPDH. 
Triplicate samples from at least three independent biological replicates were 
analysed to generate standard deviations. Different PCR reaction conditions used for 
different HAX1 isoforms are listed in Table 2.5. 
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Table 2.5 PCR primers and conditions for each reaction. 
2.11 Fluorescence Activated Cell Sorting (FACS) 
Cells infected with Turbo-GFP tagged shRNA were harvested by trypsinisation and, 
to maintain sterility, antibiotic (1.25 µg/ml of puromycin) was added. Cells were 
sorted on a FACS machine (Aria II: Beclon-Dickinson) by Dr. G. Rosignoli in the 
Cell Imaging and Analysis Lab, Barts Cancer Institute. 100,000 cells from the top 
10% GFP-positive cells were sorted and re-cultured in a well of a 24 well plate, 
incubated at 37 °C. Cells were expanded and re-analysed for GFP and HAX1 
expression. 
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2.12  Flow Cytometry 
Confluent cells were trypsinised and washed with E4/0.1/0.1 buffer (DMEM/ 0.1% 
(w/v) BSA [Bovine Serum Albumin, Invitrogen]/ 0.1% (w/v) sodium azide) three 
times. The cells were mixed well by pipetting to generate single cell suspensions and 
were labelled with appropriate antibodies (10µg/ml 10D5: against αvβ6 integrin, 
Chemicon, #MAB2077Z; 23C6: against αvβ3 integrin, Chemicon, #CBL544; P1F6: 
against αvβ5 integrin, Chemicon, #GEM1961; 4F1: against αvβ8 integrin, 
Chemicon; L230: against αv integrin subunit, Chemicon; P4C10: against β1 integrin, 
Chemicon, #MAB1987;) or mouse IgG isotype control (10µg/ml, BD) on ice for 45 
minutes. After three washes, cells were labelled with appropriate secondary 
antibodies: Alexafluor 488 conjugated goat-anti-mouse antibody (Invitrogen, 
#A11001) or Alexafluor 647 conjugated donkey-anti-mouse antibody (Invitrogen, 
#A31571) for GFP-expressing cells and incubated on ice for 30 minutes. Cells were 
analysed on a FACScalibur (Becton Dickinson) flow cytometer using Cellquest Pro 
software and data were generated from analysing 10,000 cells. 
2.13 Immunofluorescence Staining and Confocal 
microscopy 
Cells were seeded and grown on glass slides before 50nM of MitoTracker Orange 
CMTMRos was added to the cells in growth medium for 30 minutes at 37°C to stain 
mitochondria (Invitrogen, #M7510). MitoTracker Orange CMTMRos is an orange-
fluorescent dye that stains mitochondria in live cells and its accumulation is 
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dependent upon membrane potential. The dye is well-retained after aldehyde 
fixation. The cells were then fixed with actin fixer (0.5M MES, Sigma-Aldrich, 
#M5287; 1M KCl, Fisher Scientific, #p/4280/53; 1M MgCl2, Sigma-Aldrich, 
#M8266; 0.5M EGTA, Sigma-Aldrich, #E2478) for 10 minutes at room temperature 
and permeabilised in 0.1% Triton X-100 for 5 minutes before being blocked with 
blocking solution E4/0.1/0.1 buffer (DMEM/ 0.1% (w/v) BSA/ 0.1% (w/v) sodium 
azide) for 30 minutes. Cells were then incubated with the desired primary antibody 
for 1 hour at room temperature followed by appropriate secondary antibodies for 30 
minute (see 2.5). The coverslips were then mounted with 5µl Prolong Gold reagent 
with 4‟,6-diamidino-2-phenylindole (DAPI, Invitrogen, #P36931). Confocal images 
were generated on a Zeiss LSM510 and LSM710 laser scanning microscope and 
quantification analysis was generated by using Zen software. 
2.14 Cell density dependent –HAX1 expression experiments 
VB6 and H400 oral carcinoma cells were seeded with different cell numbers (2.5 x 
10
4
, 5 x 10
4
, 10 x 10
4
, 20 x 10
4
, 40 x 10
4
) in a 12-well plate, after indicated time 
points of culture (24, 48 and 72 hours), cells were harvested at the different 
confluences. Protein concentrations were determined and equivalent amounts of 
protein were added to 12 % gels for Western blot analysis. 
2.15 MTT colorimetric assay 
100 µl of MTT solution (0.2mg/ml) (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium , Sigma Chemicals, #5655) diluted in serum-free medium was 
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added to the cells after removal the culture medium, and incubated at 37°C for an 
additional 45 minutes. The reaction was terminated and formazan crystals were 
dissolved with dimethylsulphoxide (DMSO, 100 µl per well). Absorbance values 
were determined at 550nm by using a spectrophotometer. Data are expressed as 
mean percentage of survival. Experiments were repeated at least three times in 
quadruplicate wells. 
2.16 Cell fractionation 
2.16.1 Cell harvest 
Confluent cells cultured in a 10cm dish were washed in cold PBS once and washed 
in cold hypotonic buffer (10mM HEPES pH 6.9, 10mM KCl). The cells were then 
lysed and scraped in 500 µl hypotonic buffer with protease inhibitor cocktail (1:100, 
Calbiochem). The cell lysate was then incubated on ice for approximately 25 
minutes (cells were observed to lose cell membrane potential by microscopy) and 
then I separated the supernatant and pellet by centrifugation at 1000 x g for 3 
minutes at 4°C. The resulting supernatant comprised the cytoskeletal fraction 
(process to 2.16.2) while the pellet contained the cytosolic and heavy membrane 
fractions (process to 2.16.3).  
2.16.2 Nuclear fraction isolation 
The resulting pellet was subsequently washed with 150µl NTENT lysis buffer 
(10mM Tris-HCl pH 7.2, 10mM NaCl, 1mM EDTA, 1% Triton X-100, 1:100 
 130 
 
protease inhibitor cocktail). The resulting pellet was resuspended in 100µl NTENT 
buffer and centrifuged at 14000 x g for 3 minute at 4°C. The pellet represented the 
nuclear fraction. 
2.16.3 Cytosolic fraction isolation 
The pellet contained the cytosolic and heavy membrane fractions (from 2.16.1) were 
centrifuged at 14,000 x g for 30 min at 4°C. The resulting supernatant contained the 
cytosolic fractionation. The pellet was then processed to isolate the heavy membrane 
fraction (to 2.16.4). 
2.16.4 Heavy membrane fraction isolation 
The pellet was suspended in 150µl NTENT buffer before being centrifuged at 14,000 
x g for 30 min at 4°C. The resulting supernatant contained the heavy membrane 
fraction. 
Western blotting was employed to examine the proteins in each fraction. Markers for 
the protein fractionation are used to validate the purity of the fractions: β6 for heavy 
membrane (β6 was found in heavy membrane in the previous study from my lab), 
actin for the cytoplasm and lamin for the cell nucleus. The fractionation protocol is 
adapted from [219]. 
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2.17 Functional assays 
2.17.1 Clonogenic assay 
100 cells were plated in triplicate wells of 6-well plates. Cells were cultured for 10 
days with media changed every three days. The cells were then stained with 0.1% 
crystal violet in methanol for 1 hour at room temperature. The excess stain was 
removed with running water and the plates were left to dry. Image J software was 
used to measure the number of colonies from triplicate wells. 
2.17.2 Proliferation assay 
Cells were seeded at 5000 cells per well in 96-well plates and grown in growth 
media at 37°C and harvested at predetermined time points (1, 2, 4, 6, 8 days). 
Proliferation was measured by Picogreen-based fluorescence assay. PicoGreen is a 
fluorescence-generating dye, which binds to DNA, and the relative fluorescence can 
be detected quantitatively by a fluorimeter. 200 µl TE buffer (10 mM Tris-HCl, 1 
mM EDTA, pH 7.5) was added to the cells and mixed with PicoGreen fluorescent 
dye (Invitrogen, #P7581) and incubated for 5 minutes at room temperature, protected 
from light, following manufacturer‟s guideliness. After incubation, the sample 
fluorescence was measured by using a fluorescence microplate reader at 
480nm/520nm. To ensure that the sample readings remain in the detection range of 
the fluorimeter, the gain was set so that the sample containing the highest DNA 
concentration yields fluorescence intensity near to, but below, the fluorimeter‟s 
maximum. To minimise photobleaching effects, the time for fluorescence 
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measurement was constant for all samples. The data represent triplicate samples 
from one of two independent experiments showing similar results. 
2.17.3 Migration assay 
Cell migration assays were performed with Transwell inserts (Corning, #3422) with 
8µm polycarbonate pores. Before use, the underside of the membranes were pre-
coated with 70µl of 0.5% BSA or extracellular matrix substrate (0.5µg/ml LAP, 
Sigma-Aldrich, #L3408; 10µg/ml laminin, Sigma-Aldrich, #L2020; 10µg/ml 
collagen, Sigma-Aldrich, #C7774; 10µg/ml fibronectin, Sigma-Aldrich, #F2006) for 
30 minutes at room temperature. Cells were trypsinised, washed in serum-free 
media. 100 µl of cells (5 × 10
4
) were plated into the top chamber of the Transwell 
filters with the lower chamber containing 480µl of migration buffer (1g of BSA and 
5ml glutamine in 200ml serum-free media). Cells were allowed to migrate for 16 
hours at 37°C. The cells were then trypsinised to detach separately from both the top 
and bottom chambers and counted on a CASY-1 cell counter (Scharfe System 
GmbH). Percentage migration was determined by the number of cells in the lower 
chamber relative to the total number of cells in the well. Data are expressed as mean 
percentage of cells migrating. Experiments were repeated at least three times in 
quadruplicate wells. 
2.17.4 Scratch-wound healing assay 
1 x 10
5 
cells were plated in 24-well plates with coverslips and allowed to grow to a 
confluent monolayer. Experimental wounds were made by dragging a plastic blue 
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pipette tip across the cell culture. Cultures were then rinsed with PBS three times to 
remove non-adherent cells and replaced with fresh culture media and cells were 
allowed to migrate overnight. Cells were then incubated with 300µl of 50nM 
mitotracker (Invitrogen, #M7510) for 30 minutes at 37°C and fixed with actin fixer 
for 10 minutes at room temperature. Permeabilisation was done with 0.1% Triton X 
in PBS for 5 minutes before blocking with blocking buffer for 30 minutes. The 
procedure for staining is outlined in section 2.13. 
2.17.5 Invadopodia formation-ECM degradation assay 
2.17.5.1 Preparation of fluorescent Rhodamine-gelatin 
50ml buffer solution was made with 61 mg NaCl (Sigma-Aldrich, #21346) and 
50mM sodium borogydrate (Sigma-Aldrich, #21346). 100mg of gelatin (Sigma-
Aldrich, #120240) was dissolved in the buffer solution at 37°C for 1 hour. 1.8mg of 
Rhodamine (Sigma-Aldrich, Rhodamine123) was then added, mixed and covered in 
the dark for 2 hours at room temperature. The solution was placed in a Slide-a-Lyzer 
(Thermo Fisher) and dialysed in PBS for 48 hours at 4°C. Two litres of PBS were 
changed three times each day. 136 x g spin for 30 seconds was applied to remove 
insoluble material before adding 1g sucrose. The homogenous Rhodamine-gelatin 
solution was aliquoted and stored at 4°C till use.   
2.17.5.2 Coating coverslips with Rhodamine-gelatin 
Rhodamine-gelatin was warmed in a waterbath and quickly centrifuged to remove 
the insoluble materials before use. Coverslips were inverted on a 40µl drop of gelatin 
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and incubated for 15 minutes in dark. The coverslips were then transferred to 20µl of 
0.5% glutaraldehyde (Sigma-Aldrich, #G5882) for 5 minutes, and gently washed 
three times with PBS in a well of a 24-well plate. Coverslips were incubated with 
200 µl of NaBH4 (Aldrich Chemicals) at 37°C for 3 minutes. After washing three 
times with PBS, 70% ethanol was then added to the coverslips for 5 minutes. Ethanol 
was washed away by PBS and the coverslips were incubated with growth media for 
1 hour at 37°C. The coverslips were then ready to use. 
2.17.5.3 Invadopodia assay 
1.5 x 10
5
 of cells were seeded on the Rhodamine-getatin coated coverslips in a well 
of a 12-well plate and incubated for 1, 2, 3, and 4 hours. PBS was used to rise off 
unattached cells and 300 µl of actin fixer (0.5M MES, Sigma-Aldrich, #M5287; 1M 
KCl, Fisher Scientific, #p/4280/53; 1M MgCl2, Sigma-Aldrich, #M8266; 0.5M 
EGTA, Sigma-Aldrich, #E2478) was applied to the coverslips for 20 minute to fix 
the cells. After washing with PBS, cells were then incubated with 500µl of 50mM 
NH4Cl for 10 minutes. To detect actin, 200µl of 10 µg/mL of FITC-labelled 
phalloidin (Sigma-Aldrich, #P5282) was added and incubated for 20 minutes. The 
final wash was then performed with PBS for three times and followed by distilled 
water for three times. The coverslips were then mounted with 5µl Prolong Gold 
reagent with DAPI (Invitrogen, #P36931). The samples were examined on an 
Axioplan upright fluorescence microscope (Zeiss, UK) using x40 and x63 objective 
oil-immersion objective lens. The image analysis was done by using Image J 
software.   
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2.17.6 Invasion assay 
Invasion assays were performed using Transwell plates (8µm pore, 6.5mm diameter, 
Corning, #3422) which allow any invasive cell to go through. Matrigel (BD 
Bioscience, #354234), which is a mixture of basement membrane-like proteins, 
including laminin, collagen IV, heparan sulphate proteoglycans, entactin/nidogen 
and growth factors such as TGF-beta, epidermal growth factor, insulin-like growth 
factor, fibroblast growth factor, tissue plasminogen activator, was added to the upper 
chamber (70 µl Matrigel [1:2 dilution in α-MEM]) and incubated at 37 °C for an 
hour to allow gelling. Cells (5x 10
4
) in 200 µl serum-free α-MEM were then placed 
into the upper chamber and 500 µl of KGM was added in the lower chamber as a 
chemoatractant. After 72 hours incubation, invaded cells were harvested by 
trypsin/EDTA to detach cells in the lower chamber and on the undersurface of the 
filter. Cell numbers were counted on a CASY1 Cell counter (Scharfe Systems, 
Germany). Transwell invasion assay experiments were repeated three times, with 
sextuplicate wells for each treatment. Invasion analysis showed the number of cells 
invaded through to the lower chamber. 
2.17.7 Organotypic invasion assay 
The organotypic gels were composed of a 1:1 mixture of Matrigel and type 1 
collagen (Upstate, Millipore) containing 5 x10
5 
human fibroblasts. Once set in a well 
of a 24 well plate 5 x 10
5
 carcinoma cells were added. The mixtures were plated into 
wells of a 24-well plate and the growth media was changed every 2 days for 14 days 
incubation. The gels were then fixed in 10% formal saline, bisected, and embedded 
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to paraffin. Bright field images of H&E staining were taken at ×630 magnification. 
All cell counts and analyses were done in six random fields per gel from at least 
three independent gels. Image J software was employed to analyse the images. The 
invasion index was calculated using the product of the average depth of invasion, the 
number of invading particles, and the area of the invading particles. Method adapted 
from [220]. 
2.17.8 Autophagy assay 
2.17.8.1 Blockage of autophagosome-lysosome fusion by chloroquine 
Cells were grown to sub-confluence and the growth media was replaced with normal 
growth media with or without 50μM chloroquine (CQ, Sigma-Aldrich, #C6628) for 
24 hours before fxation for the confocal microscopy examination. For Western blot, 
the cells were rinsed twice with HBSS (Invitrogen, #14025-076) before adding 
HBSS containing 50μM CQ for starvation with CQ treatment, or normal growth 
media with CQ. The cells were returned to the incubator for designated time courses. 
Method adapted from [221]. 
2.17.8.2 Starvation-induced autophagy 
Cells were grown to sub-confluence and the growth media was replaced with HBSS 
for “starvation” (two rinses in HBSS before being placed in HBSS). The cells were 
then incubated in HBSS for various time points. 
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2.17.8.3 Rapamycin-induced autophagy 
The cells were grown to about sub-confluence and the 1, 10 or 20 μM rapamycin 
(Sigma-Aldrich, #R0395) was added and incubated for designated time points. 
2.17.8.4 Confocal microscopy 
Confocal images of LC3b signals were generated on a Zeiss LSM510 and LSM710 
laser scanning microscope. The detailed procedure is referred to in section 2.13. 
2.17.9 Cytotoxic assay 
Cells were seeded at 5000 per well in 96-well plates and grown in media overnight. 
Induction of cell death was performed by incubation with various concentrations of 
cytotoxic drugs (5-FU; Etoposide; Taxol; Cisplatin) for 72 hours. After treatment, 
cell viability was determined using MTT colorimetric assay (see section 2.15.). 
Experiments were repeated at least three times in quadruplicate wells.  
2.18 Statistical analysis 
Statistical differences between experimental groups were evaluated by Student‟s t 
test (two tailed). The Mann-Whitney U test was advised to evaluate the significance 
of the changes in the cytotoxic assay by statistician Mr. Adam Brentnall (Barts 
Cancer Institute). The statistical calculations were conducted by using Prism 
software. 
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CHAPTER 3.  CHARACTERISATION OF HAX1 
ANTIBODIES 
3.1 Introduction 
There is a broad range of commercially available HAX1 antibodies and the variation 
between each antibody may give different results for HAX1 expression, functions or 
subcellular localisations. Thus it is very important to characterise the HAX1 
antibodies and choose the optimal antibody for each application.  
I tested a panel of five different antibodies to HAX1: E20 from Santa Cruz, sc-
34273; P20 from Santa Cruz, sc-16637; N17 from Santa Cruz sc-16636; BD from 
BD Transduction Laboratories, 610825; RD from R&D Systems, AF5458. Among 
these, the BD antibody had been used most widely in various studies [1,20,26,30-
32,110,140,144,149,222].  
I examined the different HAX1 antibodies for their ability to Western blot and also 
for their ability to immunostain since there are various subcellular localisations 
which have been reported for HAX1: predominantly in the cell mitochondria (in 
HeLa, COS-7, HEK293, DG75, B lymphoma and striated muscle cells 
[3,12,19,26,27]), also found in the nucleus (COS-7 and DG75 [3,27]), ER (in COS-
7, HeLa, HEK293 cells [3,12,28]), cytoplasm (COS-7 and HEK293 cells [21,29]) 
and in the plasma membrane and the lamellipodia in COS-7 cells [8].  
 139 
 
3.2 Results 
3.2.1 siRNA oligos target to HAX1 
To verify that the antibodies used in this study recognised HAX1, I tested siRNAs to 
HAX1 that could knockdown all HAX1 isoforms. Two different siRNA duplexes 
were designed by Dr. Delphine Lees and produced by Dharmacon RNAi 
Technologies. The sequences were validated by using BLAST (Basic Local 
Alignment Search Tool). Table 3.1 shows the sequences and the targeting HAX1 
isoforms: si192 targets to the 3‟UTR of HAX1 recognising isoforms1-8; si1-6 targets 
to exon2 and knocksdown HAX1 isoforms 1-6.  
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Table 3.1 Sequences of siRNA oligos and the sequences targeted.  
siRNA oligos which target to different regions of HAX1 are shown in (a). si1-6 
recognises exon 2 of HAX1 whereas si192 targets 3‟UTR of HAX1. (b) shows 
targeted HAX1 isoforms by siRNAs and the isoforms are indicated as “V”. 
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3.2.2 Testing HAX1 antibodies by Western blotting 
I firstly characterised the different HAX1 antibodies by Western blot. Oral squamous 
carcinoma cells VB6 were treated with control siRNA (siNTC) or HAX1 siRNA 
(si1-6) to transiently knockdown the endogenous HAX1. The lysates were prepared 
48 hours after transfection and equal amounts (30µg) of protein were loaded onto a 
12% SDS-PAGE gel. Western blots probed with different anti-HAX1 antibodies 
(E20 from Santa Cruz, sc-34273; P20 from Santa Cruz, sc-16637; N17 from Santa 
Cruz sc-16636; BD from BD Transduction Laboratories, 610825; RD from R&D 
Systems, AF5458, Table 3.2) and suitable secondary antibodies (see Methods 
section). Table 3.2 also shows the epitopes for the antibodies, the antibodies from 
BD and RD recognise the HAX1 sequence from amino acid 10-148 and 2-261, 
respectively, whereas the antibodies from Santa Cruz (P20, E20, P17) were not 
characterised in full detail. Results show that BD and RD antibodies successfully 
detected endogenous HAX1 as around a 34 kDa band whereas other antibodies (E20, 
P20 and N17) were not sufficient for detecting HAX1 by Western blotting (Figure 
3.1). This band of the endogenous HAX1 is confirmed by the absence of a similar 
band following by siRNA (si1-6) treatment (Figure 3.1). 
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Table 3.2 Souces of antibodies to HAX1.  
Different antibodies to HAX1 are listed in the Table. The antibodies from BD and 
RD recognise the HAX1 sequence from amino acid 10-148 and 2-261, respectively, 
whereas the antibodies from Santa cruz (P20, E20, P17) did not give the full detail of 
the immunogen used. 
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Figure 3.1 Testing different HAX1 antibodies by Western blot.  
VB6 were treated with HAX1 siRNA (si1-6) or control siNTC [shown as (-)] and the 
cell lysates were prepared 48 hours after transfection. Equal amounts of protein were 
loaded onto 12% SDS-PAGE gels. After Blotting, Ponceau Red was used to stain the 
Blot which was then cut into five separate strips which were then probed with 
different anti-HAX1 antibodies. HSC70 served as loading control. Results show that 
BD and RD antibodies successfully detected endogenous HAX1 whereas the other 
antibodies (E20, P20 and N17) did not. Please note, even though this experiment was 
repeated the E20 antibody always generated a non-specific Blotting (lane 3 and 4) 
which resulted a black background after Chemiluminescence-HRP detection. 
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3.2.3 Antibodies from BD and RD showed endogenous HAX1 
localised in mitochondria  
In order to examine the subcellular distribution of endogenous HAX1 in VB6 cells, 
different HAX1 antibodies were tested for immunofluorecence and analysed by 
confocal microscopy. The endogenous HAX1 was knocked-down by HAX1 siRNA 
(si1-6) and the control cells were treated with control siRNA (siNTC). Cells were 
incubated with the mitochondrial dye, Mitotracker (MitoTracker is a fluorescent dye 
that passively diffuses across the plasma membrane and accumulates in active 
mitochondria), before staining with the different HAX1 antibodies and DAPI. Thus, 
labelling control siRNA treated cells showed that BD and RD antibodies gave a 
similar pattern of staining (green, Figure 3.3 and Figure 3.4) which colocalised with 
the Mitotracker labelling (red). The data suggest that the dominant localisation of 
endogenous HAX1 is either on or in mitochondria in VB6 cells. To confirm this, the 
HAX1 siRNA (si1-6) was used to knockdown HAX1 and the repeated 
immunostaining results showed that the mitochondrial labelling was absent in the 
HAX1 siRNA treated cells (Figure 3.3 and Figure 3.4). Of note, sometimes nuclear 
staining of HAX1 was observed, (BD and RD, Figure 3.3 and Figure 3.4) consistant 
with previous reports [3,12,28]. Other antibodies (E20, P20 and P17) did not show 
detectable staining for endogenous HAX1 (Figure 3.2 and Figure 3.3).  
In order to confirm the subcellular localisation of HAX1, cell fractionation was also 
performed followed by Western blotting with the RD antibody. To confirm the 
purity of each fraction, blotting for β6, actin, and lamin was used as the markers for 
heavy membrane, cytoplasm, and nuclear fractions respectively (Figure 3.5). 
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Endogenous HAX1 was detected at approximately 34 kDa (Figure 3.5); the identity 
of the band was confirmed by the reduction in the band intensity after HAX1 siRNA 
treatment [shown as (+)] (Figure 3.5, lane 2, 4 and 6). Data show that the 
endogenous HAX1 was located in the heavy membrane fraction (lane 5 and 6) and 
also in nuclear fraction (lane 3 and 4).  Cytosolic HAX1 was at very low levels (lane 
1 and 2, Figure 3.5). 
Together, antibodies from BD Transduction Laboratories (610825) and R&D 
Systems (AF5458) successfully detected endogenous HAX1 by Western blot and 
immunofluorecence staining. Table 3.3 summarises the suitable applications for 
commercially available HAX1 antibodies. 
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Figure 3.2 Testing the anti-HAX1 antibodies P20 and E20 by 
immunofluorescence.  
VB6 cells treated with control siRNA or HAX1 siRNA (si1-6) were incubated on the 
coverslips for 48 hours. Mitotracker was employed to stain the mitochondria (red) 
before fixation and permeabilisation. Cells subsequently were stained with anti-
HAX1 antibodies (BD and E20) and DAPI (blue). FITC-labelled donkey-anti-goat or 
goat-anti-mouse antibodies were used as corresponding secondary antibodies to 
visualise HAX1 expression (green). Confocal images showed P20 and E20 antibody 
did not detect endogenous HAX1. Scale bar, 10 µm. 
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Figure 3.3 Testing the anti-HAX1 antibodies N17 and BD by 
immunofluorescence.  
VB6 cells treated with control siRNA or HAX1 siRNA (si1-6) were incubated on the 
coverslips for 48 hours. Mitotracker was employed to stain the mitochondria (red) 
before fixation and permeabilisation. Cells subsequently were stained with anti-
HAX1 antibodies (N17 and BD) and DAPI (blue). FITC-labelled donkey-anti-goat 
or goat-anti-mouse antibodies were used as corresponding secondary antibodies to 
visualise HAX1 expression (green). Confocal images showed N17 antibody was not 
able to detect endogenous HAX1 whereas BD antibody successfully stained for 
endogenous HAX1 which was concentrated in the mitochondria as shown by 
colocalisation with Mitotracker (indicated as yellow from red and green). Note there 
is also the nuclear staining with BD antibody. Scale bar, 10 µm. 
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Figure 3.4 Testing the anti-HAX1 antibody RD by immunofluorescence.  
VB6 cells treated with control siRNA or HAX1 siRNA (si1-6) were incubated on the 
coverslipes for 48 hours. Mitotracker was employed to stain the mitochondria (red) 
before fixation and permeabilisation. Cells were subsequently stained with anti-
HAX1 antibodies (RD) and DAPI (blue). FITC-labelled donkey-anti-goat or goat-
anti-mouse antibodies were used as corresponding secondary antibodies to visualise 
HAX1 expression (green). Confocal images showed RD antibody successfully 
detected endogenous HAX1, and that it was concentrated in the mitochondria as 
shown by colocalisation with Mitotracker (indicated as yellow from red and green) 
and also showed the expression in the nucleus. Scale bar, 10 µm. 
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Figure 3.5 HAX1 subcellular distribution.  
VB6 cells were treated with an siRNA which targets to exon 2 of HAX1 (si1-6; 
indicated as [+]) or control siRNA (indicated as [-]), and protein fractionation was 
performed to determine the band(s) for the endogenous HAX1. The equal amounts 
of protein were loaded for each fraction and the endogenous HAX1 was detected 
around 34 kDa (by RD antibody). Western blot shows the expression of HAX1 is 
located in the nuclear fraction (lane 3 and 4) and the heavy membrane fraction (lane 
5 and 6) whereas the HAX1 level is only a trace in the cytosolic compartment (lane 1 
and 2). The markers for the protein fractionation are β6 (110kDa, for heavy 
membrane), actin (42kDa, for cytoplasm) and lamin (lamin A/C, 74 and 65 kDa, for 
cell nucleus). 
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Table 3.3 Characterisation of HAX1 antibodies.  
HAX1 antibodies from different sources were used to examine the suitable 
applications. Results from Figure 3.1, Figure 3.2, Figure 3.3 and Figure 3.4 show the 
antibodies from BD Transduction Laboratories (610825) and R&D Systems 
(AF5458) successfully detected endogenous HAX1 by Western blot and 
immunofluorescence staining. Santa Cruz antibodies (P20, E20, N17) were 
ineffective. x= poor or ineffective, v= good/ effective. 
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3.2.4 HAX1 expression is cell density-dependent 
3.2.4.1 HAX1 protein is expressed at levels which depend on cell density 
Integrin αvβ6 expression has been shown to be dependent on cell density [223] I 
therefore investigated if cell density also affected the expression of the αvβ6 binding 
partner HAX1. To examine whether HAX1 expression is affected by different cell 
densities, VB6 and H400 oral carcinoma cells were seeded into 12-well plates at 
different cell densities (2.5, 5, 10, 20, and 40 x 10
4
 cells, Figure 3.6, a and b), and 
cells were harvested after 24 hours incubation. Protein concentrations were 
determined and equivalent amounts of protein were added to 12% SDS-PAGE gels. 
The results of Western blotting show that the expression of HAX1 varied 
significantly depending on the cell density (Figure 3.6, a and b) in both H400 and 
VB6 oral cancer cell lines. Thus Figure 3.6 (c and d) shows the densitometry from 
three independent experiments indicating that when either VB6 or H400 oral cancer 
cell lines cells were grown in low density (e.g. plated at 2.5 x 10
4
) they expressed 
very little HAX1 protein whereas when the cells were plated at high density they 
expressed significant amounts of HAX1. The experiment, which was repeatable with 
similar results (data not shown), also showed that HSC70 was not an accurate 
loading control for this experiment (24 hours time point) since it also seems to be 
expressed at reduced levels in low density cells (Figure 3.6.). 
As both HAX1 and the loading control HSC70 were affected by cell density 24 
hours after seeding, it was considered that maybe 24 hours after cell seeding was too 
short to be an accurate time point to assess stable protein expression. Thus Western 
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blot analysis was repeated with cells cultured and harvested at longer time points (48 
and 72 hours after plating). Data demonstrated that all control loading proteins 
examined (HSC70, actin, tubulin) and HAX1 showed cell density-dependent 
expression at all time points (Figure 3.7, a, b and c). However, while HAX1 
expression was still much more varied with cell density at 48 h and 72 h (Figure 3.7, 
b and c), the expression of the control proteins (HSC70, actin and tubulin) were more 
consistent (especially HSC70). These data revealed that HAX1 protein expression 
correlates with cell density. Hence all the subsequent analyses of HAX1 expression 
were performed on confluent cells that had been plated for at least 48 hours and I 
chose HSC70 as a loading control. 
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Figure 3.6 Density-dependent expression of HAX1 protein.  
VB6 and H400 cells were seeded at different cell numbers and were harvested after 
24 hours. Equal amounts of protein were loaded onto 12% SDS-PAGE gels and 
Western blots were probed with anti-HAX1 antibody (BD). The bands were analysed 
by densitometry and HAX1 expression was plotted with the loading control HSC70. 
Data show that the expression of HAX1 varies significantly depending on cell 
density (a, b). In both VB6 and H400 oral cancer cell lines, cells grown at low 
density have very little HAX1 whereas cells at high density have significant amounts 
of HAX1 (c, d). Note that at low density, the expression of HSC70 also is reduced. 
Experiments were repeated at least three times and the figures (a and b) show one of 
the experiments. Data show mean +/- one standard deviation of at least three 
experiments. 
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Figure 3.7 Analysis of HAX1 protein expression at different cell densities.  
VB6 and H400 cells were seeded at 2.5, 5, 10, 20 and 40 x10
4
 into wells of 12-well 
plates. Cells were harvested at 24 (a), 48 (b) and 72 (c) hours, protein concentrations 
were determined and equal amount of protein was loaded onto 12% SDS-PAGE 
gels. The membranes were probed for HAX1 (BD), HSC70, actin and α-tubulin. The 
bands were quantified by densitometry and expression of proteins was plotted 
against cell density.  
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3.2.4.2 HAX1 changes its subcellular localisation in different density cultures   
In order to investigate further the density-dependent expression of subcellular 
distribution patterns, immunocytostaining was employed to examine HAX1 
localisation under the conditions of sparse culture versus confluent culture. Images 
from confocal microscopy showed HAX1 is localised predominantly in 
mitochondria in sparse culture, whereas in confluent monolayers an increased 
amount of HAX1 was seen also in the cytosol, distinct from the mitochondria 
(Figure 3.8, a). To quantify these differences, the colocalisation coefficient of HAX1 
signal and mitochondrial signal was analysed with Zen software. This analysis 
showed that in dense culture HAX1 colocalisation in mitochondria was significantly 
(p< 0.0001) reduced compared with cells in sparse culture (Figure 3.8, b) indicating 
that HAX1 protein can both change localisation as well as modify the level of 
expression at different cell densities. 
To validate the observations from staining, the cell fractionation technique also was 
employed to separate the cell compartments. To ensure the purity of each fraction, 
the appropriate markers were also Blotted (actin for cytosolic marker; beta6 for 
heavy membrane marker; lamin for nucleus marker). Fractionation data also showed 
the increased HAX1 expression in the cytosolic fraction at high cell density culture 
(Figure 3.8, (c), cytosolic H) compared with low cell density culture (Figure 3.8, (c), 
cytosolic L).  
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Figure 3.8 Sub-cellular localisation of HAX1 protein varies with cell density.  
To determine the sub-cellular distribution of HAX1, VB6 cells were labelled with an 
antibody which recognises all HAX1 isoforms (RD). The cells were fixed with 
methanol/acetone and then stained with Mitotracker (red), anti-HAX1 antibody 
(green) and DAPI for cell nucleus (blue). HAX1 expression was primarily localised 
in mitochondria in sparse culture (a, top panel), whereas more diffuse staining was 
observed in confluent cell culture (a, lower panel). Scale bar, 10 µm. Figure (b) 
shows the HAX1 localisation in mitochondria is significantly less at high cell density 
compared with low cell density. Quantification was done with Zen software (Zeiss 
LSM710) with 30 cells from 3 random fields, colocalisation coefficient represents 
relative number of colocalising pixels as compared with the total number of pixels, 
(0: no colocalisation, 1: all pixels colocalise). *** = p value < 0.0001. (c) VB6 cells 
were harvested at confluence or sparse culture and samples fractionated into 
cytosolic, nuclear and heavy membrane fractions. Purity of fractions was confirmed 
by Blotting for actin, lamin or β6 as shown. Membrane was blotted with anti-HAX1 
antibody (RD). L: low cell density, H: high cell density.  
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3.2.4.3 mRNA of HAX1 isoforms was not altered by different cell densities 
In order to analyse the relationship between the cell density and HAX1 isoform 
expression, semi-quantitative PCR was employed to detect each HAX1 isoform 
mRNA level by using specific primer pairs. To optimise PCR conditions and 
determine the amount of template to use, initially, variable amounts of cDNA 
templates (1, 5, 25, 50, 100 and 200 ng) were used to perform PCR for each isoform, 
in triplicate. After electrophoretic separation of the PCR products, densitometric 
digital images were analysed by Image J. Figure 3.9 shows the plots for the PCR 
products for each isoform. From these data, I chose 50 ng of template for semi-
quantitative PCRs for each reaction so that the reactions remained in the exponential 
amplification range. 
In order to examine the cell density and HAX1 isoform expression, semi-quantitative 
PCR was performed to investigate the mRNA level of individual isoforms at 
different cell confluence. VB6 cells were seeded into 12-well plates with different 
cell numbers (2.5, 5, 10, 20, and 40 x 10
4
 cells) and total RNA was extracted after 48 
hours. 1µg of RNA was reverse-transcribed and 50 ng of cDNA was amplified with 
specific primer pairs and using the optimal, but different, PCR reactions (see 
Methods section). Figure 3.10 shows the transcripts for the HAX1 variants were 
unchanged at the different cell densities. All PCR results were performed at least 
three times and data were generated relative to GAPDH.  
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Figure 3.9 Analysis of the variation of HAX1 isoform levels.  
Variable amounts of cDNA templates (1, 5, 25, 50, 100 and 200 ng) were used to 
perform PCR for each isoform. After electrophoretic separation of the PCR products, 
densitometric digital images were analysed by Image J.  GAPDH was used as 
control. The plots are the mean of three independent experiments. 
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Figure 3.10 HAX1 variant mRNA expression at different cell densities.   
Semi-quantitative RT-PCR was employed to analyse the mRNA level of HAX1 
isoforms. VB6 cells were seeded into 12-well plates with different cell numbers (2.5, 5, 
10, 20 and 40 x10
4
) and cells were harvested at different stages of confluence after 
48 hours. 1µg of RNA was reverse-transcribed and 50 ng of cDNA was amplified 
with specific primer pairs using the optimal but different PCR reactions. Data show 
that equal amounts of mRNA were expressed for all isoforms at the different cell 
densities. All PCR data were from experiments performed at least three times, 
GAPDH is employed as loading control. 
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3.3 Discussion 
There are various commercially available antibodies for HAX1 and it was important 
to characterise the HAX1 antibodies before choosing which antibody was suitable 
for specific applications in my project. Herein, I tested various HAX1 antibodies by 
Western blot and immunofluorescence staining. The results showed that HAX1 
antibodies (from BD and RD) are efficient for both applications. Another method I 
could have used to evaluate the antibody specificity is by pre-incubation of antibody 
with the immunogen prior to its use immunochemically. If the antibody bound to the 
specific blocking peptide used to generate the antibody, then it would no longer be 
available to bind to the epitope present in the protein on the western blot or in the 
cell, resulting an absence of staining. The antigen used for the BD monoclonal 
antibody to HAX1 was the peptide sequence a.a 10-148. In contrast, the RD goat 
antibody is to a.a 2-261 of HAX1, almost the whole protein. The antibody from BD 
antibody demonstrated a weaker signal for Western blotting (it needs higher 
antibody concentration as well as longer exposure time for the chemiluminescent 
signals) compared with RD antibodies, probably because the latter is a polyclonal 
with multiple anti-HAX1 antibodies in the mixture. Thus I primarily use the RD 
antibody for the following experiments. 
HAX1 has been reported to localise in multiple cellular compartments 
(mitochondria, ER, cell nucleus) [3,19,27]. In VB6 cells, the endogenous HAX1 
showed a predominant localisation to the mitochondria and this was confirmed by 
two different HAX1 antibodies (BD and RD) (unpublished data from my lab). The 
mitochondrial HAX1 staining was absent following treatment with HAX1 siRNA, 
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confirming this is genuine HAX1 expression. In line with the immunofluorecence 
staining results, cell fractionation experiments also demonstrated the abundant 
expression of HAX1 in heavy membrane compartment (which includes cell 
membrane and mitochondria) and this is also the major localisation reported for 
HAX1 [19,27,30-32]. Despite the predominated mitochondrial expression, HAX1 
also appeared in cell nucleus using immunofluorescent staining approach, indicating 
the nuclear localisation. By fractionation, endogenous HAX1 also appeared in the 
cell nuclear fraction, this observation has also been reported previously [27,32,224]. 
In addition, minor expression of HAX1 was observed in the cell cytoplasm, in line 
with other studies [29,38,65]. 
Contact inhibition is a process by which cells stop proliferating when they reach 
confluence, despite the availability of extracellular nutrients and growth factors 
[225,226]. Cancer cells develop mechanisms to escape contact inhibition resulting in 
unlimited growth [227].  Interestingly, αvβ6 has been reported to be expressed in a 
density-dependent manner. Niu et al showed that high cell density selectively 
enhanced expression of β6 (with unchanged levels of the αv-subunit) in a protein 
kinase C (PKC)–dependent manner in colon cancer cells [223], resulting in a marked 
increase in MMP-9 secretion as cells reached confluence. This may facilitate ECM 
degradation, which helps overcome cell crowding and restore cell proliferation as 
well as cell invasion [223]. We investigated whether HAX1 is also influenced by cell 
density. Results showed that endogenous HAX1 expression, like integrin αvβ6, 
increased with increasing cell density. Data show the relatively lower expression of 
the protein in cells grown in the sparse culture while abundant amounts of HAX1 
were expressed in confluent culture. Of note, overcrowding and excessive cell death 
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was observed in the highest cell density (40 x 10
4
) after 48 hours culture, indicating 
this seeding density caused stress by overcrowding the cells. The second dense 
confluency (20 x 10
4
) showed a confluent and healthy cell culture after 48 hours 
incubation, thus it was chosen as the confluency that I should use for further 
experiments. These experiments also showed the density dependent expression of all 
“loading control” proteins tested (HSC70, tubulin and actin) especially at the 24 
hours time point post-plating while they seen stabilised at the longer time points. 
HSC70 performed as the most stable marker among these molecules therefore I used 
HSC70 as my loading control for all the following experiments. Taken together, 
these observations are very important for my study of the cellular functions of HAX1 
and thus I always ensured experiments were done with confluent cells (20 x 10
4
 in a 
well of a 12-well plate). Interestingly, the RT-PCR showed there was no significant 
change in the mRNA levels of HAX1 isoforms 1, 2, 4, 5 and 6 at the different cell 
densities, suggesting the increase in HAX1 protein must be post-translational. It also 
is possible that HAX1 half-life increases at higher cell densities but I have not 
evaluated this possibility. 
Immunofluorescence staining was performed with different densities of cell cultures 
to examine subcellular distribution of HAX1. This revealed a striking expression 
pattern of endogenous HAX1: from a predominantly mitochondrial expression in 
sparse culture, HAX1 appeared at a markedly higher level in the cytosol in confluent 
cells.  HAX1 has been reported to change its subcellular distribution in order to 
execute certain cellular functions. For example, exogenous HAX1 was located in 
mitochondria but when it was co-expressed with either PKD2 in HeLa cells or 
cortactin in COS-7 cells, it preferentially concentrated into the plasma membrane 
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and at the tips of cell processes, respectively, where its binding partners were also 
located [8]. This redistribution of HAX1 was shown in migrating cells, further 
suggesting that it may be involved in cell motility and migration through its direct 
binding to cytoskeletal proteins such as PKD2 or cortactin [8].  
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CHAPTER 4.  HAX1 REGULATES MIGRATION IN 
VARIOUS CANCER CELL LINES  
4.1 Introduction 
HAX1 has been reported to regulate cell migration via different mechanisms. HAX1 
binds to cytoskeleton associated molecules such as Gα13, Cortactin, PKD2, PELO 
which contribute to actin dynamics and cell movement [8,49,56]; a recent study also 
showed it interacts with urokinase-type plasminogen activator (uPA) receptor 
(uPAR) and enhances breast cancer cell migration [65]; the previous work from in 
my lab, by Ramsay et al, showed that HAX1 binds to the cytoplasmic tail of integrin 
αvβ6, and the interaction is essential for the endocytosis of the integrin and this 
internalisation of αvβ6 is also crucial for oral squamous carcinoma cell migration 
and invasion [1]. 
Integrins act as adhesion receptors by binding cells to extracellular ligands such as 
collagens, laminins, or fibronectin and vitronectin [158]. The interaction between 
integrins and their ligands controls cell behaviour by signalling from the 
extracellular environment [158]. Latency-associated peptide (LAP) is the protective 
propeptide of latent TGF-β and it is also a ligand for certain integrins [216]. LAP-β1 
and LAP-β3 contain the integrin-recognition motif Arg-Gly-Asp site (RGD). Eight 
integrins recognise the RGD site in their ligands: α5β1, α8β1, αvβ1, αvβ3, αvβ5, 
αvβ6, αvβ8 and αIIbβ3, of these αvβ6 and αvβ8 are high affinity receptors for LAP-
β1 and LAP-β3 [216].  
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In this section, I will firstly repeat the experiments from Ramsay et al [1] to examine 
whether HAX1 regulates oral cancer cell migration, and then I will test HAX1-
regulated migration in other cancer cell lines (breast, pancreas and cervix) in order to 
see whether this is an oral cancer cell-specific or a general phenomenon for a broad 
range of cancer cells. Also I will test which integrins HAX1 regulates for cell 
migration in these cancer cell lines. Finally I shall test the immortalised human 
keratinocyte line HaCat cells as an example of a non-cancerous keratinocyte for the 
role of HAX1 in noncancerous cell migration. 
4.2 Results 
4.2.1 HAX1 regulates oral carcinoma cell migration 
As described in the previous section (see 3.2), siRNA1-6 targets isoforms 1-6 of 
HAX1 and was used to knockdown HAX1 in the oral squamous carcinoma VB6. 
Western blotting showed the level of HAX1 expression was reduced with siRNA 
(Figure 4.1, a). Transwell cell migration assays were performed toward LAP where 
the migration of VB6 cells is modulated solely through αvβ6 [181]. The depletion of 
HAX1 by HAX1 siRNA significantly decreased migration toward LAP (Figure 4.1, 
b), in line with previous data reported from my lab [1]. Figure 4.1 (c) shows the 
growth study over the same period of time and revealed that there was no significant 
difference in cell number, indicating the change of migration was not due to the 
change of cell growth. 
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Figure 4.1 HAX1 knockdown inhibits oral squamous carcinoma cell 
migration toward LAP.  
VB6 cells were transfected with control siRNA (siNTC) or HAX1 siRNA (si1-6) and 
Western blotting showed the decreased HAX1 expression by HAX1 siRNA (a). (b) 
Cell migration assays were performed across Transwell membranes whose underside 
was coated with 0.5% bovine serum albumin (BSA) or 0.5μg/mL LAP. Data showed 
knockdown of HAX1 suppressed migration by 51%. (c) To determine if HAX1 
knockdown affected cell growth, the total number of cells in the well was determined 
by harvesting the cells from the Transwell. The total cell number was calculated as 
the sum from the cell number of upper chamber and lower chamber. No significant 
change was seen in cell growth. Data showed the mean of quadruplicate samples 
from four separate experiments and error bar represents one standard deviation; ***: 
p-value <0.001. 
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4.2.2 HAX1 regulates cancer cell migration in cell lines from 
multiple tissues 
Since I confirmed that HAX1 regulated oral squamous carcinoma cells‟ migration 
toward LAP (Figure 4.1) I wished to ask whether this is a general phenomenon for 
cancer cells. I therefore tested a panel of cancer cells derived from other tissues 
including: breast epithelial cell, (MCF10 CA1a); pancreas (CFPac1 and Panc 04.03); 
and cervix (HeLa). Two different siRNAs (si1-6 and si192) were used to target the 
HAX1 isoforms to avoid potential off-target effects by using only one siRNA. 
Western blotting showed that siRNA (1: si1-6; 2: si192) decreased the level of 
endogenous HAX1 protein in all treated cells (Figure 4.2 a, b, e and f). Figure 4.2 c, 
d, g and h show that cell migration toward LAP was significantly (p<0.01) inhibited 
by the absence of HAX1 in all the cancer cell lines tested. Notably, β6 expression 
sometime was also suppressed by HAX1 knockdown (Figure 4.2, a and b), and this 
also probably contributes to the decreased cell migration. These data illustrate that 
HAX1 is a central regulator for cell migration as it is not only required for oral 
squamous carcinoma cell migration, but also is crucial for breast, pancreatic and 
cervical cancer cell migration toward LAP. 
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Figure 4.2 HAX1 regulates cell migration toward LAP in breast, pancreatic, 
and cervical cancer cell lines.  
MCF10.CA1a (breast), CFPAC1 (pancreas), Panc04.03 (pancreas) and HeLa 
(cervix) carcinoma cell lines were transfected with non-targeting control (siNTC) or 
two different HAX1 siRNAs (1: si1-6; 2: si192) and then tested in migration assays 
across Transwell membranes coated with 0.5% BSA or 0.5 μg/ml LAP. HAX1 
expression was decreased by siRNA (a, b, e, f) and this inhibited the cell migration 
in all cancer cell tested by up to 60% (c, d, g, h). The % of migration was determined 
by the number of cells in the lower chamber relative to the total number of cells in 
the well. Data show the mean of quadruplicate samples from four separate 
experiments and error bar represents one standard deviation; **: p-value <0.01, ***: 
p-value <0.001. 
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4.2.3 HAX1 modulates αvβ6- and αvβ1–mediated cancer cell 
migration 
Flowcytometry was performed to examine the cell-surface integrin expression 
profile in each of the cancer cell lines using subunit-specific antibodies. Bound 
antibodies were detected with Alexa-488 secondary antibodies then examined on a 
FACS Calibur cytometer (BD Bioscience) and analysed using Cellquest Pro 
software. Figure 4.3 (a-i) shows the different integrin expression patterns determined 
in HeLa cells as an expamle.   
Figure 4.3 (j) summarises integrin expression patterns in the cell lines utilised in my 
studies. Thus all cell lines express the αv and β1 subunits. Using heterodimer-
specific antibodies, Figure 4.3 (j) shows MCF10.CA1a expresses αvβ3 and αvβ6, CF 
Pac1 expresses αvβ6 and αvβ8, Panc04.03 expresses αvβ5 and αvβ6 whereas HeLa 
expresses αvβ5.  
To determine which integrin mediates migration toward LAP, Transwell migration 
assays were performed with the cells treated with specific antibodies against 
individual integrins or their subunits. Figure 4.4 (a) shows that migration of 
MCF10.CA1a, CFPac1 and Panc 04.03 toward LAP was inhibited only by an 
antibody that blocked αvβ6. Blockage of αvβ3, αvβ5 or β1 integrin had no effect. 
Thus these cells lines exhibit αvβ6-dependent migration toward LAP. In contrast, 
blockade of αv integrins or β1 integrins inhibited migration of HeLa cells toward 
LAP. Since blockade of αvβ5 had no effect, and as HeLa cells lack αvβ3, αvβ6 and 
αvβ8, the data suggest HeLa cells express αvβ1 and that this mediates migration to 
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LAP. Taken together, these data show that HAX1 is required for αvβ6 and αvβ1-
dependent migration.  
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Figure 4.3 Integrin screening by flowcytometry.  
Confluent cell were harvested and incubated with specific antibodies which 
recognise individual integrins. Panels (a-i) show the intergrin analyse in HeLa cells. 
Antibodies to individual integrins were used to label cells (10µg/ml 10D5: against 
αvβ6 integrin, Chemicon, #MAB2077Z; 23C6: against αvβ3 integrin, Chemicon, 
#CBL544; P1F6: against αvβ5 integrin, Chemicon, #GEM1961; 4F1: against αvβ8 
integrin, Chemicon; L230: against αv integrin, Chemicon; C4P10: against β1 
integrin, Chemicon, #MAB1987;) or mouse IgG isotype control (10µg/ml, BD). 
Alexafluor 488 conjugated goat-anti-mouse antibody (Invitrogen, #A11001) was 
used as secondary antibody. Cells were analysed on a FACScalibur (Becton 
Dickinson) flow cytometer using Cellquest Pro software and data were generated 
from analysing 10,000 cells. Histograms plot forward scatter (FSC) versus mean 
fluorescent intensity. (j) summarises the different integrin expression profile of each 
cell line. 
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Figure 4.4 αvβ1-dependent and αvβ6-dependent migration toward LAP. 
(a, b, c, d): integrin-dependent migration assay. Various antibodies specific to 
individual integrins were used to block integrins prior to migration assay. L230: 
antibody for αv, P4C10: antibody for β1, LM609: antibody for αvβ3, P1F6: antibody 
for αvβ5. 10D5: antibody for αvβ6. Final concentration is 10µg/ml. Data show 
mean+/- one standard deviation of quadruplicate samples from one experiment. *: p-
value <0.05, **: p-value <0.01, ***: p-value <0.001. 
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4.2.4 HAX1 does not affect cell migration on collagen, fibronectin 
and laminin 
In order to examine whether HAX1 regulates cell migration toward other ligands, 
migration assays were performed with HeLa and MCF10.CA1a cells toward three 
different matrix ligands: collagen, fibronectin and laminin. Inhibition of HAX1 
expression with either of two siRNAs (si192 and si1-6) failed to affect cell migration 
on any of these three ligands in HeLa cells (Figure 4.5, a, c, e); in addition the 
growth rate overnight was not affected by the HAX1 knockdown (Figure 4.5, b, d, f). 
Similarly, HAX1 depletion did not affect migration on these ligands in 
MCF10.CA1a (Figure 4.6, a, c, e) and there was no change in cell growth (Figure 
4.6, b, d, f).  
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Figure 4.5 HAX1 depletion does not change the cell migration toward the 
extracellular ligands collagen, fibronectin nor laminin in HeLa cells.  
HeLa cells were treated with control siRNA (siNTC) or HAX1 siRNA (si1-6 or 
si192) and then were tested in migration assays across Transwell membranes whose 
undersides were coated with 0.5% BSA or 10 μg/ml fibronectin, type 1 collagen, 
laminin-1 (a, c, e). Cells were detached by trypsin and counted. (b, d, f) The total cell 
number was calculated as the sum from the cell number in upper chamber and lower 
chamber. Percentage migration was determined as the number of cells in the lower 
chamber relative to the total number of cells in the well. Data show mean+/- one 
standard deviation of quadruplicate samples from two experiments.  
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Figure 4.6 HAX1 depletion did not change the cell migration on the 
extracellular ligands collagen, fibronectin and laminin in MCF10 CA1a cells.  
MCF10.CA1a cells were treated with control (siNTC) or HAX1 siRNA (si1-6 or 
si192) and then were tested in migration assays across Transwell membranes coated 
with 0.5% BSA or 10 μg/mL extracellular matrix substrate: fibronectin, type 1 
collagen, laminin (a, c, e). Cells were detached by trypsin and counted. (b, d, f) The 
total cell number was calculated as the sum from the cell number in upper chamber 
and lower chamber. Percentage migration was determined as the number of cells in 
the lower chamber relative to the total number of cells in the well. Data show 
mean+/- one standard deviation of quadruplicate samples from two experiments.  
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4.2.5 HAX1 is not required for migration of HaCat human 
keratinocyte cells towards LAP 
Previous sections have demonstrated that HAX1 regulates migration of various 
cancer cells toward LAP. To determine whether HAX1 also affects normal cells 
migration, I examined the immortal, but non-transformed, human keratinocyte cell 
line HaCat for migration toward LAP. Western blotting showed that the HAX1 
knockdown was efficient with two different siRNAs to HAX1 (Figure 4.7, a, d). The 
Transwell migration assays however showed that the HAX1 depletion did not affect 
cell migration of HaCat cells when assayed at either 8 hours or 16 hours migration 
time point (Figure 4.7, b, e); cell growth was not affected by the HAX1 knockdown 
(Figure 4.7, c, f). Collectively, the data may suggest that HAX1 is an important 
regulator of migration toward LAP for various cancer cell types but not for the 
noncancerous human keratinocytes as represented by HaCat cells. Additional 
experiments with keratinocytes are required to confirm these observations and I 
would have performed such analyses had I had more time available. 
 183 
 
 
Figure 4.7 HAX1 knockdown did not affect migration toward LAP in HaCat 
cells.  
HaCat cells were treated with control siRNA (siNTC) or HAX1 siRNA (si1-6 or 
si192) to knockdown HAX1 (a, d). The cells were then tested in migration assays 
across Transwell membranes coated with 0.5% BSA or 0.5 μg/ml LAP for 8 hours 
(b) or 16 hours (e). Cells were then trypsinised and the cell numbers were calculated 
by a CASY cell counter. Percentage of migration was determined by the number of 
cells in the lower chamber relative to the total number of cells in the well. Cell 
proliferation was also measured and shown to be unchanged (c, f). Total cell number 
was calculated from the numbers of cells in the upper chamber and lower chamber 
(c, f). The error bar represents standard deviation, done in quadruplicate from three 
experiments. 
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4.3 Discussion 
Reportedly, HAX1 has been shown to regulate oral squamous carcinoma cell 
migration via integrin αvβ6 [1]. In the present study, I am the first to demonstrate 
that HAX1 is a central factor that regulates migration of various cancer cells (breast, 
pancreas and cervix cancer cells). Interestingly, HAX1 depletion did not affect the 
migration of the non-transformed keratinocyte HaCat cell line. If this were found to 
be repeated with primary keratinocytes, this may offer an opportunity to target 
cancer cells but not normal cells via approaches aimed at limiting HAX1 activity.  
When I examined whether HAX1 mediated cell migration on other extracellular 
ligands apart from LAP, including collagen, laminin and fibronectin, the data 
showed that although all three ECM ligands enhanced migration of HeLa and 
MCF10.CA1a cells, HAX1 depletion did not affect cell migration on any of these 
ligands. Cancer cell migration depends on the interaction of integrin-ECM ligands, 
and these data suggest that HAX1 regulates cell migration mainly on LAP but not 
collagen, fibronectin or laminin. The reasons for these observations are not known.  
LAP, latency associated peptide, is the pro-peptide of the cytokine TGF-β and its 
presence blocks the activation of the cytokine. TGF- can switch from tumour 
suppressor in normal/ pre-malignant cells, through its ability to suppress epithelial 
cell growth, to tumour promoter in malignant cells, that often become refractory to 
its anti-proliferative effects [228]. TGF-β is secreted in a latent complex consisting 
of three proteins: TGF-β, LAP, and LTBP (latent TGF-β binding peptide, which 
anchors the complex to the ECM) [162]. LAP contains an integrin-binding site 
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(RGD), and the RGD-binding integrins αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, αIIbβ3, α8β1 
and α5β1, are all reported to bind LAP; however only integrins αvβ6 and αvβ8 are 
strong activators for TGF-β [162]. When integrins bind to the RGD sequence in 
LAP, the activation of TGF-β is triggered by a conformational change of the 
complex [216]. This then exposes active TGF-β and allows it bind to its receptor, 
probably on adjacent cells, thus initiating downstream pathways [181]. Activation by 
v6 requires the cytoplasmic domain of integrin and a functional actin 
cytoskeleton, suggesting that force generated by the actin cytoskeleton and 
transmitted via the integrin to LAP is required for activation [162]. In contrast, v8 
binds to LAP and brings latent-TGF- into close proximity of MT1-MMP which 
cleaves the LAP and reveals the TGF- molecule for its receptor on an adjacent cell 
[162]. 
Adaptor proteins play an important role in regulating cell functions by interacting 
with regulatory molecules including integrins. As HAX1 is a binding partner for β6 
[1], and my study is the first to show that HAX1 regulates multiple cancer cell lines‟ 
ability to migrate via integrin αvβ1 and αvβ6 toward LAP, these data indicate the 
potential role of HAX1 in activating TGF-β. Figure 4.3 shows the different integrin 
expression pattern to different cell lines. By blocking integrins with specific 
antibodies prior to migration assay, it was shown that MCF10.CA1a, CF Pac1 and 
Panc 04.03 depend on αvβ6 to migrate on LAP whereas HeLa cells used αvβ1 to 
migrate on LAP (Figure 4.4). TGF-β-integrin interaction is important for cancer 
progression, not only for the independent activity of the TGF- but also as it has 
been shown to promote cell migration and MMP expression in carcinoma [69,181]. 
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My results have extended our knowledge of the potential regulation of TGF-β 
activation.  It would be very interesting to determine whether v1 also can activate 
TGF- and also to investigate the detailed mechanisms of how HAX1 might 
influence the activation of TGF-β, and therefore regulate TGF-dependent 
processes. 
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CHAPTER 5. DEVELOPMENT AND 
CHARACTERISATION OF STABLE HAX1-
KNOCKDOWN 
5.1 Introduction 
Since HAX1 was shown to regulate migration of various cancer cell in vitro in the 
previous sections, it was necessary to generate stable HAX1 knockdown cell lines in 
order to test the role of HAX1 in vivo. In this section, I will describe the generation 
of stable HAX1 knockdown cell lines using four different lentiviral plasmids to 
HAX1 and then describe a variety of biological functions, including cell growth, 
apoptosis, cell migration and invasion, and how they were affected by this HAX1 
depletion.  
5.2 Results 
5.2.1 Establishment of HAX1-stable knockdown cell lines 
5.2.1.1 Bioinformatic analysis of the pGIPZ vectors targeting HAX1  
To generate stable HAX1-knockdown cells, lentiviral encoding vectors were used. 
Four pGIPZ plasmids (p86, p87, p89, p90) were obtained from Open Biosytems, 
each encoding a different shRNA to HAX1. pGIPZ vectors encode both turbo-GFP 
and puromycin drug resistance marker allowing drug-selection of infected cells and 
identification of infected cells by flow cytometry or fluorescence microscopy (the 
detailed vector map of pGIPZ lentiviral vectors is shown in Appendix I, a and b). 
Empty (EMP) vector and non-targeting control (NTC) vector are also included in the 
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experiments as negative control. The EMP vector is the pGIPZ lentiviral vector 
without a shRNA insert and shRNA encoded from NTC contains no homology to 
known mammalian genes (information from Open Biosystem). The plasmid vectors 
were amplified and then purified on QIAGEN columns. The fidelity of each vector 
was confirmed by DNA sequencing (Figure 5.1). All the plasmids were also verified 
as being able to recognise the HAX1 gene by BLAST analysis. CLC Sequence 6 
software (CLC Bio) was used to analyse the shRNA sequences and Figure 5.1 shows 
the sequences of the hairpins of shRNAs which are comprised of a 19 nucleotide (nt) 
loop and two 22 nucleotide sequences that form the double stranded shRNA. 
Each vector was predicted to target different HAX1 variants as they targeted 
different regions of HAX1 as shown in Figure 5.1. By analysing the sequences via 
Ensembl, the results showed that shRNA produced by p86 vector binds to the 5‟ end 
of exon 3, and thus recognises HAX1.1 to HAX1.6. p87 shRNA targets the end of 
exon 2, recognising HAX1 variants 1 to 5.  p89 vector, which generates shRNA to 
exon 5, recognises all isoforms except isoform 3. Targeting to exon 3, p90 shRNA 
binds to isoforms 1,2,4,5,6,7 and 8. All the sequences are shown in the Figure 5.2. 
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Figure 5.1 pGIPZ vector shRNA sequence analysis with CLC sequence 6 
software.  
Sequencing of the vectors confirmed that the vectors encoded 22 nucleotides (nt) of 
shRNA and a 19 nt loop. Pink bars display the level of conservation at each point in 
the alignment. 
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Figure 5.2 pGIPZ vectors target to different regions of HAX1 and thus target 
different HAX1 isoforms.  
pGIPZ plasmids encode a different shRNA to different HAX1 exons. All of the 
vectors were checked by sequencing. Figure (a) shows the HAX1 targeting 
sequences of each shRNA and figure (b) shows the binding regions as coloured 
arrows of these shRNAs on the HAX1 genomic structure.  Dark grey boxes are 
exons and light boxes indicate introns. 
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5.2.2 Stable HAX1 knockdown generated by pGIPZ-lentiviral 
shRNA in VB6 and H400 cells 
HEK293T cells were used for the virus packaging. HEK293T cells were transfected 
with the lentiviral plasmids using the Fugene 6 method with the two packaging 
plasmids and the pGIPZ plasmid vectors (see Methods section for the experimental 
details). 48 hours after transfection the medium which contained released virus, was 
collected and HEK293T cells were analysed by flow cytometry to detect GFP for the 
efficiency of transfection. 
Lentiviral conditioned media containing lentiviruses encoding HAX1 shRNA were 
then applied to VB6 and H400 oral squamous carcinoma cells. The sub-clones were 
named according to the shRNA (VB6-86, VB6-87, VB6-89, VB6-90, VB6-EMP and 
VB-NTC; H400-86, H400-87, H400-89, H400-90, H400-EMP and H400-NTC). 24 
hours after HAX1 shRNA-viral infection, cells were selected with 1.25 µg/ml 
puromycin as the pGIPZ vectors contain this drug-resistance sequence. Cells reached 
confluence about 3-4 days after viral infection, and cell lysates were harvested for 
Western blot analysis. Results show that H400 clones have a great reduction of 
HAX1 protein level in infected cells (Figure 5.3, a). In contrast, Western blotting 
demonstrated that there was no difference in HAX1 expression after viral infection 
of VB6 cells (Figure 5.3, b).  
To investigate this, I analysed the efficiency of viral infection in the target cells 
H400 and VB6, using flow cytomery to observe GFP expression (pGIPZ encodes a 
turbo-GFP gene). Data showed most H400 cells expressed high levels of GFP 
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(>90%) whereas only ~40% of VB6 showed GFP-expression. Since VB6 already is 
puromycin-resistant whereas H400 is puromycin-sensitive, this might explain the 
observed results [70]. In order to select the GFP-positive VB6 cells, I used two 
approaches: one was to increase puromycin concentration to ten-fold (10 µg/ml) in 
order to eliminate vector-free puromycin-resistant VB6 cells, and the other was to 
select GFP-positive cell using FACS.  
In the puromycin-selection approach, cells were treated with a higher puromycin 
concentration (10µg/ml) for three weeks before Western blot analysis. Cell death 
was observed in the first week of treatment, indicating cells were sensitive to 
increased puromycin concentration and the theory was that only cells which express 
the vector-encoded gene would be able to survive from the drug-selection. However, 
Western blotting showed that there was no significant change in HAX1 expression in 
the 10µg/ml puromycin treated cells (Figure 5.4, lane5). Thus this method was 
abandoned.  
FACS was employed to select GFP-positive VB6 sub-populations from lentiviral-
infected cells. Non-infected cells were used as negative control and the top 10% 
GFP-expressing cells were selected from the whole population (Figure 5.5). All 
virally infected-VB6 cell lines, including non-targeting control (NTC), and empty 
vector (EMP), underwent the same selection method. These cells were expanded in 
vitro and then analysed by Western blot. Cell lysates were generated from confluent 
cultures of all lines and Blotted with HAX1 antibody.  Figure 5.6 (a and c) shows 
that the level of HAX1 protein was decreased significantly by all four lentiviral 
vectors when compared with EMP (empty) and NTC (non-targeting control) 
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controls. The knockdown was analysed regularly while cells were in culture and seen 
to be stable even after continuous growth. Results demonstrated that HAX1 protein 
expression was reduced by 50-90% in both the VB6 and H400 cell lines infected 
with pGIPZ vectors. In H400 cells, p87 shRNA and p89 shRNA reduced HAX1 
expression greatly, knocking down nearly 90% of endogenous HAX1 protein (Figure 
5.6, b) whereas p86 shRNA and p90 shRNA resulted in the best knockdown in VB6 
cells (Figure 5.6, d). The densitometry showed the expression of HAX1 normalised 
with HSC70 from >6 independent experiments each with H400 and VB6 cells. 
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Figure 5.3 HAX1 protein expression in lentiviral–infected VB6 and H400 
cells.  
Cells were harvested 3-4 days after viral infection, and lysates were harvested for 
Western blot analysis. (a) H400 is a puromycin-sensitive cell line, and showed a 
great reduction of HAX1 protein level in infected cells. (b) There was no change in 
HAX1 protein expression levels in the lentiviral infected VB6 lines. HSC70 served 
as the control for equal loading. 
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Figure 5.4 HAX1 protein expression in lentiviral-infected cells after elevated 
puromycin concentration treatment.  
To select a HAX1-knockdown cell population, cells were treated with 10µg/ml 
puromycin. Resistant cells were harvested after 3 weeks in puromycin treatment.  
Western blot showed HAX1 expression remained relatively unchanged (lane5: VB6-
86+puro). 
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Figure 5.5 Selection of high shRNA expressing VB6 cells using FACS. 
Lentiviral-infected VB6 cells (here showing an example from VB6-87) were 
monitored for the GFP expression and the top 10% turbo-GFP expressing cells 
(shown as blue events in the box) were collected. 
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Figure 5.6 pGIPZ-lentiviral vectors knockdown HAX1 protein expression in 
H400 and VB6 cell lines.  
H400 sub-populations were selected in puromycin, but, as VB6 already are 
puromycin-resistant, FACS was used to select those cells expressing the highest 
amount of GFP. Western blotting (a, c) shows that the four shRNA vectors all 
reduced HAX1 expression significantly. Samples from at least 7 separate cultures 
were analysed by Western blotting independently, and the degree of HAX1 reduction 
analysed by densitometry, compared with the non-targeting control (NTC). Data 
were expressed as (mean +/- 1 S.D.) and was shown in (b, d). Data show that shRNA 
vectors p86, p87 and p89 were the most effective in both cell lines. *** indicates P 
value < 0.001. 
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5.2.3 Individual HAX1 isoforms are reduced in pGIPZ cell lines at 
the mRNA level 
To examine the effects of shRNA of the mRNA level, RT-PCR was performed. To 
monitor HAX1 isoform expression, cells were seeded into 6 well plates and total 
RNA was extracted with the Stratagene Absolutely RNA kit. Total RNA was 
quantified on the Nanodrop spectrophotometer. 1µg of RNA was reverse-transcribed 
and 50 ng of cDNA was amplified with specific primer pairs and these were used for 
the optimised, but different, PCR reactions (see Methods section). Figure 5.7 shows 
all HAX1 variants were reduced significantly by each of the four shRNAs 
(sequences were described in Figure 5.1). Using densitometry of triplicate 
experiments, Figure 5.8 shows the relative reduction in mRNA of each isoform. p86 
and p87 shRNA achieved the best HAX1 knockdown in general, achieving up to 
80% reduction, whereas p90 shRNA was the least effective. All PCR results were 
performed at least three times and data were expressed relative to GAPDH. 
 
 200 
 
 
 
Figure 5.7 Lentiviral HAX1 shRNAs decrease expression of multiple HAX1 
isoforms.   
Semi-quantitative PCR was employed to analyse the mRNA level of HAX1 
isoforms. Data showed all HAX1 variants were reduced by the four shRNAs. Data 
shown are from one of three experiments showing similar results. GAPDH was used 
as control. 
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Figure 5.8 Relative reduction of mRNA for each HAX1 isoform by pGIPZ 
vectors.  
Figures a-d show the expression of each HAX1 isoform normalised to GAPDH by 
densitometry and the % of HAX1 expression generated relative to non-targeting 
control cell lines (VB6-NTC and H400-NTC respectively). 86 and 87 shRNA 
performed the best HAX1 knockdown in general, achieving up to 80% reduction, 
whereas p90 shRNA was the least effective. All PCR analyses were performed at 
least three times. 
 202 
 
5.2.4 Unchanged αvβ6 expression in HAX1 knockdown cell lines 
Since HAX1 regulates integrin αvβ6 endocytosis, and this is essential for cancer cell 
migration [1], it is important to evaluate whether that HAX1 knockdown also 
affected the expression of αvβ6. Include in my earlier “transient” knockdown 
experiments I had shown that HAX1 depletion frequently was associated with a 
reduction in β6 levels. Cells were harvested from confluent density and protein 
concentrations were equalised. Western blot shows shRNAs reduced HAX1 
expression greatly but the total β6 protein remained unchanged in all HAX1 
knockdown cell lines (Figure 5.9, a and c). To determine surface αvβ6 levels, the 
cells were stained with antibody against β6 (10D5) and flow cytometry was used to 
monitor αvβ6 expression. The results demonstrated there was no obvious change in 
expression of β6 surface levels in any of the HAX1-reduced cells. Data are shown 
for p87 (Figure 5.9 b and d but similar data were seen for p86, p89 and p90 infected 
cells (data not shown). 
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Figure 5.9. Integrin subunit β6 expression is unaffected by reduction of 
HAX1 expression.  
Western blot showed the total β6 protein remained unchanged in HAX1 knockdown 
cell lines (a, b). To determine surface αvβ6 levels, cells were stained with 10D5 
antibody against β6 and analysed by flow cytometry. Data showed there was no 
change in β6 surface protein in any of the HAX1-reduced cells. Data are shown for 
p87 (b and d) but similar results were seen for p86, p89, p90 and pEMP. Mouse IgG 
staining was set as negative control. 
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5.2.5 Functional assays for stable HAX1-knockdown cell lines 
5.2.5.1 Stable HAX1 knockdown did not affect cell proliferation 
To examine the effect of HAX1 on cell proliferation, clonogenic assays were 
performed with control and HAX1 stable knockdown cell lines. Cells were plated at 
100 cells per well into a 6-well plates and incubated for 10 days and the colonies 
were stained with crystal violet (Figure 5.10, a). The colony numbers were then 
counted as shown in Figure 5.10 (b and c). Figure 5.10, (b and c) showed there was 
no difference in the colony number between control and HAX1 knockdown cells for 
either H400 or VB6 sub-lines. 
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Figure 5.10 Clonogenic assay to assess the effect of stable HAX1 knockdown.  
100 cells were seeded into a 6-well plate and incubated for 10 days, 0.1% crystal 
violet was then used to stain for colonies (a). (b, c) The number of colonies was 
counted with Image J software and the quantitative analysis shows surviving 
colonies of each cell line. Data demonstrate HAX1-knockdown cell lines did not 
alter clonogenicity of either H400 or VB6 cells. Columns represent mean of colonies 
in triplicate from one of 3 experiments showing similar results and data show mean 
+/- 1 S.D.. 
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5.2.5.2 Stable HAX1-knockdown did not alter cell migration on LAP 
To determine the effect of HAX1 in cell migration, Transwell migration assays were 
performed with the two best stable HAX1-knockdown cells, VB6-86 and VB6-87. 
Cells were seeded on the Transwell membrane coated with BSA or LAP (for which 
migration of VB6 cells is mediated through αvβ6). After 16 hours incubation, cells 
were then trypsinised and cell numbers were counted. Western blot analysis showed 
the levels of HAX1 expression were reduced stably with Lentiviral shRNA. Figure 
5.11 (a) shows stable HAX1 knockdown did not affect migration towards LAP 
compared with the control cell line (VB6-NTC). A proliferation assay run in parallel 
showed there was no change in cell number during the same period of incubation 
(Figure 5.11 c). These results which were in contrast to my findings in “transient” 
knockdown studies, are considered in the Discussion which follows this section of 
my results. 
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Figure 5.11 Migration of stable HAX1 knockdown cells toward LAP.  
VB6 cells stably transfected with lentiviral shRNA against HAX1 (VB6-86 and 
VB6-87) or non-targeting control (VB6-NTC) were tested for migration across 
Transwell membranes whose undersides were coated with 0.5 % bovine serum 
albumin (BSA) or 0.5 µg/ml LAP. Percentage of migration was calculated by the 
number of cells in the lower chamber divided by total cell number. Western blot 
analysis confirmed that HAX1 expression was suppressed and the β6 levels were 
unchanged (b). The cell migration of the stable HAX1-knockdown cell lines showed 
no significant difference to that of the control cell line (VB6-NTC) (a). Data are 
presented as mean +/- 1 SD from one of three experiments which were performed in 
quadruplicate. 
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5.2.5.3 Stable HAX1-knockdowns did not affect invadopodia formation 
ability  
Invadopodia are actin-rich membrane protrusions found in cancer cells which are 
responsible for degrading the underlying substrate during invasion [229,230]. 
Interestingly, cortactin is one of the few cytoskeleton proteins required for the 
assembly of invadopodia in carcinoma cells [231] and it also forms a complex with 
HAX1 [49]. Therefore to determine whether HAX1 affects invadopodia formation 
and ECM degradation, cells were seeded onto coverslips pre-coated with rhodamine-
gelatin and incubated for 2, 3 and 4 hours. Invadopodia activity was observed by the 
black degradation in the red background (rhodamine in Figure 5.12, a) and the cell 
nucleus was stained with DAPI, whereas GFP represents shRNA-positive cells. 
Figure 5.12 (a) shows the 4 hours incubation on a thin (approximately 1 µm) layer of 
fluorescently conjugated gelatin. The cells formed focal areas of digested matrix that 
appear as dark spots or „holes‟, denoting invadopodia activity. GFP-positive staining 
showed the cells expressing lentiviral vectors, and the analysis was conducted only 
with GFP-positive cells. Data showed there was no significant change in the number 
of invadopodia positive cells or the number of Invadopodia-positive cells per GFP-
positive cell (Figure 5.12, b and c). 
 209 
 
 
Figure 5.12 Invadopodia formation assay.  
(a) shows 4 hours culture on a thin layer of fluorescently conjugated gelatin, cells 
form focal areas of digested matrix that appear as dark spots or „holes‟.(b) shows the 
number of invadopodia degraded “holes” per cells at 2 , 3 and 4 hours time points. 
Figure (c) shows the percentage of invadopodia positive cells. All the cells analysed 
were GFP-positive (shRNA-expressing cells). 
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5.2.5.4 No significant effect of stable HAX1 knockdown on cancer cell 
invasion 
Previous studies from my lab had shown that endogenous HAX1 was required both 
for integrin αvβ6-dependent migration and carcinoma invasion in a transient 
knockdown model with siRNA [1]. In Chaptor 4 I showed that I was able to replicate 
these results, and indeed I was able to extend the observation to additional cell lines, 
with regard to migration toward an αvβ6 liand, LAP. Because my stable knockdown 
lines had no such reduction in migratory capacity I next sought to examine whether 
their invasive activity was affected. Matrigel invasion assays were performed to 
examine the effects of stable HAX1 knockdown on invasive ability comparing with 
control cell line (NTC) and HAX1 knockdown cell lines (86, 87, 89 and 90). 
Invasion assays were performed over 72 hours, and the cells invaded through to the 
lower chamber were trypsinised and counted. Transwell invasion assay experiments 
were repeated three times, with sextuplicate wells for each treatment. Data showed 
there was no significant change between HAX1 knockdown cells and control cells 
derived from either H400 or VB6 (Figure 5.13, a, b). I also examined invasion using 
a quantitative three-dimensional organotypic gel assay, which is designed to reflect 
more closely the in vivo tumour environment than the Matrigel invasion assays 
[220]. Thus cells were cultured on three-dimensional gels composed of Matrigel and 
type 1 collagen embedded with fibroblasts and grown for 14 days. The gels were 
then fixed, bisected, and processed to paraffin. Figure 5.13 (c-f and h-k) shows 
bright field images of H&E stained sections. H400-86 cells demonstrated a 
significant reduction compared with NTC control, however this decrease was not 
meaningful in comparison with another control cell line VB6-EMP (Figure 5.13, g). 
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A similar trend was also observed in VB6 cell lines where no significant difference 
was seen (Figure 5.13, i). The invasion index was calculated using the product of the 
average depth of invasion, the number of invading particles, and the area of the 
invading particles. 
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Figure 5.13 Effect of stable HAX1 knockdown on invasive propensity.  
Invasion assays were performed with stable HAX1-knockdown H400 (a) and VB6 
cell lines (b). Data showed there was no significant change in control and HAX1-
knockdown cells. Transwell invasion assay experiments show one from three similar 
experiments, with sextuplicate wells for each treatment. (c-l) Three-dimensional 
organotypic tumour cell invasion assays were performed and assays terminated after 
14 days. (c-f and h-k) show bright field images of H&E stained sections and (g and l) 
show the invasion index that compares 86 and 87 cells with control cell lines NTC 
and EMP. Invasion index was calculated as previously described and plotted as a bar 
chart. Data show results for three individual organotypic gels and represent mean +/- 
SD, *: p-value <0.05 
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5.2.5.5 Stable HAX1 knockdown did not affect the susceptibility to drug-
induced apoptosis 
Overexpression of HAX1 is found in lesional psoriasis patients where it is linked to 
increased epidermal proliferation and reduced apoptosis of keratinocytes [23]. On 
the other hand, HAX1 deletion caused neuronal cell apoptosis in mice [135]. 
Moreover, HAX1 was shown to protect cells from apoptosis induced by Bax [12], 
hydroxia/rexygenation [21], etopside [123] and 5-FU [109] treatments. To determine 
the effect of HAX1 on susceptibility to apoptosis, a cytotoxic assay was performed 
with three cytotoxic drugs: Cisplatin, Taxol and 5-FU, all known to induce 
cytotoxity by causing apoptosis [115,232,233]. Different doses of the drugs (10
-8
, 10
-
7
, 10
-6
, 10
-5
, 10
-4
, 10
-3
, 10
-2
, 10
-1
, 10
0
, 10
1
µM) were used to induce cell death in 
HAX1 knockdown cell lines (VB6-86 and VB6-87; H400-86 and H400-87 were 
chosen as they exhibited the best HAX1 knockdown among four shRNAs) in 
comparison with control cells (VB6-NTC; H400-NTC). The cells were exposed to 
different concentrations of drugs for 72 hours and the cell viability was determined 
by the MTT assay. Data showed HAX1 knockdown did not affect susceptibility to 
cytotoxic drugs in VB6 and H400 HAX1-knochdown cell lines (Figure 5.14 and 
Figure 5.15). This result was observed to be repeatable (n=3). 
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Figure 5.14 Stable HAX1-knockdown in VB6 cell line showed no change in 
sensitivity to cytotoxic drugs.  
HAX1-knockdown VB6 lines were treated with the drugs Taxol, Cisplatin and 5-FU 
at different doses for 72 hours (10
-8
, 10
-7
, 10
-6
, 10
-5
, 10
-4
, 10
-3
, 10
-2
, 10
-1
, 10
0
, 
10
1
µM). Cell viability after drug treatment was measured by the MTT assay. Data 
showed that the susceptibility to the cytotoxic drugs was similar in the VB6-86 cell 
line (red) and the VB6-87 cell line (blue) in comparison with two control cell lines 
VB6-NTC and VB6-EMP. Data are presented as mean +/- one S.D of optical density 
(OD) readings of four replicate samples. Figure shows one of three independent 
experiments. 
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Figure 5.15 Stable HAX1-knockdown in H400 cell line showed no change in 
sensitivity to cytotoxic drugs.  
HAX1-knockdown H400 lines were treated with the drugs Taxol, Cisplatin and 5-
FU at different doses for 72 hours (10
-8
, 10
-7
, 10
-6
, 10
-5
, 10
-4
, 10
-3
, 10
-2
, 10
-1
, 10
0
, 
10
1
µM). Cell viability after drug treatment was measured by the MTT assay. Data 
showed that the susceptibility to the cytotoxic drugs was similar in the H400-86 cell 
line (red) and the H400-87 cell line (blue) in comparison with two control cell lines 
H400-NTC and H400-EMP. Data are presented as mean +/- 1 S.D of optical density 
(OD) readings of four replicate samples. Figure shows one of three independent 
experiments. 
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5.3 Discussion 
Following on from my findings in Chapter 4, when I showed a marked impact of 
HAX1 depletion on cell function in transient experiments, I thought it would be 
important to establish stable HAX1 depleted cell lines. 
To establish stable HAX1 knockdown cell lines, I used four lentiviral vectors from 
OpenBio systems to achieve the goal. The pGIPZ lentiviral system is a powerful 
RNAi tool in most cell types as the replication incompetent lentivirus is able to 
infect both dividing and non-dividing target cells efficiently [234]. Also, the vector 
integrates into the genome of the target cell enabling long-term expression of the 
genetic cargo. 
RNA interference (RNAi) was first discovered in plants, the mechanism showing 
that double-stranded RNA (dsRNA) targets homologous mRNA for degradation 
[235,236]. Since then this specific gene silencing has been used widely. RNAi can be 
induced by synthetic small-interfering RNAs (siRNAs) or by intracellular generation 
of siRNA from short-hairpin RNAs (shRNAs) delivered as part of a plasmid. 
siRNAs are about 20-24 nucleotides long regulatory RNAs that provide the 
protection against exogenous nucleic acids, such as from viruses [237], and have 
been transfected into cells for gene silencing. However, the gene suppression is only 
for a transient period as siRNA is diluted and degraded with cell division [238,239] 
Therefore, delivery of shRNA encoding vectors has been investigated for RNAi, as 
the effects are long lasting because they are continually produced in the cells [240]. 
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Using the pGIPZ vectors I was able to generate four HAX1 stable knockdown cell 
lines in both VB6 and H400 cells with p86, p87, p89 and p90 vectors. Western blot 
showed HAX1 protein expression was reduced by 50-90% in both VB6 and H400 
cell lines. At the mRNA level, quantitative RT-PCR was used to examine HAX1 
isoform expression by specific primers of the four plasmids. It was shown that p86 
and p87 shRNA achieved the best HAX1 knockdown, in general, achieving up to 
80% reduction, whereas p90 shRNA was the least effective. All the shRNAs showed 
a reduction of HAX1 isoforms. 
Disappointingly, none of the stable HAX1-knockdown cell lines exhibited any 
biological functions that differed from the controls. I observed in VB6 cells, where 
HAX1 transiently was knocked down with siRNA, the ability to migrate to LAP was 
suppressed significantly (Figure 4.1). However repeated attempts showed no change 
in migration toward LAP of any of the stable knockdowns. This lack of difference 
compared with empty and non-targeting controls also was observed in cell growth 
assays (Clonogenic assay), sensitivity to cytotoxic agents, and invasive activity. 
Clonogenic assays evaluate the ability of individual cells to undergo sufficient 
proliferation so as to form a macroscopically visible colony [241]. Caution should be 
used in such experiments so as to make sure that the environment of the clonogenic 
assay remains undisturbed throughout the assay. However, in the protocol that I have 
used, I have changed the growth media which may have affected the final results and 
must be considered in interpreting these data.  
I also tested the behaviour of HAX1-modified cells in the organotypic gel assay, 
which is designed to reflect more closely the in vivo tumour environment. The effect 
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of stable HAX1 knockdown cells were evaluated by invasion index which was 
calculated by using the product of the average depth of invasion, the number of 
invading particles (ie groups of cells), and the area of the invading particles, assessed 
from image analysis of sections cut from the gels. These data showed no significant 
difference between the cells analysed. However I did not plot the size of the invading 
particles and the area of the invading particles separately, and these measurements 
would have provided different aspects to the analysis and may have shown 
differences overall. 
It was disappointing, given the effort I had put into establishing the stable lines, to 
find that there was no apparent impact of HAX1 depletion on the monitored cellular 
characteristics. At this time I am unable to account for the differences, repeatable 
differences, between the stable and the transient experiments (though the apparent 
reduction in β6 levels in the transient versus the stable lines might be an avenue 
worth pursuing). Given that transient knockdown experiments appear to “work”, it 
may be that HAX1 is so important to cell homeostasis, at stable HAX1 knockdown 
cells re-programme to address the loss of HAX1. It must be considered that it could 
also be potential “off-target” effects explain the inability of stable knockdown cells 
to replicate transient knockdown phenotypes. There is also the possibility that the 
clones I chose to analyse were peculiar in some way. Whatever the reasons behind 
these disappointing results I resolved not to use the stable cell lines further. Thus for 
the later part of my thesis I choose to use transient knockdown methods to study 
HAX1 biology. 
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CHAPTER 6. RESTORATION OF INDIVIDUAL HAX1 
ISOFORMS IN TRANSIENTLY HAX1-DEFICIENT 
CELLS  
6.1 Introduction 
In order to study the biological functions of individual HAX1 isoforms, a specific 
siRNA, (si86) which targets to isoforms 1-6, was used to knockdown all major 
isoforms of HAX1. Then, individual HAX1 isoforms, which were mutated so as to 
be resistant to si86-siRNA degradation, were transfected into these transiently 
HAX1-null cells. This model enabled me to study the roles of individual HAX1 
isoforms in cell migration, apoptosis and autophagy. In this section I will firstly 
describe the characterisation of the RNAi-resistant isoforms then describe their 
subcellular distributions in VB6 and HeLa cells. Secondly, I will demonstrate the 
role of individual HAX1 isoforms in cell migration, apoptosis and autophagy.    
6.2 Results 
6.2.1 Mutated HAX1 isoforms are protected from siRNA 
degradation 
6.2.1.1 Design of HAX1 siRNA (si86) and si86-resistant HAX1 isoforms 
To achieve the HAX1 knockdown, si86 siRNA was designed to knockdown 
endogenous HAX1. Blast and CLC analysis showed si86 recognises the beginning of 
exon 3 and this targets to HAX1.1-HAX1.6, as shown in the schematic illustration in 
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Figure 6.1 (a). In order to study the biological functions of individual HAX1 
isoforms, mutated HAX1 isoforms were generated that would resist siRNA 
degradation (designed and generated by Dr. Delphine Lees, Barts Cancer Institute). 
Even though a single nucleotide mismatch should be sufficient to abolish the activity 
of an siRNA [242], three bases were mutated to ensure the RNAi-resistance in these 
HAX1 isoforms. Site-directed mutagenesis was used to insert three silent mutations 
(T390C.G393A.T396C) into exon 3 of FLAG-tagged HAX1 isoform constructs 
(Figure 6.1, a). As the altered codons still encoded the original amino acids (Leu, 
Lys and Tyr) the biological activity of mutant isoforms should be similar to the wild-
type versions (Figure 6.1, b). Mutated isofoms were generated for isoforms 1, 2, 4 
and 5 as they all contain the αvβ6 binding site (see Introduction).  
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Figure 6.1 Creation of FLAG-tagged isoforms 1,2,4,5 by site-directed 
mutagenesis.  
(a) si86 siRNA recognises the 5‟end of exon 3 and targets to HAX1.1-HAX1.6 as 
shown by pink arrows. Dark boxes indicate exons and light boxes represent introns, 
the red lines show the alternative splicing. (b) The mutated sequence was marked 
from si86 targeted sequence by site-directed mutagenesis. The mutated bases are 
replaced by point mutations (shown as red: TC; GA; TC) and the sequence 
codes for the same amino acids (Leu, Lys and Tyr).  
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6.2.1.2 Mutant HAX1 isoforms are protected from si86-induced RNAi 
To examine the efficiency of si86 siRNA, VB6 cells were transfected and the cell 
lysates harvested after 48 hours. Western blot analysis showed si86 efficiently 
knocked down the expression of endogenous HAX1 compared with control siRNA 
(siNTC) in Figure 6.2 (a). To examine expression of the mutated HAX1 isoforms, 
the mutated isoforms were transfected into VB6 cells 24 hours after si86 siRNA 
transfection and the cell lysates were harvested after two days incubation. Western 
blotting showed that the mutant HAX1 isoforms were successfully expressed in the 
siRNA-treated VB6 cells (Figure 6.2, b). The HAX1 expression was validated by 
both anti-HAX1 (RD) and anti-FLAG antibodies, and the Blot displayed different 
molecular weights for the individual isoforms (HAX1.1 is about 31 kDa, HAX1.2 is 
about 28 kDa, HAX1.4 is about 26 kDa and HAX1.5 is about 32 kDa). The HAX1 
Blot demonstrated multiple bands for each isoform, indicating that overexpression of 
isoforms may result in degradation in the cell (Figure 6.2, b). Vec indicates control 
cells which were treated with control vector after si86 knockdown. 
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Figure 6.2 HAX1 isoforms are protected from siRNA-degradation.  
(a) VB6 cells were treated with si86 siRNA or control siRNA (NTC) for 48 hours, 
and the lysates were subjected to Western blot. Data showed si86 efficiently knocks 
down the endogenous HAX1. (b) Mutant isoforms (HAX1.1-5) or empty vector 
(vec) were transfected into HAX1 siRNA (si86) treated VB6 cells. Cell lysates were 
harvested two days after isoform restoration and antibodies to HAX1 (RD) and 
FLAG were employed to Blot the molecules. HSC70 served as a loading control. 
The mutant isoforms were successfully expressed in si86-treated cells and displayed 
different molecular weights (HAX1.1 is approximately 31 kDa, HAX1.2 is 
approximately 28 kDa, HAX1.4 is approximately 26 kDa and HAX1.5 is 
approximately 32 kDa). Vec: control vector. 
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6.2.2 Subcellular distribution of HAX1 
6.2.2.1 HAX1 isoforms 1, 4 and 5 predominantly associate with 
mitochondria whereas isoform 2 exhibits a cytoplasmic expression 
pattern 
The literature has reported that HAX1 is expressed in multiple subcellular 
localisations in different cell types and is associated with different binding partners 
(see Introduction-1.1.3.2: Subcellular localisation of HAX1). In order to gain a better 
understanding of the subcellular expression of HAX1 isoforms, immunofluorescent 
staining was performed to investigate the subcellular distribution of individual 
HAX1 isoforms. HAX1 isoforms were transfected into si86-treated VB6 and HeLa 
cells and the immunofluorescent staining was performed 48 hours after transfection. 
Mitotracker was incubated with the cells for 30 minutes to label mitochondria prior 
to harvesting. Cells were labelled with the anti-HAX1 antibody (RD) or anti-FLAG 
to stain the restored HAX1 isoforms after fixation and permeabilisation. Confocal 
microscopy revealed that HAX1.1, HAX1.4 and HAX1.5 are localised mostly to 
mitochondria (Figure 6.3 and Figure 6.4 for VB6 cells, Figure 6.5 and Figure 6.6 for 
HeLa cells). In contrast, HAX1.2 exhibited a predominantly cytoplasmic localisation 
with a small amount of membrane localisation (Figure 6.3 for VB6 and Figure 6.5 
for HeLa). Negative control cells (si86 transfection without any isoform restoration) 
did not show any staining by anti-HAX1 and anti-FLAG antibodies (indicates as 
si86, Figure 6.3 and Figure 6.5) 
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Figure 6.3 The subcellular distribution of HAX1 isoforms 1 and 2 in VB6 
cells.  
si86 siRNA treated VB6 cells were transfected with mutant HAX1 isoforms and 
mitotracker was incubated with the cells for 30 minutes prior to harvesting. Cells 
were labelled with the anti-HAX1 antibody (RD) and anti-FLAG to stain the restored 
HAX1 isoforms after fixation and permeabilisation. Cell nuclei were stained with 
DAPI. Confocal microscopy revealed that HAX1.1 localised mostly to mitochondria 
as the two colours (green for HAX1 and red for mitochondria) from different 
fluorochromes merged (as yellow) whereas si86 only transfected cells did not show 
any staining pattern. HAX1.2 revealed a very unique expression pattern in 
cytoplasm. The staining from both anti-HAX1 and anti-FLAG antibodies 
demonstrated similar patterns of HAX1 expression for each isoforms. Scale bar 
indicates 10µm. 
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Figure 6.4 The subcellular distribution of HAX1 isoforms 4 and 5 in VB6 
cells.  
si86 siRNA treated VB6 cells were transfected with mutant HAX1 isoforms and 
mitotracker was incubated with the cells for 30 minutes prior to harvesting. Cells 
were labelled with the anti-HAX1 antibody (RD) and anti-FLAG to stain the restored 
HAX1 isoforms after fixation and permeabilisation. Cell nuclei were stained with 
DAPI. Confocal microscopy revealed that HAX1.4 and HAX1.5 localised mostly to 
mitochondria as the two colours (green for HAX1 and red for mitochondria) from 
different fluorochromes merged (as yellow). The staining from both anti-HAX1 and 
anti-FLAG antibodies demonstrated similar patterns of HAX1 expression for each 
isoform. Scale bar indicates 10µm. 
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Figure 6.5 The subcellular distribution of HAX1 isoforms 1 and 2 in HeLa 
cells.  
si86 siRNA treated HeLa cells were transfected with mutant HAX1 isoforms and 
mitotracker was incubated with the cells for 30 minutes prior to harvesting. Cells 
were labelled with the anti-HAX1 antibody (RD) and anti-FLAG to stain the restored 
HAX1 isoforms after fixation and permeabilisation. Cell nuclei were stained with 
DAPI. Confocal microscopy revealed that HAX1.1 localised mostly to mitochondria 
as the two colours (green for HAX1 and red for mitochondria) from different 
fluorochromes merged (as yellow) whereas si86 only transfected cells did not show 
any staining pattern. HAX1.2 revealed a very unique expression pattern in 
cytoplasm. The staining from both anti-HAX1 and anti-FLAG antibodies 
demonstrated similar patterns of HAX1 expression for each isoform. Scale bar 
indicates 10µm. 
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Figure 6.6 The subcellular distribution of HAX1 isoforms 4 and 5 in HeLa 
cells.  
si86 siRNA treated HeLa cells were transfected with mutant HAX1 isoforms and 
mitotracker was incubated with the cells for 30 minutes prior to harvesting. Cells 
were labelled with the anti-HAX1 antibody (RD) and anti-FLAG to stain the restored 
HAX1 isoforms after fixation and permeabilisation. Cell nuclei were stained with 
DAPI. Confocal microscopy revealed that HAX1.4 and HAX1.5 localised mostly to 
mitochondria as the two colours (green for HAX1 and red for mitochondria) from 
different fluorochromes merged (as yellow). The staining from both anti-HAX1 and 
anti-FLAG antibodies demonstrated similar patterns of HAX1 expression for each 
isoform. Scale bar indicates 10µm. 
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6.2.2.2 Wound healing experiments showed HAX1 isoforms did not 
change their subcellular localisation in migrating cells 
HAX1 has been reported to regulate cell migration in both some normal and certain 
cancer cells (see Introduction: 1.1.4.3: HAX1 regulates cell migration). A recent 
study also demonstrated that HAX1 appeared in the leading edge and at the rear 
uropod localisation of migrating neutrophils [20]. In order to investigate the 
localisation of HAX1 isoforms in motile cells, scratch wound healing assays were 
performed on the HAX1-knockdown si86-treated VB6 cells in which the mutant 
HAX1 isoforms had been restored. Once the transfected cells had reached 
confluency, the wound scratches were then generated and the cells were allowed to 
migrate for approximately 16 hours. Cells were subsequently fixed and stained for 
HAX1 (RD antibody), mitochondria (Mitotracker) and nucleus (DAPI). Confocal 
microscopy showed representative cells that had migrated into the scratch (Figure 
6.7, a, c, e, g); several cells in the leading front to the wound were examined at high 
power and were representative of the migrating cells (Figure 6.7, b, d, f, h). All the 
isoforms displayed their subcellular distributions observed in non-migrating cells. 
Thus HAX1.1, HAX1.4 and HAX1.5 remained localised to mitochondria (Figure 
6.7, a, b, e, f, g, h) whereas HAX1.2 remained distributed in the cytoplasm and 
sometimes also was observed in cell membrane (Figure 6.7, c and d).  
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Figure 6.7 Distribution of HAX1 isoforms in migrating cells.  
HAX1.1, HAX1.2, HAX1.4 and HAX1.5 were transfected into VB6 cells whose 
endogenous HAX1 was knocked down with siRNA si86. A scratch wound was made 
in confluent monolayers and cells were allowed to incubate at 37 °C for 16 hours. 
Mitochondria (red) were labelled 30 minutes before cells were fixed and HAX1 
isoforms were labelled with anti-FLAG antibodies (green) and the nuclei were 
labelled with DAPI (blue). Cells at the leading edge were examined closely. Figures 
show low power image (10x magnification objective lens) and a high power image 
(63x magnification objective lens) of a representative cell from the image. Data 
showed HAX1.1 (a, b), HAX1.4 (e, f) and HAX1.5 (g, h) were distributed in a 
mitochondrial pattern in migrated cells. HAX1.2 (c, d) again located to the 
cytoplasm and plasma membrane. The images were scanned and collected using a 
Zeiss confocal microscope (Zeiss LSM 710). 
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6.2.3 Overexpression of individual HAX1 isoforms did not affect 
cell growth 
6.2.3.1 Knockdown of endogenous HAX1 does not affect growth of HeLa 
cells 
To examine the effect of HAX1 on cell growth (ie the sum of cell proliferation and 
cell death), HeLa cells were transfected with the HAX1 siRNA (si86) or control 
siRNA (siNTC). The cells were then seeded into 96-well plates for various times (1, 
2, 4, 6, 8 days) and the proliferation was measured by labelling nuclei with DNA-
binding fluorescent dye PicoGreen (Invitrogen). The relative fluorescence was 
quantitatively measured using a 96-well plate fluorospectrophotometer. Western blot 
analysis showed the HAX1 knockdown by siRNA si86 was effective for up to 8 days 
into the proliferation assay (Figure 6.8, a). Picogreen staining showed that HAX1-
knockdown did not affect cell growth of the HeLa cells (Figure 6.8, b).   
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Figure 6.8 HAX1 knockdown did not affect HeLa cell growth.  
HeLa cells were transfected with control siRNA (siNTC) or HAX1 siRNA (si86) 
and then were cultured in a 96-well plate for 1, 2, 4, 6 and 8 days.  (a) HAX1 protein 
levels were determined by Western blotting at day1 and day8. HAX1 expression was 
suppressed by siRNA (si86). HSC70 was used as control. (b) Picogreen growth 
assay demonstrated no difference in the HAX1-depleted cells (si86) compared with 
control cells (siNTC). The data represent triplicate samples from one of two 
independent experiments and are expressed as mean +/- 1 SD. 
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6.2.3.2 HAX1 isoforms did not alter cell growth 
To examine the effect of individual HAX1 isoforms on cell growth, HeLa cells were 
trasfected with HAX1 siRNA (si86) and then restored with HAX1.1, HAX1.2, 
HAX1.4 and HAX1.5. The cells were then seeded into 96-well plates for various 
times (1, 2, 4, 6, 8 days) and the proliferation was measured by Picogreen staining. 
Figure 6.9 (a) shows that HAX1.1, HAX1.2 and HAX1.5 were successfully 
expressed over the 8 days period of the proliferation experiment. However the 
expression of HAX1.4 was very poor and thus it was not possible to draw 
conclusions. Picogreen staining showed there was no difference in cell growth 
caused by any of the transfected isoforms compared with control cells (vec: control 
vector only treatment) (Figure 6.9, b, c, d, e). 
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Figure 6.9 Individual HAX1 isoforms do not alter cell growth.  
Individual HAX1 isoforms were transfected with HAX1 siRNA (si86) and then were 
cultured in a 96-well plate for 1, 2, 4, 6, 8 days. The fluorescent dye Picogreen was 
employed to measure total DNA and it is correlated with the relative number of cells. 
(a) Western blot analysis showed that the HAX1 isoforms were expressed from the 
first day through to the eighth day. Growth assays were performed with cells 
expressing HAX1 isoforms versus vector (vec) and showed no difference (b-e). Note 
that HAX1.4 expression was relatively poor and only seen after longer exposure time 
of the blot (data not shown) therefore was not possible to draw conclusions. The data 
represent triplicate samples from two independent experiments and are expressed as 
mean +/- 1 SD. 
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6.2.4 HAX1.2 negatively regulates cell migration 
To examine the effect of HAX1 isoforms on cell migration, migration assays were 
performed with HAX1-knockdown cells reconstituted with different individual 
isoforms. Thus VB6 cells were transfected with HAX1 siRNA (si86) to knockdown 
all HAX1 isoforms and the FLAG-tagged isoforms (HAX1.1, HAX1.2, HAX1.4 or 
HAX1.5; or vector only: vec) were restored 24 hours later. Western blotting 
confirmed that the mutant isoforms were protected from the siRNA degradation 
(Figure 6.10, a). A parallel proliferation assay showed no significant difference in 
total cell numbers during the same period of time caused by any of the treatments 
(Figure 6.10, c). Cell migration was examined toward BSA or TGF-β latency 
associated peptide (LAP) coated-Transwells. Results showed expression of HAX1.2 
significantly decreased cell migration compared with control cells (vec) (Figure 6.10, 
b). These result was observed repeatedly (n=5). To confirm this effect I also used an 
siRNA that specificanlly knocks down HAX1.2 (si1p2, see Methods). RT-PCR 
showed that si1p2 efficiently suppresses HAX1.2 but did not affect cell growth 
(Figure 6.10, d and f). In contrast to the results obtained with isoform transfection, 
knockdown of HAX1.2 was sufficient to increase cell migration toward LAP 
compared with the non-targeting control siRNA treated cells (Figure 6.10, e). 
Together, these findings indicate HAX1.2 exhibits a distinct role from the other 
isoforms as it appears negatively regulates αvβ6-dependent cell migration in VB6 
cells. 
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Figure 6.10 HAX1.2 negatively regulates migration. 
VB6 cells migration toward TGF-β latency associated peptide (LAP) is αvβ6-
dependent [181]. To test the role of different HAX1 isoforms in this process, VB6 
cells were initially transfected with HAX1 siRNA (si86) to knockdown endogenous 
HAX1. The individual HAX1 isoforms (HAX1.1, HAX1.2, HAX1.4 and HAX1.5) 
were restored into these HAX1 depleted cells. Western blotting showed the isoforms 
were protected from siRNA degradation (a). (b) Cell migration assays were 
performed across Transwell membranes coated with 0.5% bovine serum albumin 
(BSA) or 0.5μg/mL LAP. HAX1.2 exhibited significantly (p<0.01) decreased cell 
migration while the proliferation did not show difference as a consequence of these 
treatments (c). The data represent one of five independent experiments. In reverse 
experiments, VB6 cells were transfected with non-targeting siRNA (siNTC) or si1p2 
that targets only HAX1.2 (see Methods). RT-PCR studies confirmed that HAX1.2 
was knocked down by si1p2 (d). GAPDH served as control. (d) Transwell migration 
assays were performed with these siRNA treated VB6 cells. The HAX1.2 depletion 
elevated the cell mobility on LAP compared with the control cells (e). The data 
represent one of four independent experiments showing similar results. (f) A parallel 
proliferation study did not show a significant difference between treatments.  
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6.3 Discussion 
HAX1 is a family of proteins generated by alternative splicing, comprised of 
generally similar proteins with different molecular weights. I expressed individual 
HAX1 isoforms, which are mutated to protect the coding sequence from siRNA 
degradation, in cells transiently rendered HAX1-null by siRNA; successful 
expression of HAX1 isoforms was confirmed by blotting both HAX1 and FLAG. 
Different segments of HAX1 isoforms were observed by probing with an anti-HAX1 
antibody, indicating some degradation might occur in these overexpressing cells. 
Several intracellular molecules have been reported to target to HAX1. HAX1 may be 
degraded by Omi in cells treated with various apoptotic stimuli (H2O2, Etoposide, 
cisplatin) [30]. Caspase-3 interacts with HAX1 and this is reported to cleave HAX1 
in apoptotic cells [118]. A recent study also showed that Granzyme B cleaves HAX1 
into two major fragments: an N-terminal fragment that localises to mitochondria and 
a C-terminal fragment that localises to the cytosol [243]. Thus excessive expression 
of HAX1 could be degraded by different pathways. 
Immunofluorescent staining revealed the different subcellular distributions of HAX1 
isoforms. HAX1.1, HAX1.4 and HAX1.5 showed a “classic” HAX1-mitochondrial 
pattern whereas HAX1.2 demonstrated a diffuse expression pattern in cells. 
Structurally, HAX1.2 lacks the first exon, and uses an alternative start codon 27 
bases inside exon 2 (of HAX1.1). This produces a protein that lacks the first 26 a.a. 
of HAX1.1, starting just 3 a.a. before the acid box, with a predicted molecular mass 
of 28.64 kDa [2]. Interestingly, the N-terminus of HAX1 (a.a. 1-59) was reported as 
a required sequence for entry into mitochondria [130]. The lack of these N-terminal 
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amino acids may account for the lack of mitochondrial-specific localisation shown 
by HAX1.2 and also refine the specific sequence required for mitochondrial 
localisation. 
HAX1 has been reported to regulate cytoskeleton proteins as well as integrins to 
mediate cell migration. To investigate individual isoforms in migration, assays were 
performed with the cells expressing different HAX1 isoforms. Results from 
Transwell migration assays showed that expression of HAX1.2 significantly down 
regulated cell migration on LAP by 40 % (compared with vector control). In the loss 
of function experiments, knocking down isoform 2 only by specific siRNA showed 
the opposite effect increasing migration. Together these data show a very unique role 
for HAX1.2 which is expressed in every cell type analysed thus far where it could 
exert its biological activity of negatively regulating cell migration.  
The results from cell proliferation assays showed there was no difference in HAX1 
isoform expression cells compared with vector control treated cells. However, the 
level of HAX1.4 was very poor and thus was not possible to conclude the role of this 
isoform in cell proliferation.  
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CHAPTER 7. THE ROLE OF HAX1 IN AUTOPHAGY  
7.1 Introduction 
HAX1 has been implicated as having a substantial role in regulation of autophagy. It 
has been reported that HAX1 is a substrate for Omi/HtrA2 [30], a protease 
responsible for degradation of caspases [244], and which also is a positive regulator 
of autophagy [245]. Moreover, HAX1 is a substrate for caspase-3, a protease that can 
cleave Beclin-1 to inhibit autophagy during the terminal stages of apoptosis [246]. A 
recent study also demonstrated a direct link between HAX1 and autophagy. Li et al 
showed that HAX1 inhibits autophagy by binding to Beclin-1 and the authors 
suggested that Omi/HtrA2 activates autophagy through interactions with, or 
cleavage, of HAX1 [87]. Taken together, HAX1 has been indicated to regulate 
autophagy, which is an important process for tumourigenesis. Thus I investigated 
further the role of the different HAX1 isoforms in autophagy in this section.  
7.2 Results 
7.2.1 Chloroquine (CQ) induces autophagosome accumulation in 
VB6 cells. 
To investigate the association of HAX1 and autophagy, chloroquine (CQ) was used 
to regulate autophagy via autophagosome formation [81,85]. CQ inhibits autophagy 
by raising the lysosomal pH, which in turn, leads to inhibition of the fusion of the 
autophagosomes with lysosomes and consequently lysosomal enzyme-dependent 
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protein degradation is inhibited (Figure 7.1, a) [81]. The microtubule associated 
protein light chain 3b-II (LC3b-II) was used as a marker for the induction of 
autophagy since, during autophagy, cytosolic LC3b-I is processed to its lipidated 
form, LC3b-II [81]. The LC3b-II associates with newly formed autophagophores and 
subsequently participates in both membrane elongation and cargo recognition, and 
its presence continues on mature autophagosomes ([81] and Figure 7.1 [a]). Thus, 
accumulation of a punctate LC3b pattern in cells represents the formation of 
autophagosomes and evidence of the process of autophagy (Figure 7.1, a) [81,247-
249].  
To determine whether CQ causes an accumulation of autophagic vesicles in VB6 
cells, the levels of LC3b were monitored in cells treated with CQ. The cell lysates 
were collected from VB6 cells treated with 50 µM CQ for 24 hours and subjected to 
Western blot analysis using an LC3b antibody that recognises both cytosolic LC3b-I 
and the autophagy-specific LC3b-II. Figure 7.1 (b) shows there was a significant 
increase in the level of LC3b-II expressed in the CQ-treated cells compared with the 
basal endogenous expression of LC3b in the untreated cells, as determined by 
Western blotting. To confirm that autophagosomes form in VB6 cells, the cells also 
were examined by confocal microscopy. Immunofluorescent staining showed the 
presence of LC3b positive vesicles in the cytoplasm of cells treated with CQ (Figure 
7.1, c). In contrast, no such vesicles were detected in control cells (Figure 7.1, c).  
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Figure 7.1 Chloroquine (CQ) induces autophagosome accumulation in VB6 
cells.  
(a) Schematic diagram of autophagy. Autophagy is a catabolic process that results in 
the degradation of the cytosolic contents including abnormal protein aggregates and 
excess or damaged organelles. The general process of autophagy involves 
sequestration of cytosol contents into a double-membrane vesicle, termed the 
autophagosome, which then fuses with lysosomes to become autolysosomes where 
the cargo is degraded by acidic lysosomal enzymes. The Beclin-1 complex is 
essential for initiation of the formation of the phagophore. Cytosolic LC3b-I is then 
conjugated to phosphatidylethanolamine (PE) as the autophagy specific form LC3b-
II which attaches to the autophagosome membrane. CQ is an inhibitor of autophagy 
by blocking lysosome–autophagosome fusion and the subsequent lysosomal protein 
degradation. (b) Western blot analysis of VB6 whole cell lysates collected at 24 
hours after 50 µM CQ treatment. Western blotting showed an increased level of 
autophagy specific LC3b-II expression in CQ-treated cells (CQ[+]). HSC70 served 
as loading control. (c) VB6 cells plated on coverslips were treated with 50 µM CQ 
for 24 hours and then LC3b was detected by fluorescence immunochemistry (LC3b 
Ab; Cell Signalling). The confocal microscopy images demonstrated the 
accumulation of punctate LC3b immunoreactivity (magenta) in CQ-treated cells 
[CQ(+)] whereas the untreated cells [CQ(-)] did not display any LC3b staining. Cell 
nuclei were counterstained with DAPI (blue). Scale bar= 10µm 
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7.2.2 Endogenous HAX1 is not colocalised with autophagic vesicles 
To investigate whether HAX1 physically localised to the autophagosome, confocal 
microscopy was used to examine the subcellular localisation of HAX1 in CQ-treated 
cells. VB6 cells were exposed to 50 µM CQ for 24 hours to induce the accumulation 
of autophagosomes and both HAX1 and LC3b antibodies were used in double 
immunofluorescence staining experiments. Confocal images showed that the 
endogenous HAX1 was localised in its typical mitochondrial-like pattern (green) 
whereas anti-LC3b antibody identified cytoplasmic vesicles (red) (Figure 7.2). Thus 
there is no colocalisation observed for endogenous HAX1 and LC3b (Figure 7.2) in 
VB6 cells. 
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Figure 7.2 HAX1 does not colocalise to autophagosomes. 
VB6 cells were treated with 50 µM Chloroquine (CQ) for 24 hours and then the cells 
were fixed and permeabilised before labelling for HAX1 (RD, green) and 
autophagosomes (LC3b; Cell Signalling, red), and nuclei (DAPI, blue). Confocal 
microscopy images demonstrated the accumulation of LC3b immunoreactivity in 
CQ-treated cells compared with the absence of LC3b staining in CQ(-) cells, 
confirming CQ induction of autophagosomes. HAX1 expression pattern did not 
colocalise with the LC3b staining and remained in a mitochondrial-like pattern. 
Scale bar indicates 10µm.  
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7.2.3 Autophagy is activated by both serum starvation and 
rapamycin treatment in VB6 cells 
Although there appeared to be no physical colocalisation of HAX1 and 
autophagosomes, the study from Li et al still suggested HAX1 regulates autophagy 
by repressing Beclin-1 [87]. In order to investigate the role of HAX1 in autophagy, I 
first examined whether autophagy is activated in response to different stimuli in VB6 
cells. It was reported that rapamycin or amino acid deprivation induced autophagic 
flux [250,251], but the sensitivity to these stimuli depended on the cell type [78]. 
Therefore I cultured VB6 cells in nutrient-rich growth media or incubated them for 
0.5, 2, 4, 6, 24 and 48 hours in serum-deficient media under what represent 
starvation conditions. Western blotting showed that maximum expression of LC3b-II 
and Beclin-1 increased at 6 hours and decreased after 24 hours (Figure 7.3, a).  
To test rapamycin-induced autophagy, the VB6 cells were treated with 1, 10, 20 μM 
of rapamycin for 24 or 48 hours in growth media. Wetsern Blot analysis showed an 
increase in expression of LC3b-II and Beclin-1 in response to all concentrations of 
rapamycin used (Figure 7.3, b). Thus at 24 hours there was a 1.8 fold increase in 
LC3b-II at 1µM, 1.6 fold at 10 µM and 1.3 fold at 20 µM. Beclin-1 was increased 
1.5, 1.6 and 2-fold for all 3 concentrations. At 48 hours the increase in LC3b-II was 
slightly reduced (maximum 1.2 fold at 1 µM) whereas Beclin-1 showed maximum 
expression at 10 µM (3.5 fold). However, it should be noted that at 48 hours 
rapamycin treatment, the cells clearly exhibited cytotoxicity (data not shown). 
Taking the data together, 6 hours of serum starvation and 1μM rapamycin treatment 
 255 
 
for 24 hours were established as the parameters to be used for autophagy induction in 
my study. 
 
Figure 7.3 Induction of autophagy in VB6 cells by serum starvation and 
rapamycin treatment.  
(a) VB6 cells were cultured in nutrient-rich growth media or incubated for 0.5, 2, 4, 
6, 24, 48 hours under serum starvation conditions. Cells were then lysed and the 
proteins resolved by SDS-PAGE. Western blotting showed increased levels of the 
autophagy-specific protein LC3b-II in response to serum deprivation for up to 6 
hours, a similar response was seen for Beclin-1 expression. By 24 hours the level of 
LC3b-II and Beclin-1 had diminished dramatically. (b) For the rapamycin-induced 
autophagy, the VB6 cells were treated with 1, 10 or 20 μM of rapamycin for 24 or 48 
hours. Western blot was employed to detect endogenous LC3b-I, LC3b-II and 
Beclin-1. Data showed that, relative to the untreated cells (0 µM), the LC3b-II and 
Beclin-1 protein levels were increased in all rapamycin treatments (1, 10, 20 µM) at 
both the first 24 hours and 48 hours treatments. 
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7.2.4 Endogenous HAX1 negatively regulates autophagy 
To investigate the role of endogenous HAX1 in autophagy, VB6 cells were treated 
with control siRNA (siNTC) or HAX1 siRNA (si86) and cultured for 24 hours in 
growth media as control (Figure 7.4, a, lane 1 and 2) or 1μM rapamycin for 24 hours 
(Figure 7.4, a, lane 3 and 4), or serum starvation for 6 hours (Figure 7.4, a, lane 5, 6) 
to induce autophagy. Western blots showed that, in the control siRNA (siNTC) 
treated cells, the amount of Beclin-1 and LC3b-II increased after rapamycin and 
serum deprivation treatments, indicating increased autophagy flux (Figure 7.4, a, 
lane 3 and 5 compared with 1, densitometry shown in b and c). Western blotting 
showed that the HAX1 expression level was sufficiently inhibited by the si86 siRNA 
(Figure 7.4, a, lane 2, 4, 6) and HAX1 depletion increased levels of both LC3b-II and 
Beclin-1 (Figure 7.4, a, 4 and 6) compared with control cells (Figure 7.4, a, 3 and 5) 
in response to both rapamycin and serum starvation. These observations of the 
elevated levels of Beclin-1 and LC3b-II in HAX1 depleted cells suggest that 
endogenous HAX1 negatively regulates autophagy. 
An accumulation of autophagosomes (as indicated LC3b-II on a Western blot), could 
reflect either increased autophagosome formation, due to increases in autophagic 
activity, or reduced turnover of autophagosomes (by blockade the fusion of 
autophagosome and lysosome) [78]. The latter can occur when there are defects in 
fusion between the autophagosome and the lysosome, thus a block in autophagy 
results in autophagosome accumulation and this needs to be differentiated from fully 
functional autophagy [55]. To evaluate whether the increase of LC3b-II in the HAX1 
depleted cells is due to increased autophagy or reduced turnover of autophagosomes, 
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the autophagy inhibitor chloroquine (CQ) was employed in this experiment. CQ is a 
molecule that blocks the autophagosome-lysosome fusion by raising intralysosomal 
pH of lysosomes [78]. The level of LC3b-II would increase in the normal autophagy 
flux after treating cells with CQ and this allows one to distinguish from the blockage 
of autophagosome degradation [78,85]. Western blotting showed the LC3b-II level 
was increased after the inhibition of autophagosome-lysosome fusion by the CQ 
treatment (Figure 7.5, a and b, lane 3) as compared with the CQ untreated cells (lane 
1), indicating that the increased autophagy is due to increased autophagic flux and 
not to blockage of autophagosome turnover. Compared with the CQ-untreated 
HAX1 knockdown cells (Figure 7.5, a and b, lane 2), the CQ treatment (lane 4) also 
showed increased LC3b-II levels indicating there was competent autophagy flux. 
Densitometry was used to analyse the change from three independent Western blot 
analysis (Figure 7.5, b). Taken together, the data showed HAX1 depletion increased 
the induction of autophagy flux but did not affect the turnover of autophagosomes; 
these data therefore suggested that endogenous HAX1 is a negative regulator for 
autophagy. 
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Figure 7.4 Endogenous HAX1 suppresses autophagy.  
(a) VB6 cells were transfected with HAX1 siRNA (si86) or control siRNA (siNTC). 
After 24 hours incubation, the cells were then cultured in nutrient-rich growth media 
(lane 1, 2) or in 1µM rapamycin treatment for 24 hours (lane 3, 4) or incubated in 
starvation conditions for 6 hours (lane 5, 6) Lane 2, 4, 6 showed the efficient HAX1 
protein knockdown by HAX1 siRNA (si86). Induction of autophagy with either 
Rapamycin (lane 3 and 4) or serum starvation (lane 5 and 6) resulted in an increased 
expression of both LC3b-II and Beclin-1. Moreover, in the absence of endogenous 
HAX1 (lane 4 and 6), this increase was enhanced further. Thus HAX1 inhibits 
autophagy induced by these methods. The densitometry data represent three 
independent experiments and are expressed as mean +/- 1 SD. 
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Figure 7.5 HAX1 does not affect autophagosome turnover.  
VB6 cells were treated with HAX1 siRNA (si86) or control siRNA (siNTC) for 24 
hours. Media was then replaced with serum-free media or serum free-media with 
50M CQ for 6 hours. The cell lysates were harvested and subjected to Western blot. 
HAX1 Blot showed the efficient HAX1 knockdown in the siRNA treated cells (lane 
2 and 4). LC3b and Beclin-1 showed the increase of autophagy flux after serum 
starvation in HAX1 depleted cells (lane 2) compared with control cells (lane 1). CQ 
treatment showed increased LC3b-II in both control cells (lane 3) and HAX1 
depleted cells (lane 4) compared with CQ-non-treated cells (lane 1 and 2 
respectively), indicating the existence competent autophagy flux. (b) Densitometry 
was used to analyse the change from Western blot and it represents three 
independent experiments and are expressed as mean +/- 1 SD. 
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7.2.5 HAX1.1, HAX1. 2 and HAX1.5 increase autophagy 
To investigate the roles of individual HAX1 isoforms in autophagy, HeLa cells were 
employed as the model for this study (as this model was that used in the study from 
Li et al [87]). Individual HAX1 isoforms were restored into the HAX1 siRNA-
treated HeLa cells (si86) and then cultured in growth media or serum-free media. 
Western blotting for HAX1 showed the mutant isoforms were protected from the 
siRNA degradation (Figure 7.6, a and d), again it was apparent that each isoform has 
a different molecular weight (Figure 7.6, a and d). Serum starvation triggered 
autophagy as shown in the increased levels of LC3b-II in all cell lines with restored 
HAX1 isoforms and control (Figure 7.6, a and d, and densitometry showed in e 
compared with b) and the increased level of Beclin-1 (Figure 7.6, a and b, and the 
densitometry showed in f compared with c). Note HAX1.4 expression was poor, 
both LC3b and Becin-1 levels were similar to basal level of vector control (Figure 
7.6, d, e and f). In serum starvation treatment (Figure 7.6, d), the expression of 
LC3b-II (Figure 7.6, e) and Beclin-1 levels (Figure 7.6, f) showed that HAX1.1, 1.2 
and 1.5 increased the autophagy flux compared with the control vector (vec) whereas 
HAX1.4 exhibited weak expressing level therefore is unable to draw conclusion 
(Figure 7.6, d). These data suggested HAX1.1, HAX1.2 and HAX1.5 induce 
autophagy by increasing Beclin-1 and LC3b-II levels. 
To evaluate the role of HAX1 isoforms in the turnover of autophagosomes, CQ 
treatments were also included in the experiments. If the autophagy flux is competent 
(no blockage in the autophagosome-lysosome fusion) in the cell, an increased LC3B-
II level should be observed after CQ treatment. Western blotting showed that the 
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LC3b-II level increased in vector control cells after CQ treatment (Figure 7.6, h) 
compared with non-CQ treatment (Figure 7.6, e), indicating the presence of a 
competent autophagy flux. Thus, it was concluded that the increased LC3b-II and 
Beclin-1 levels were due to the increased induction of autophagy in control cells. On 
the other hand, LC3b-II did not increase in HAX1.1, HAX1.2, HAX1.4 (with poor 
expression) and HAX1.5 expressing cells after the inhibition of autophagosome-
lysosome fusion by CQ (Figure 7.6, h compared with e), indicating the 
autophagosome-lysosome degradation blockage had occurred in these isoform 
expressing cells. Taken together, the data appear to indicate that HAX1.1, HAX1.2 
and HAX1.5 positively regulate autophagy by increasing the activation of autophagy 
(increased Beclin-1 level in serum-starvation) and also by blocking the lysosome-
dependent degradation (unchanged LC3b-II in CQ treatment). 
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Figure 7.6 The role of HAX1 isoforms in modulating autophagy. 
HAX1 isoforms, or empty vectors, were transfected into HAX1-depleted (si86-
treated) HeLa cells.  Cells were then cultured in growth media or under conditions of 
serum starvation for 6 hours and the cell lysate subjected to Western blot. (a, d and 
g) Blot for HAX1 show the HAX1 isoforms were protected from RNAi degradation 
(HAX1.4 displayed a weak expression). (d, e and f) shows the general increased 
LC3b-II and Beclin-1 levels in serum starvation treatment compared with non-
treated cells (a, b and c). HAX1.1, HAX1.2 and HAX1.5 showed the more 
pronounced increase in both LC3b-II and Beclin-1 compared with the control vector 
(e and f). CQ treatment showed the increased LC3b-II level in control cells (vec; h 
compared with e) whereas the HAX1 isoforms did not show the same change. The 
densitometry data represent two independent experiments with similar results. 
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7.3 Discussion 
It is suggested that cancer cells alter autophagy in order to meet the requirement for 
increased metabolism [252]. Currently, there are nearly 20 clinical trials registered 
with the USA National Cancer Institute (http://www.cancer.gov/clinicaltrials) 
exploring anti-autophagy strategies in a variety of human cancers, indicating this is a 
potential novel approach to target cancer cells [252]. 
Omi/HtrA2 and caspase-3, the reported binding partners of HAX1, are involved in 
the regulation of autophagy [245,246]. HAX1 also was reported to associate with 
autophagy [87]. To examine the role of HAX1 in the autophagy process, I first 
attempted immunofluorescent staining for HAX1 and LC3b. LC3b proteins play a 
key role in the maturation of the autophagosome [78]. LC3b precursors are 
proteolytically processed to form cytosolic LC3b-I [78]. Upon initiation of 
autophagy, the C-terminal glycine is modified by addition of 
phosphatidylethanolamine (PE) to form LC3b-II, which translocates to 
autophagosomes in a punctate distribution which is a pattern that can be observed 
under microscopic examination [78]. Immunofluorescent staining showed there was 
no co-localisation or interaction of endogenous HAX1 and autophagosomes 
(detected as punctate LC3b staining). 
Although there was no interaction between HAX1 and LC3b, the study from Li et al 
reported that HAX1 inhibited autophagy by binding to Beclin-1 and it was suggested 
that Omi/HtrA2 activates autophagy through interactions with, or cleavage of, HAX1 
[87]. Thus I performed experiments to examine the association between HAX1 and 
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the autophagy molecules Beclin-1 and downstream LC3b-II. Western blot showed 
that HAX1 depletion by siRNA increased the levels of Beclin-1 and LC3b-II in both 
rapamycin- and serum starvation- induced autophagy. CQ is a molecule which 
blocks autophagosome-lysosome fusion by raising intralysosomal pH of lysosomes, 
therefore it can be used to distinguish the increased autophagy flux from the 
blockage of autophagosome degradation [78]. CQ treatment increased the level of 
LC3b-II in si86-treated cells, suggesting the increased autophagy (LC3b-II and 
Beclin-1) is due to increased autophagic flux. Thses data suggest the inhibitory role 
of endogenous HAX1 in regulating autophagy and the observation is in line with 
other study [87]. 
To evaluate the role of individual isoforms, the mutated isoforms were transfected 
into the si86-treated cells. Western blot showed HAX1.1, 1.2 and 1.5 increased the 
LC3b-II and Beclin-1 levels compared with the control vector, whereas HAX1.4 
expression was very poor, I cannot confidently conclude anything definite about its 
likely role in these experiments. Moreover, the levels of LC3b-II were not affected 
by CQ treatment in HAX1.1, HAX1.2 and HAX1.5 expressing cells, indicating the 
autophagosome-lysosome degradation blockage had occurred in these isoform 
expressing cells. Taken together, the data suggest HAX1.1, HAX1.2 and HAX1.5 
positively regulate autophagy both by increasing the activation of autophagic flux 
(increased Beclin-1 level in serum-starvation) and also by blocking the lysosome-
dependent degradation (unchanged LC3b-II in CQ treatment). The fact thet 
endogenous HAX1 and isoforms are conflicting to each other in autophagy 
regulation is confusing, however these are the results I obtained and the repeatable 
data indicate the reliability in these experiments. It raises the question that whether 
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HAX1 isoforms infeluence each other or there are external molecules that control the 
functions of HAX1, certainly, more investigation is needed.    
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CHAPTER 8. THE ROLE OF HAX1 IN CELL DEATH  
8.1 Introduction 
Apoptosis is a complex biological process that kills unrequired cells during animal 
development, normal homeostasis and the immune response [253]. Apoptosis is 
mediated by a family of aspartate specific cysteine proteases known as caspases [99]. 
Among the caspase family, caspase-3, an effector caspase, plays a crucial role in the 
execution of apoptosis [99]. Caspase-3 is activated by an initiator caspase, such as 
caspase-9, through cleavage at a specific internal aspartate residue [92]. Activated 
caspase-3 cleaves downstream substrates such as PARP [poly(ADP-ribose) 
polymerase], lamin, fodrin, and also Bcl-2, leading to the characteristic 
morphological changes in apoptotic cells [92,97-99]. Caspase activation is also under 
delicate and balanced regulation. IAP (inhibitor of apoptosis protein) proteins inhibit 
caspase activity, whereas Smac/Diablo antagonises IAP [122,254]. XIAP, a 
ubiquitous IAP, can inhibit both caspase-9, the initiator caspase of the mitochondrial 
apoptotic pathway, and the downstream effector caspases, caspase-3 and caspase-7 
[122,254]. 
Studies have indicated that HAX1 is involved in apoptosis regulation. HAX1 is a 
substrate for caspase-3 but overexpression of HAX1 also inhibits caspase-3 catalytic 
activity and blocks the initiation of apoptosis [117,118]. Other studies also showed 
HAX1 represses post-mitochondrial caspase-9 activation and cell death during 
hypoxia-reoxygenation and this protects cardiac myocytes from cell death [21,119]. 
Moreover, a HAX1/XIAP complex is reported to inhibit apoptosis by enhancing the 
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stability of XIAP against proteosomal degradation [123]. Additionally, several point 
mutations and frame shift mutations within the HAX1 gene are associated with 
neutrophil depletion by causing increased sensitivity to apoptosis and this is linked 
to the human disease SCN [16,24]. Thus in this chapter I will investigate the role of 
several HAX1 isoforms in apoptosis. 
8.2 Results 
8.2.1 Endogenous HAX1 exhibits a diffuse expression pattern in 
apoptotic cells 
HAX1 has been reported to interact with caspase-3 by acting as a substrate for this 
enzyme [118]. To investigate the subcellular distribution of HAX1 and caspase-3 in 
apoptosis, 100 μM 5-FU was added to culture for 72 hours to induce cell death in 
VB6 cells. Indirect four-colour immunofluorescence staining was employed to 
analyse simultaneously for HAX1, caspase-3, mitochondria and the cell nucleus. 
Activated caspase-3 was used as the indicator for the apoptotic cells and the staining 
appeared in the cell nucleus, as reported previously [255,256]. Confocal images 
showed the activated caspase-3 was observed in the 5-FU treated VB6 cells, 
indicating that apoptosis had occurred (Figure 8.1, a). Endogenous HAX1 was 
predominantly concentrated in mitochondria in the cells cultured in growth media 
whereas in apoptotic cells (caspase-3 staining positive cells) HAX1 appeared in a 
more diffuse pattern with localisations in nucleus, mitochondria and also cytoplasm 
(Figure 8.1, a). The images also demonstrated the negative caspase-3 staining under 
normal conditions (no 5-FU treatment) whereas in the apoptosis conditions, HAX1 
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was expressed in the cell nucleus where caspase-3 also appeared (Figure 8.1, a). 
Mitochondrial remodelling and fragmentation have been described in connection 
with many modes of apoptosis [257], and it was also observed in some apoptotic 
cells (activated caspase-3 positive cells) after 5-FU treatment (Figure 8.1, b, arrow). 
Again, Figure 8.1, (b) shows that HAX1 presents a typical mitochondrial staining in 
the caspase-3 negative cells (Figure 8.1, b, arrow head) whereas it displayed a more 
diffused pattern in the apoptotic cells (Figure 8.1, b , arrow).  
In order to confirm the changes of the subcellular localisation of HAX1 which were 
observed by confocal microscopy, cell fractionation was performed with VB6 cells 
treated with/without the 100 µM of 5FU. Equivalent amounts of protein extracted 
from the different cellular fractions were subjected to Western blot. To ensure the 
purity of each fraction, the appropriate markers were also blotted for indicator 
proteins (actin for cytosolic marker; 6 interin subunit for heavy membrane marker; 
lamin for nucleus marker). The data showed HAX1 is expressed abundantly in the 
heavy membrane fraction and a small amount in the cell nucleus fractions (Figure 
8.1, c, lane 3, 4, 5, 6). Consistent with the immunofluorescence images, cell 
fractionation showed the expression level of cytosolic HAX1 is increased by 5-FU 
treatment (Figure 8.1, c, lane 1 compares with lane 2), a slight increase of HAX1 in 
the nucleus and heavy membrane fractions was also observed in the 5-FU treatment 
(Figure 8.1, c, lane 3 compared with lane 4; lane 5 compared with lane 6).  Thus 
endogenous HAX1 relocates/ increases its expression in the cytosol of apoptotic 
cells. 
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Figure 8.1 HAX1 changes localisation during cell apoptosis 
(a) VB6 cells were treated with 100 µM of 5-FU or growth media for 72 hours and 
the cells were then labelled for HAX1 (RD), nucleus (DAPI; blue), mitochondria 
(Mitotracker; red) and caspase-3 (Cell signalling; magenta). HAX1 is concentrated 
in the mitochondria in the cells grown in media whereas a rather diffuse expression 
pattern, showing nuclear and cytosolic expression, of HAX1 was evident in cells 
under 5-FU treatment. Caspase-3 was used as an indicator of cell apoptosis. Scale 
bar =10 µm. (b) Apoptotic cells and non-apoptotic cells in the same field. Arrows 
indicated the apoptotic cells with positive caspase-3 staining and deformed 
mitochondria as well as a diffuse HAX1 expression pattern; arrowhead indicates a 
caspase-3-negative cell with normal mitochondria and mitochondrial HAX1 
expression. (c) Equivalent amount of protein extract from cellular fractions showed 
that HAX1 is dominantly present in heavy membrane and nuclear fractions (lane 3, 
4, 5, 6). The cytosolic expression of HAX1 is elevated in the 5-FU treatment (lane 1 
compare to lane 2). To ensure the purity of each fraction, the appropriate markers 
were also Blotted (actin for cytosolic marker; beta6 for heavy membrane marker; 
lamin for nucleus marker). Note there is weak β6 in the nuclear fraction that may 
suggest some contamination with the heavy membrane fraction. 
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8.2.2  Endogenous HAX1 promotes cell apoptosis 
Studies have shown that HAX1 regulates HeLa cell apoptosis induced by etopiside 
[30,118]. Etoposide is a cytotoxic drug that induces cell apoptosis by inhibiting 
topoisomerase and inducing double-strand breaks in the DNA [258,259]. To 
investigate further the role of endogenous HAX1 in apoptosis, Etoposide-induced 
cell death was used as a model in this experiment. HeLa cells were transfected with 
HAX1 siRNA (si86) or control siRNA (siNTC) and apoptosis was induced with 
1μM Etoposide for 24 hours. Western blotting was employed to blot for the 
apoptotic molecules: cleaved (activated) caspase-3 and the downstream cleaved 
PARP. Activated caspase-3 is an effector caspase that cleaves the downstream target 
proteins, such as PARP, and that consequently induce cell apoptosis [98]. Figure 8.2 
(a) shows that Etoposide treatment induced cleaved caspase-3 and cleaved PARP 
confirming cell apoptosis was induced in the control siRNA (siNTC) treated cells. 
Western blotting showed the efficient knockdown of HAX1 by si86, and this 
significantly decreased the amount of cleaved caspase-3 and cleaved PARP induced 
by Etoposide treatment compared with control cells ( Figure 8.2, a). To quantify this 
change, densitometry analysis was performed for cleaved caspase-3 and cleaved 
PARP from three independent experiments and this is plotted is in Figure 8.2, b and 
c. These data showed >50% reduction in the levels of cleaved caspase-3 and cleaved 
PARP in HAX1-depleted cells. 
To verify the changes observed from Western blotting, cytotoxic assays were 
performed with three different cytotoxic drugs: Taxol, Etoposide and 5-FU, each of 
which exert different mechanisms to induce apoptosis [30,109,259]. Taxol binds to 
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the microtubules and leads to the cell mitosis arrest [260]; Etoposide acts as a 
topoisomerase inhibitor to induce DNA strand breaks [258]; and 5-FU irreversibly 
inhibits thymidylate synthase [261]. HeLa cells were transfected with control siRNA 
(siNTC) or HAX1 siRNA (si86) and exposed to different concentrations of the 
cytotoxic agents. The cell viability was measured by the MTT assay after 72 hours. 
Compared with the control cells, HAX1 knockdown cells (si86) displayed a small, 
but significant, increased cell survival in Taxol treatments (Figure 8.2, d and e): 
HAX1 siRNA significantly increased the cell survival in general (p<0.05), especially 
in the low concentration range treatment (from 0.001-0.1 nM, p<0.01). Apexdix III 
shows three independent Taxol-induced cell death experiments and all three 
experiments demonstrated the increased cell survival by HAX1 knockdown. In 
contrast HAX1 knockdown had no consistent effect on cyctotoxicity induced by 
either etoposide or 5-FU (Appendix IV and Appendix V). Experiments were 
performed in quadruplicate and repeated three times. In consultation with statistician 
Adam Brentnall (Barts Cancer Institute), the Mann-Whitney U test was used to 
analyse the significance of the change in the survival fraction between control cells 
and HAX1 knockdown cells using the combined data (Figure 8.2, f, g, h). These 
observations indicate a possible pro-apoptotic function for endogenous HAX1 in 
Taxol-induced cell death. However, since there was no consistent effect on cell death 
caused by etoposide or 5-FU, and as these three drugs induce cell death by three 
different mechanisms, this may indicate that the involvement of HAX1 is determined 
by the mechanism of activation of the cell-death process. 
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Figure 8.2 The role of endogenous HAX1 in response to cytotoxic drug-
induced cell apoptosis and cell death.  
(a) Apoptosis was induced by exposure to 1 μM Etoposide for 24 hours. Elevated 
levels of cleaved caspase-3 and cleaved PARP indicated apoptosis was induced. 
Western blotting showed the Etoposide-induced increase in cleaved caspase-3 and 
cleaved PARP were reduced by siRNA knockdown of HAX1. (b, c) Densitometry 
showed an average >50% reduction in cleaved caspase-3 and cleaved PARP from 
three independent experiments. (d, f, h) MTT assays were performed with cells 
treated with various concentrations of Taxol (d), Etoposide (f) and 5-FU (h) for 72 
hours. HAX1 knockdown (si86) cells displayed increased cell viability compared 
with control cells (siNTC) in treatments with Taxol. Data are presented as 
percentage of survival which base on the optical density (OD) readings of 
quadruplicates. The data show one of three indenedent experiment and are presented 
as mean +/- 1 S.D. (e, g, i). The results from all three experiments are shown in 
Appendix III, IV and V. Mann-Whitney U test was employed to determine statistical 
significance. *, P < 0.05, **, P < 0.01. 
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8.2.3 HAX1.1 increases the levels of cleaved caspase-3 and cleaved 
PARP 
To investigate the roles of individual isoforms in cell apoptosis, HAX1.1 was 
transfected into the HAX1 transiently knocked-down cells (by si86) and then 
exposed to 1μM Etoposide for 24 hours. Cell lysates were prepared and subjected to 
Western blotting analysis. Figure 8.3 (a) shows that the HAX1.1 was protected from 
the siRNA degradation. The levels of cleaved caspase-3 and downstream cleaved 
PARP were significantly increased by the presence of HAX1.1 during the Etoposide-
induced cell apoptosis (Figure 8.3, a, b). Again, cytotoxic assays were performed 
with three different cytotoxic drugs: Taxol, Etoposide and 5-FU. The cells were 
exposed to different concentrations of drugs for 72 hours and the cell viability was 
determined by MTT assay. Data show HAX1.1 expressing cells did not affect cell 
viability in all treatments (Figure 8.3, d, e, f, g, h and i; Appendix VI, VII and VIII). 
Althought one of three independent experiments showed a significant decreased cell 
survival caused by HAX1.1 in low concentration (0.001-0.1 μM) of Etoposide 
treatment (Appendix VII, c and d), there was no significant changes observed in the 
other two experiments (Appendix VII, a, d, e and f). Thus HAX1.1 increases cleaved 
caspase-3 and cleaved PARP, but does not alter the cell survival after Taxol and 5-
FU treatment. It is difficult to draw conclusion in the effect of this isofom in 
Etoposide-induced cell death due to the inconsistent results.  
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Figure 8.3 The role of HAX1.1 in cytotoxic drug-induced cell death.  
(a) HeLa cells were transfected with si86 to knockdown endogenous HAX1 and then 
restored with HAX1.1. Apoptosis was induced by exposure to 1 μM Etoposide for 
24 hours. Western blotting showed that the presence of HAX1.1 increased the 
amount of cleaved caspase-3 and cleaved PARP compared with vector control (vec: 
empty vector control). Densitometry from three independent experiments showed an 
increase in cleaved caspase-3 and cleaved PARP (b and c). (d, f, h) MTT assays were 
performed with HAX1.1 expressing cells treated with Taxol (d), Etoposide (f) and 5-
FU (h) for 72 hours. HAX1.1 expression did not cause changes in cell viability in all 
drug treatments (d, e, f, g, h and i). Data are presented as percentage of survival 
which base on the optical density (OD) readings of quadruplicates. The data show 
one of three indenedent experiment and are presented as mean +/- 1 S.D. (e, g, i). 
The results from all three experiments are shown in Appendix VI, VII and VIII. 
Mann-Whitney U test was employed to determine statistical significance. 
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8.2.4 HAX1.2 promotes cell survival from Etoposide and 5-FU 
induced cell death 
To evaluate the role of HAX1.2 in cell apoptosis, HAX1.2 was transfected into the 
HAX1 transiently-deficient cells (by si86) which then were exposed to 1μM 
Etoposide for 24 hours. Cell lysates were then prepared and subjected to Western 
blotting analysis. Figure 8.4 (a) shows that the mutant HAX1.2 was protected from 
the siRNA degradation. Western blot demonstrated that there was no significant 
change in the levels of cleaved caspase-3 and downstream cleaved PARP as a result 
of the presence of HAX1.2 from three independent experiments (Figure 8.4, a, b, c). 
Cytotoxic assays were performed with three different cytotoxic drugs. The cells were 
exposed to different concentrations of drugs for 72 hours and the cell viability was 
determined by MTT assay. Data showed cell viability was increased with HAX1.2 in 
the one of three Taxol treatment (Figure 8.4, d and e, Appendix IX).  The cell 
survival also was small but significantly, increased by HAX1.2 in two of three 
(Figure 8.4, h and i, Appendix XI) 5-FU treatment and in all three independent 
experiment in Etoposide treatments (Figure 8.4, f and g, Appendix X). The sizes of 
these changes were not dramatic but the trend was repetable, and thus these 
observations suggest HAX1.2 protects cells from Etoposide and 5-FU-indiced cell 
death, possibly, through a caspase-3-independent pathway. 
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Figure 8.4 HAX1.2 exhibits anti-apoptotic function.  
Apoptosis was induced by exposure HeLa cells to 1 μM Etoposide for 24 hours. 
Western blotting showed no difference in the levels of cleaved caspase-3 and cleaved 
PARP in cells expressing HAX1.2 induced by Etoposide compared with the control 
(vec: empty vector control) (a, b, c). MTT assays were performed with cells treated 
with three different cytotoxic drugs: Taxol (d), Etoposide (f) and 5-FU (h) for 72 
hours. Cell expressing HAX1.2 displayed increased cell viability compared with 
control cells (vec) in Etoposide and 5-FU treatments (f, g, h and i). Data are 
presented as percentage of survival which base on the optical density (OD) readings 
of quadruplicates. The data show one of three indenedent experiment and are 
presented as mean +/- 1 S.D. (e, g, i). The results from all three experiments are 
shown in Appendix IX, X and XI. Mann-Whitney U test was employed to determine 
statistical significance. *, P < 0.05. 
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8.2.5  HAX1.5 did not alter cell survival in response to cytotoxic 
drugs 
To evaluate the role of HAX1.5 in cell apoptosis, HAX1.5 was transfected into the 
HAX1 transiently-knockdown HeLa cells (si86) and such cells then were exposed to 
1μM Etoposide for 24 hours. Cell lysates were then prepared and subjected to 
Western blotting analysis. Figure 8.5 (a) shows that HAX1.5 was protected from the 
siRNA degradation, it also demonstrated that there was no change in the levels of 
cleaved caspase-3 or the downstream cleaved PARP in the presence of HAX1.5 
(Figure 8.5, a, b and c). Cytotoxic assays were performed with three different 
cytotoxic drugs. The cells were exposed to different concentrations of drugs for 72 
hours and the cell viability was determined by MTT assay. The results show that 
there was no change in cell survival in HAX1.5 expressing cells compared with 
control cells in overall drug treatments (Figure 8.5, d, e, f, g, h and i). Significant 
increased cell survival was also observed in HAX1.5 expressing cells in one of each 
three independent experiments (Appendix XII-XIV). The changes were very small 
and not repeatable. It is difficult to draw a conclusion in this isoform as the data were 
not consistent. 
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Figure 8.5 HAX1.5 and cell death.  
(a, b, c) Apoptosis was induced by exposure of HeLa cells to 1 μM Etoposide for 24 
hours. Western blotting showed no difference in the levels of cleaved caspase-3 and 
cleaved PARP in cells expressing HAX1.5 compared with the control (vec: empty 
vector). MTT assays were performed with cells treated with three different cytotoxic 
agents: Taxol (d), Etoposide (f) and 5-FU (h) for 72 hours. Mann-Whitney U test 
was employed to determine statistical significance (e, g, i). Overall, HAX1.5 did not 
alter the cell survival (d, e, f, g, h and i). But small and significant increases were 
observed in one of three independent experiments of all three drugs (Appendix XII-
XIV). Data are presented as percentage of survival which base on the optical density 
(OD) readings of quadruplicates. The data show one of three indenedent experiment 
and are presented as mean +/- 1 S.D.  
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Table 8.1 Summary of the effect of the HAX1 isoforms in drug induced cell 
death. 
This table summarises the significant changes by HAX1 knockdown (si86) and 
HAX1 isoform restoration in cell death from three independent experiments, which 
showed in three columns under each drug trestments. Mann-Whitney U test was used 
to analyse the significant changes. “-“ indicates there is no significant change and the 
arrow show the significant increase or decrease in cell death upon different drug 
treatments. The experiments were performed in quadruplicate and the detailed results 
were shown in Appendix III- XIV.     
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8.2.6 HAX1 isoforms are degraded during cell death 
It is reported that HAX1 is degraded by caspase-3 and Omi/HtrA2 during cell 
apoptosis [30,118]. To investigate the role of isoforms in this process, individual 
HAX1 isoforms were restored into the HAX1 siRNA-treated (si86) HeLa cells and 
the cells were then treated with/without 1 μM Etoposide for 24 hours. Cell lysates 
were harvested and subjected to Western blot. Cleaved caspase-3 was used as an 
indicator for the induction of cell apoptosis (Figure 8.6, a), Western blot showed the 
increased cleaved caspase-3 levels in all cell lysates following Etoposide treatments 
(Figure 8.6, a). To quantify these changes, densitometry of the FLAG Blot from 
three independent experiments is shown in Figure 8.6, b .The Blot for HAX1 and the 
FLAG-tag showed the decreased levels of isoforms from the cells treated with 
Etoposide, suggesting that these HAX1 isoforms are regulated, and possibly 
degraded, during cell apoptosis. Again the HAX1.4 was observed to have very poor, 
or possibly, unstable expression by the end of my study. I was unable to express 
HAX1.4 reliably even after I attempted several times to re-extract the plasmids to 
improve their purity and therefore I excluded HAX1.4 from this experiment.  
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Figure 8.6 Levels of HAX1 isoforms are reduced following Etoposide 
treatment.  
Individual HAX1 isoforms were transfected into the HAX1 knockdown HeLa cells 
(si86) and the total cell lysates were prepared after 1μM Etoposide treatment for 24 
hours. The first four lanes show the lysates from cells incubated in the growth media. 
The HAX1 isoform level was decreased in the cells treated with Etoposide. Thus 
HAX1.1, HAX1.2 and HAX1.5 were reduced by 26.6%, 60% and 50% respectively. 
HSC70 was used to verify equal protein loading. Vec represents the control vector 
only treatment. Data are presented as mean +/- 1 S.D from three independent 
experiments. *, P < 0.05, **, P < 0.01. 
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8.3 Discussion 
Several reports have found that HAX1 changes its subcellular localisations and this 
can affect its interaction with certain binding partners and have an impact on 
biological functions. For example, HAX1 interacts with PLN and this association 
was found to cause a subcellular redistribution of HAX1 from mitochondria to the 
ER and this change was associated with a response which enhanced the protective 
effects of HAX1 on cell survival [28,130]. Caspase-3 is a central regulator for 
apoptosis and it is reported to interact with HAX1 and cleave HAX1 [118]. 
Therefore immunofluorescent staining was employed to examine the interaction of 
these two molecules and also to examine the localisation of HAX1 in apoptotic cells. 
Confocal images reveal that, although endogenous HAX1 is not colocalised with 
activated caspase-3, the pattern of HAX1 was altered in apoptotic cells from its 
mitochondrial staining to a more diffuse pattern. The cell fractionation and Western 
blotting studies confirmed the change of subcellular localisation of HAX1 since the 
expression was increased in the cytosolic and nuclear portions after 5-FU treatment. 
Mitochondria play a critical role in cell death via regulating the release of pro-
apoptotic proteins including cytochrome c and AIF (apoptosis-inducing factor), into 
the cytosol [262]. The released cytochrome c activates caspase-9, in concert with the 
cytosolic factor dATP (or ATP) and apoptotic protease-activating factor-1, and 
subsequently activates caspase-3 via proteolytic processing [262]. Thus when 
mitochondrial membrane permeabilisation is induced by death signals, 
mitochondrially localised HAX1 may be released by the loss of the barrier function 
of the outer mitochondrial membrane.  
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Chemotherapy has been shown to be an effective therapy for many tumours and 
drugs such as Etoposide, 5-FU and Taxol are considered as the typical 
chemotherapeutics. These agents work by inducing apoptosis, via different 
mechanisms, in treated cells. To date, this present study is the first to report the 
correlation between individual HAX1 isoforms and cell death following exposure to 
the three agents. I performed both gain and loss of function experiments to 
demonstrate the different roles of different isoforms in cell death. 
 Knockdown endogenous HAX1 by siRNA (si86) significantly increase the cell 
survival in Taxol-induced cell apoptosis and this is correlated with decreased levels 
of cleaved caspase-3 and cleaved PARP which observed by Westen blotting. Data 
show there was no significant change in cell survival in Etoposide treatment despite 
the decreased levels of cleaved caspase-3 and cleaved PARP after Etoposide 
treatment. The difference may be caused by the different incubation times between 
these two experiments: 24 hours incubation time for the Western blotting versus 72 
hours incubation time for the cytotoxic assays. More investigation is needed to 
understand the underlying mechanisms. These data suggest that endogenous HAX1 
may play a pro-apoptotic role in cell death. Although this finding is conflicting with 
the majority of studies, my results are repeatable with the same trend, indicating 
there maight be a new role of HAX1 in regulating cell apoptosis. 
In line with the finding of HAX1-knockdown decreased the levels of cleaved 
caspase-3 and cleaved PARP, the restoration of HAX1.1 showed increased cleaved 
caspase-3 and cleaved PARP after 24 hours Etoposide treatment. However, there 
was no significant change in cell survival that observed in this isoform, this may 
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indicate HAX1.1 exhibits pro-apoptotic role in the early time point (24 hours) rather 
than 72 hours drug-induced cytotoxic assays. In contrast, HAX1.2 did not cause any 
significant change in cleaved caspase-3 and cleaved PARP levels by Western blot 
after Etoposide treatment, but increased cell survival over 72 hours cytotoxic assay. 
The results showed that HAX1.2 decreased sensitivity of HeLa cells to Etoposide 
and 5-FU, suggesting that this isoforms may enhance the chemoresistance by 
protecting cell death from cytotoxic effects induced by these two drugs. The 
unchanged level of cleaved caspase-3 indicates that the possible mechanism may not 
involve the caspase-3 pathway. Although these observations were highly repeatable, 
it is clear that I have no mechanistic explaination for these changes and that more 
investigation is needed to reveal the processes behind these observations. On the 
other hand, HAX1.5 had no effect on levels of cleaved caspase-3 or cleaved PARP 
compared with control cells, and also showed unchanged (inconsistent) results in cell 
survival in overall cytotoxic experimrnts; thus this isoform did not show a consistent 
effect on cell viability. 
Reportedly, HAX1 degradation occurs due to the cleavage by different molecules 
such as Omi/HtrA2, caspase-3 and Granzyme B [30,118,243].  Lee et al showed that 
HAX1 was cleaved by caspase-3 in HeLa cells after Etoposide treatment. In my 
study I also showed the decreased expression of HAX1 isoforms (by both anti-
HAX1 and anti-FLAG Blot) after Etoposide treatment. This is the first to show 
HAX1 isoforms are associated with degredation during apoptosis. 
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CHAPTER 9. FINAL DISCUSSION  
Throughout this study I have tried to make clear that, to date, most previous studies 
that have examined the biology of HAX1, have considered HAX1 as a single 
molecule, whereas our laboratory proved that it is in fact a family of splice variant 
molecules. This probably explains why so many subcellular localisations and so 
many different functions have been attributed to HAX1. Thus I began with the 
hypothesis: 
The multiple functions and subcellular localisation attributed to HAX1 are due to 
the presence of multiple isoforms whose individual functions and subcellular 
localisation may differ from each other. 
I believe that in large part I have confirmed that my hypothesis was correct, but also 
it is clear that there is still so much more to do to determine the precise role of these 
various isoforms in different cellular behaviours. 
The nature of the HAX1 family of proteins is such that they share significant 
sequence homology between each isoform and this close relationship undoubtedly 
increased the complexity of this study. Thus it was not possible to design siRNA that 
would target each individual HAX1 isoform (except HAX1.2) and there are no 
HAX1 isoform specific antibodies available. Therefore I was forced to use siRNA-
protected isoforms with a limited panel of antibodies; technically demanding 
approaches which often provided indirect, rather than direct, evidence. 
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The first task was to check antibody specificity and efficiency for HAX1. The data in 
Figure 3.1, Figure 3.2, Figure 3.3 and Figure 3.4 show that only the goat anti-HAX1 
antibody (RD) and mouse anti-HAX1 antibody (BD) recognised endogenous HAX1 
in Western blot and by immunochemistry; siRNA to HAX1 confirming antigen 
specificity. As a result of my early studies, the Santa Cruz antibodies were no longer 
used but it does call to question the results others have achieved using these reagents. 
I was also fortunate that, prior to my arrival, a postdoctoral research fellow, Dr. 
Delphine Lees, had generated FLAG-tagged HAX1 isoform constructs and siRNAs 
that could be used for my studies. The main study could now commence. 
9.1 HAX1 expression is cell density dependent 
Integrin αvβ6 has been reported to be expressed in a density-dependent manner 
which increases MMP-9 secretion as cells reach confluence [223]. This is indicated 
to facilitate ECM degradation, which helps overcome crowding and restores cell 
proliferation as well as cell invasion [223]. In the present study, in my initial 
experiments, I observed variation in HAX1 expression levels with different cell 
cultures and thus I was encouraged to investigate whether HAX1 also is influenced 
by cell density. This revealed that endogenous HAX1 levels, like integrin αvβ6, are 
cell-density dependent; in addition the house keeping proteins (HSC70, tubulin and 
actin) also need at least 48 hours to stabilise their expression levels after seeding and 
this finding has had an impact on how other investigators in the laboratory conduct 
their investigations. 
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Many proteins are synthesised in a cell density-dependent manner (eg. TGF-β, αvβ6) 
[223,263] and this can regulate protein synthesis and therefore the functions of these 
proteins under different circumstances. For example, at high cell density of vascular 
smooth muscle cells, TGF-β promotes cell proliferation but also promotes synthesis 
of perlecan and biglycan [263]. This is suggested to be involved in the regulation of 
endothelial cell functions by growth factors and cytokines and, with the increased 
accumulation of extracellular matrix, during the repair of vascular injury [263]. As 
cell density regulates the expression of HAX1 this also may modulate biological 
behaviour of cells. Thus these observations may be very important for the study of 
cellular functions of HAX1. While I chose to analyse HAX1 biology using cells that 
were confluent, thereby ensuring highest expression, it is possible that low HAX1 
expression may cause cells to behave differently. 
9.2 HAX1 subcellular localisation 
9.2.1 Subcellular localisation of endogenous HAX1 
HAX1 has been reported to localise in multiple cellular compartments 
(mitochondria, ER, cell nucleus) [3,19,27]. In the present study, using monoclonal 
and goat polyclonal anti-HAX1 antibodies, endogenous HAX1 was localised 
predominantly to mitochondria; a pattern which was observed by using 
immunofluorescence staining and a cell fractionation technique. This is not a 
surprise finding as HAX1 is reported to interact with several mitochondrial 
molecules (Omi/HtrA2, PARL, GrB) [30,135,140,243]. By residing in the 
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mitochondria; HAX1 is reported to execute pro-apoptotic functions by maintaining 
mitochondrial membrane potentials [30,135,140]. Apart from the abundant 
expression in mitochondria, cell fractionation experiments also demonstrated 
endogenous HAX1 appeared in the cell nuclear fractions (consistent with reports of 
interactions with nuclear binding partners such as vimentin, mRNA, DNA 
polymerase β mRNA, EBNA5 [27,32,224]) and minimal expression in the cell 
cytoplasm (enabling binding to molecules such as uPAR, XIAP, Gα13, PELO and 
αvβ6 [1,49,56,64,123]). 
I examined the subcellular localisation of each individual isoform for the using 
HAX1.1, HAX1.2, HAX1.4 and HAX1.5 overexpressed in VB6 and HeLa cells. The 
confocal images revealed HAX1.1, HAX1.4 and HAX1.5 showed a “classic” HAX1-
mitochondrial pattern whereas HAX1.2 demonstrated a strikingly diffus expression 
pattern in VB6 and HeLa cells. Borgese et al have shown that the mitochondrial 
targeting signals are contained either within the N-terminal or the C-terminal regions 
of members of the Bcl-2 family, and these sequences are recognised by importing 
proteins of the outer and inner mitochondrial membranes [118,119]. In a recent 
study, Yap et al reported that the N-terminus of HAX1 (a.a. 1-59) is responsible for 
targeting to mitochondria [19]. The HAX1.2 variant produces a protein that lacks the 
first N-terminal 26 a.a. (compared with HAX1.1) by alternative splicing [2], possibly 
accounting for the mitochondrial non-specific localisation which was shown by this 
isoform. The confirmation that HAX1 isoforms existed in different subcellular 
localisations confirmed an important aspect of the central hypothesis of this thesis: it 
seems logical to suggest that if they are in different places then they probably are 
doing different things. 
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9.2.2 Different endogenous HAX1 expression patterns in apoptosis 
and confluent cultures 
Several studies have noted that HAX1 proteins can change in their subcellular 
localisation. I showed that the mitochondrial HAX1 proteins appeared to change 
their distribution to a more punctuate, cytoplasmic localisation when cells were 
highly confluent (Figure 3.8) or when exposed to cytotoxic drugs (Figure 8.1). Thus 
while HAX1.2 is predominantly cytoplasmic, this does not exclude that the others, 
mitochondrial HAX1 isoforms may also occasionally function in non-mitochondrial 
localisations. Thus when mitochondrial membrane permeabilisation is induced e.g. 
by death signals, mitochondrial HAX1 may be released by the loss of the barrier 
function of the outer mitochondrial membrane leading to variations in its localisation 
pattern. 
9.3 HAX1 and cancer cell migration 
In the present study, I have demonstrated that HAX1 is a central factor that regulates 
migration of multiple different cancer cells (breast, pancreas and cervix cancer cells). 
Intriguingly, HAX1 seemed to regulate migration only on LAP, a ligand that is 
predominantly recognised by αv-integrins. Why HAX1 should regulate only LAP-
dependent migration is unknown but might suggest HAX1 regulates functions 
related to interaction with TGF-β, since this cytokine is secreted in the latent form 
bound covalently to LAP. Integrin regulation of TGF-β activation is critical for 
wound repair [69] and, when it is over active, this cytokine can cause fibrosis [216]. 
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Thus it would be interesting to look more closely at HAX1 regulation of TGF-β 
signalling, a pathway which could have a substantial impact on tumour progression. 
To investigate the individual isoforms in cell migration, different HAX1 isoforms 
were examined. Results from Transwell migration assays showed that HAX1.2 when 
overexpressed on itsown significantly down regulated cell migration on LAP by 40 
% compared with the vector control. HAX1.2 knockdown, by specific siRNA, 
resulted in increased migration of targeted cells. Together these data suggest an 
unique role for HAX1.2 in cell migration resulting in diminished cell motility. It 
remains puzzling why I was unable to show similar effects on migration in stable 
HAX1-null cell lines and points the need for further investigation in the area.  
9.4 HAX1 in autophagy  
In this report I show conflicting data about the regulation of autophagy by HAX1. 
Thus total HAX1 depletion by siRNA increased the level of Beclin-1 and LC3b-II, 
suggesting endogenous HAX1 plays a role in repressing autophagy and this is in line 
with observations in a recent study [87].  
In contrast, Western blot showed expression of HAX1.1, 1.2 and 1.5 increased 
autophagy (LC3b-II and Beclin-1 levels were increased) in transiently HAX1-
deficient cells. One possibility is that the global knockdown of HAX1 isoforms 
regulate a key isoform, or isoforms, that is required to suppress autophagy. It is clear 
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from my studies that the role of HAX1 isoforms in autophagy also requires 
additional investigation. 
9.5 HAX1 and apoptosis 
Overexpression of HAX1 has been reported to protect cells from cell death under 
Fas treatment, γ-irradiation and serum deprivation [3], Bax-induced apoptosis [12] 
and HAX1 antisense mRNA increased ultraviolet-induced apoptosis [23]. These data 
suggest that HAX1 is involved in both death receptor (extrinsic) and non-death 
receptor (intrinsic) mitochondrial-mediated apoptosis pathways. In this study, I 
repeatedly showed that, by comparing with HAX1 knockdown, the endogenous 
HAX1 sensitised cells to increased susceptibility to cytotoxic drug treatments 
correlating with increased levels of cleaved caspase-3 and of the downstream 
cleaved PARP. These data indicate that endogenous HAX1 activates caspase-
dependent cell apoptosis. In contrast, HAX1.2 decreased sensitivity to cytotoxic drug 
induced cell death with no change in the level of cleaved caspase-3 or cleaved 
PARP, indicating HAX1.2 may link to cell death via a caspase-3-independent 
pathway. Caspase-independent cell death pathways are an important safeguard 
mechanism to protect the organism against unwanted and potential harmful cells 
when caspase-mediated routes fail; they can also be triggered in response to 
cytotoxic agents or other death stimuli [264]. For example, Omi/HtrA2, a binding 
partner of HAX1, plays a role in caspase-dependent cell death, but it can also act as 
an effector protein in necrosis-like programmed cell death [88,265]. There is a 
possibility that HAX1 could affect cell death by cooperating with its binding 
partners. To date, my study is the first to report a correlation between individual 
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HAX1 isoforms and different outcomes in relation to cell death. Thus, endogenous 
HAX1 induces a caspase-3 dependent cell apoptosis whereas HAX1.2 is sufficient to 
protect cells from caspase-independent cell death. HAX1.1 increased the level of 
cleaved caspase-3 and cleaved PARP whiout significant change in cell survival and 
HAX1.5 was not observed to alter cell viability. Again, different isoforms appear to 
perform different functions and this helps to explain why the literature, with regard 
to HAX1 and apoptosis, is so complex. 
9.6 Autophagy and apoptosis 
Autophagy and apoptosis are connected both positively and negatively, and 
extensive crosstalk exists between the two processes [253]. The functional 
relationship between apoptosis and autophagy is complex in the sense that, in several 
scenarios, autophagy constitutes a stress adaptation that avoids cell death (and de 
facto suppresses apoptosis), whereas in other cellular settings, autophagy constitutes 
an alternative pathway to cellular demise that is called autophagic cell death (or type 
II cell death) [253]. In general terms, it appears that similar stimuli can induce either 
apoptosis or autophagy depending on the circumstances and molecular pathways 
dictate the choice between autophagy and apoptosis [253]. BAX and BAK are two 
members of the BCL2 family that are required for mitochondrial outer membrane 
permeabilisation [266]. Mouse embryonic fibroblasts (MEFs) from double-knockout 
Bax–/– Bak–/– mice were shown to be resistant to a range of apoptosis inducers. When 
treated with DNA damaging agents, such as Etoposide, Bax–/– Bak–/– MEFs failed to 
undergo apoptosis and instead manifested massive autophagy followed by delayed 
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cell death [266]. HAX1.2 may use a similar route to regulate cell apoptosis and 
autophagy as it promoted autophagy but also showed the protection of cell death 
from various cytotoxic drugs. 
9.7 The distinct role of HAX1.2 
HAX1.2 displays a unique role in some biological functions: it shows a distinct 
expression in cytoplasm, inhibits cell migration, promotes autophagy and represses 
cell death induced by various cytotoxic agents. As a result of alternative splicing, 
HAX1.2 lacks the first exon, starting 27 bases inside exon 2, producing a protein that 
lacks the first 26 a.a. [2]. Interestingly, Grzybowska et al found a 26 a.a. sequence 
within the prototypical rat HAX1 isoform1 that may function in mitochondrial 
localisation [267], another report from Yap et al also showed that the N-ternimal of 
HAX1 1-59 a.a. is required for the mitochondrial localisation [19]. These studies 
explain the non-mitochondrial-specific licalisation that observed to HAX1.2 in this 
study. N-terminal sequence of full-length HAX1 also found for other functions: 1-
113 a.a. is responsible for neutrophil adhesion [20] and 1-261 a.a. associates with 
anti-apoptosis [21], the fact that many functions assigned to N-termical sequence 
may give the explaination for the dynamic roles that HAX1.2 has involved in. 
Nevertheless, a recent report showed that HAX1.2 was up-regulated in breast cancer 
tissues compared with matching normal tissues [149]. My data also indicate the anti-
cell death and inhibition of cancer cell migration, suggesting possible roles that 
HAX1.2 may involve in cancer progression.   
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9.8 Future plans 
The fact that the HAX1 family of isoforms share such high sequence homology 
significantly increased the complexity of this study. The commercial antibodies 
available for HAX1 bind epitopes that detect most isoforms of HAX1. By Western 
blotting, my data show that all these antibodies recognise the major HAX1 band at 
around 34 kDa, a molecular weight corresponding to HAX1.1 and HAX1.5. Smaller 
bands were observed in blots but their identification is complicated by the unknown 
proportions of endogenous expression levels of different individual isoforms, and 
possible differences in their degradation, both of which would cause changes in 
observed levels of these smaller HAX1-related proteins. Recently, two antibodies 
from Sigma became available that claimed to detect specifically isoform HAX1.1 
(Sigma, #PRS4711) and isoform HAX1.4 (Sigma, PRS4715). I tested these 
antibodies on cells where I had over-expressed these single isoforms, separately. 
Western blot (data not shown) revealed that the antibody for HAX1.1 also 
recognised HAX1.5 whereas the antibody for HAX1.4 failed to detect anything. For 
similar reasons, the genetic homology of the HAX1 isoforms also clearly causes a 
difficulty for designing a siRNA to target only one single HAX1 isoform. Thus it is 
extremely difficult to study the biological functions of the individual endogenous 
HAX1 isoforms.   
In the early stage of my study, I aimed to examine the individual HAX1 isoforms by 
using a lentiviral stable knockdown approach, followed by re-expression of 
individual isoforms. To generate the stable lines was time-consuming as was 
establishing the characterisation of these HAX1-null cells lines. All the biological 
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functions examined (proliferation, migration, invadopodia formation, Traswell 
invasion, organotypic invasion and apoptosis) using the stable HAX1 knockdown 
cell lines did not show the significance of HAX1 in any of these previously reported 
HAX1-associated biological activities. We suspect that HAX1 has important, but as 
yet unidentified, roles in biology that required cells to reprogram themselves in order 
to overcome the permanent absence of HAX1. It was a serious setback but by using a 
transient-knockdown method, I successfully investigated the functions of the 
individual HAX1 isoforms in the later stages of my project. There were a number of 
experiments that I was not able to perform due to the time constraints and these 
could have enhanced the value of this study; these include the following: 
  The C-terminal of HAX1 (a.a 271-279) interacts with the β subunit of 
integrin αvβ6, and regulates αvβ6 endocytosis, which is required for cancer 
cell migration and invasion [1]. Truncated HAX1 isoforms (isoforms that 
lack of the β6 binding site) have been generated by my colleague Dr 
Delphine Lees and are ready to use. This would allow the investigation of the 
impact of the interaction between individual HAX1 isoforms and αvβ6 in 
many biological aspects such as cell migration, invasion, apoptosis, 
autophagy as well as their subcellular distribution. 
 The crosstalk between autophagy and apoptosis play important roles in 
regulating cancer cell survival. In some settings, autophagy constitutes a 
stress adaptation that avoids cell death by suppressing apoptosis, and in 
others, it can lead to death itself, either in collaboration with apoptosis or as a 
back-up mechanism when the former is defective [253]. The molecular 
regulators of both pathways are inter-connected and both pathways share 
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several genes that are critical for their respective execution [253]. Thus it 
would be interesting to examine the impact of HAX1 isoforms in autophagy 
and apoptosis pathways, in the same cells.  Thus some molecules are 
implicated in both pathways; for example both Omi/HtrA2 and caspase-9 are 
reported to be involved in autophagy and apoptosis and both are binding 
partners to HAX1 [87,253]. 
 The urokinase-type plasminogen activator (uPA) receptor (uPAR) has been 
implicated in cell migration and invasion [268]. Active uPA proteolytically 
converts the inactive zymogen, plasminogen, to the active enzyme, plasmin, 
which can then break down ECM components, including the ability to cleave 
LAP and activate TGFβ [63,268]. It is reported that HAX1 interacts with 
uPAR and that HAX1 overexpression augments cell proliferation and 
migration in uPAR-stimulated cells [64,65] thus it would be interesting to 
examine the functions of specific HAX1 isoforms in the link between uPAR, 
TGF-β and migration.  
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9.9 Summary 
In summary, the central hypothesis of this thesis has been established. That is HAX1 
isoforms do exist in different subcellular localisations and do perform different 
functions. It must also be acknowledged that, when comparing global knockdown of 
HAX1 with restoration of individual HAX1 isoforms, for certain experiments the 
results appeared to be conflicting. This may suggest that the experiments were not 
directly comparable as in the si86 knockdown experiments multiple HAX1 isoforms 
were removed that may have been co-operating to exert their biological behaviours. 
In Figure 9.1 I have attempted to combine my data into a model of how HAX1 
isoforms might influence diverse cell behaviours. This should not be considered 
absolute but rather a model still in development. However, given how many 
biological processes HAX1 is involved in, further analysis of this highly complex 
and complicated family of proteins is to be encouraged as an area of investigation. 
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Figure 9.1 Schematic illustration of possible subcellular functions of HAX1 
isoforms.  
Endogenous HAX1 is required for migration of various cancer cells (oral, breast, 
pancreas and cervix) toward LAP via integrin αvβ6 and αvβ1. It also promotes cell 
apoptosis by increasing the levels of cleaved capsase-3 and downstream cleaved 
PARP. Moreover, in the autophagy process, endogenous HAX1 plays a inhibitory 
role by inhibiting the levels of Beclin-1 and LC3b. HAX1.2 is an unique isoform that 
is expressed in the cytoplasm whereas the other isoforms reside predoninantely in 
mitochondria. HAX1.2 also regulates cell migration by diminishing the cell motility 
toward LAP. HAX1.2 promotes cell survival possibly via caspase-3 independent 
pathway whereas HAX1.1 enhance the levels of cleaved capsae-3 and cleaved PARP 
without any observed changes in cell viability. HAX1.1, HAX1.2 and HAX1.5 also 
promote autophagy by increasing the levels of Brclin-1 and LC3b-II. 
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APPENDIX I- (a) 
Features of the pGIPZ vector 
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APPENDIX I- (b) 
Detailed vector map of pGIPZ™ lentiviral vector 
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APPENDIX II 
Detailed vector map of pFLAG-CMV2 vector 
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APPENDIX III 
The effect of Taxol induced cell death in HAX1-null (si86 treated) HeLa cells. 
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APPENDIX IV 
The effect of Etoposide induced cell death in HAX1-null (si86 treated) HeLa 
cells. 
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APPENDIX V 
The effect of 5-FU induced cell death in HAX1-null (si86 treated) HeLa cells. 
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APPENDIX VI 
The effect of Taxol induced cell death in HeLa cells expressing HAX1.1. 
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APPENDIX VII 
The effect of Etoposide induced cell death in HeLa cells expressing HAX1.1. 
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APPENDIX VIII 
The effect of 5-FU induced cell death in HeLa cells expressing HAX1.1. 
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APPENDIX IX 
The effect of Taxol induced cell death in HeLa cells expressing HAX1.2. 
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APPENDIX X 
The effect of Etoposide induced cell death in HeLa cells expressing HAX1.2. 
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APPENDIX XI 
The effect of 5-FU induced cell death in HeLa cells expressing HAX1.2. 
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APPENDIX XII 
The effect of Taxol induced cell death in HeLa cells expressing HAX1.5. 
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APPENDIX XIII 
The effect of Etoposide induced cell death in HeLa cells expressing HAX1.5. 
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APPENDIX XIV 
The effect of 5-FU induced cell death in HeLa cells expressing HAX1.5. 
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